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ABSTRACT 
 
Neomycin is an aminoglycoside antibiotic known for its high affinity for RNA 
duplex structures.  Recent developments from our labs have indicated that 
aminoglycoside binding is not limited to RNA, but to nucleic acids that, like RNA, adopt 
conformations similar to A-form.  Our group sought to further expand the utility of 
aminoglycoside binding to B-DNA structures by conjugating neomycin, an 
aminoglycoside antibiotic, with the B-DNA minor groove binding ligand Hoechst 33258.  
Envisioning a dual groove-binding mode, we have extended the potential recognition 
process to include a third, intercalative moiety.  Furthermore, we observe remarkable 
recognition of such conjugates with RNA duplex.  Spectroscopic studies such as UV 
melting, differential scanning calorimetry, isothermal fluorescence titrations, and circular 
dichroism together illustrate the multi-recognition properties of the novel neomycin-
based conjugates. 
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CHAPTER 1 
NUCLEIC ACIDS AND SMALL MOLECULE RECOGNITION 
 
Nucleic Acids 
DNA contains the genetic information that is conserved through living 
generations.  Genes are represented by specific sequences of DNA within chromosomes, 
and carry the complete instructions for making proteins.  The process leading to protein 
synthesis involves two key steps: transcription and translation.  Transcription is the 
process by which single stranded DNA, unwound from duplex form with enzyme 
assistance, is copied via synthesis of complementary RNA.  Translation is the encoding 
of this messenger RNA (mRNA) in the ribosome, leading to protein synthesis (Figure 
1.1).  The successful targeting of DNA (antigene) or RNA (antisense) strategies to 
combating diseases such as cancers or viruses is therefore a major goal in the 
pharmaceutical movements.  
Well before the elucidation of the structure of DNA, its biological importance was 
demonstrated as early as 1944 with work by Oswald Avery who demonstrated that a 
“nucleic acid of the deoxyribose type” was responsible1 for the transformation of a non-
pathogenic mutant of pneumococcus to a pathogenic form by the addition of a cell extract 
of a pathogenic form which had been killed by heat.
2
  The modern history of nucleic 
acids arguably begins with the elucidation of the DNA double helix by Watson and Crick 
in 1953.
3
  A compendium of outside research contributed to their proposal: (a) X-ray 
diffraction data generated by Rosalind Franklin, Raymond Gosling, and Maurice Wilkins 
and colleagues,
4,5
 (b) biochemical studies of base composition ratios by Chargaff 
 2 
 
illustrating base compositions of adenine were equal to thymine, and guanine equal to 
cytosine,
6
 and (c) the 5′ deoxycytidine crystal structure indicating favorable 
conformations of the sugar and its bonds between the phosphate between the base.
7
  What 
resulted was a molecular model consisting of two right-handed helical strands possessing 
phosphate-sugar backbones, with heterocycles oriented inward from the outside 
backbone.  The strands ran antiparallel to each other.  The heterocyclic bases consisted of 
both purine and pyrimidine motifs, between which formed a “base-pair” through 
hydrogen bonding.  Furthermore, the base pairs, consisting of guanine-cytosine and 
adenine-thymine pairs, were spaced along the helical axis 3.4 Å apart.  The fascination 
today with Watson and Crick’s discovery is due to the validity of their model throughout 
the progressive years of structural analysis techniques.  Improved fiber
8
 and single 
crystal
9
 diffraction studies of DNA have, to a large degree, confirmed Watson and 
Crick’s original model. 
Figure 1.1 Steps toward protein synthesis involve transcription and translation of genetic 
information that leads to protein synthesis. 
 
  
mRNA DNA protein 
transcription translation 
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Figure 1.2 (left) General structure of DNA, indicating the different grooves; (right) 
structures of nucleotides found in DNA. 
 
The features of a DNA duplex are shown in Figure 1.2.  A strand of DNA 
consists of 2′-deoxyribose rings connected via phosphodiester linkages from the 3′ and 5′ 
positions.  At the 1′ position of the deoxyribose are the heterocyclic bases adenine (A), 
guanine (G), thymine (T), or cytosine (C).  Purine bases (A and G) are connected at the 
N-9 position, and pyrimidine bases (T and C) are connected at the N-1 position, both via 
a -glycosidic linkage (Figure 1.2).  Two strands of DNA come together to form a 
double helix, dominated by Watson-Crick base-pairing rules, A with T, and G with C.  
major 
groove 
minor 
groove 
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The backbone of the helix features the phosphate regions, whereas the internal area of the 
helix contains the base-pairs.  The phosphates maintain a negative charge at physiological 
pH, therefore making the DNA backbone polyanionic.  Charge-charge repulsion between 
the two strands is mediated by counterions such as Na
+
, K
+
, or Mg
2+
.  Protection of the 
internal bases and their genetic information by the phosphate backbone minimizes 
chemical medication by outside agents, maintaining genetic integrity.    DNA also 
features two different grooves, formed as a result of helix formation.  These include a 
wide, shallow major groove and a deep, narrow minor groove.  The minor groove is on 
the side of the base pairs facing the sugar-phosphate backbone, and approximately 5.7 Å 
in width (measured between the phosphates across the groove).  The major groove is on 
the opposite side.  Its width is approximately 11.7 Å.  Each groove has distinct base 
heteroatoms responsible for recognition through H-donating and accepting sites (Figure 
1.3).  The stability of the duplex is attributed to both H-bonding between the bases and 
base stacking between adjacent base pairs. 
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Figure 1.3  Hydrogen-bonding pattern between nucleic acid bases and their positions 
with respect to the DNA grooves. 
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 The original Watson-Crick model was that of B-form DNA.  B-form DNA is the 
most abundant form founding nature.  Two other major structural classes of DNA have 
been shown to exist, namely A-form and Z-form.  A-form DNA was a major focus of 
Rosalind Franklin, who originally observed that with variable hydration conditions, x-ray 
diffraction data indicated two structurally different forms.
10
  A-DNA was attributed to the 
DNA structure formed in a low humidity environment, and B-DNA under high humidity 
conditions.  Though found to exist seven years earlier,
11
 the crystal structure of Z-DNA 
was solved in 1979 and featured a left handed helix with a “Zigzag”-like backbone, 
contrasting with the right handed forms in A and B forms.
12,13
 Also, Z-DNA is known 
only to form with sequences of alternating pyrimidine-purine bases, primarily G-C bases 
(e.g., polyd(GC)2). Figure 1.4 depicts structural models of the three major nucleic acid 
conformations.   
 Structural attributes to A-form DNA include a wide and shallow minor groove, 
and deep and narrow major groove.  Groove widths are nearly opposite that of B-DNA, 
with a minor groove approximately 11.0 Å and major groove approximately 2.7 Å wide.  
The “zigzag” like backbone of Z-DNA prohibits a reliable approximation of the groove 
widths.  A correlation between sugar puckering and DNA conformation can also made.  
B-form sugar puckers tend to comprise of C-2′-endo, whereas A-form sugars adopt a C-
3′-endo conformation (Figure 1.5).  In Z-DNA, C-containing sugars adopt C-2′-endo, 
and G-containing sugars comprise of C-3′-endo conformations.  Glycosyl bonds (between 
1′ and base nitrogens) can be either syn or anti (Figure 1.6).  Both A- and B- DNA 
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glycosidic bonds maintain anti configurations, whereas in Z-DNA, cytosines adopt anti 
configurations, and guanines adopt syn configurations. 
 
Figure 1.4  Structures of three primary nucleic acid conformations. 
 
O Base O
Base
C3'-endoC2'-endo  
Figure 1.5  Sugar puckering patterns in nucleic acids. 
 
 The other member of the nucleic acid family, RNA was first identified as the 
messenger between DNA and proteins.  Eventually multiple types of RNA were 
discovered, including transfer RNA (tRNA) and ribosomal RNA (rRNA), which are 
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responsible for the ultimate translation of RNA sequence into amino acid polymers 
(proteins).  Structurally, RNA nucleotides are different from DNA by the presence of 
hydroxyl at the 2′ carbon and the furanose ring, and the absence of a methyl group at the 
5 position of the base (uracil instead of thymidine; Figure 1.7).  In duplex form, RNA 
adopts an A-conformation.  However, RNA rules for base pairing are easily bent; base 
“mismatches” are found in virtually every known RNA structure, as well as are non-
complementary bases, which result in bulges or loops within the helix.  Due to the 2′-OH 
in the ribose ring, RNA can form a number of complex three-dimensional structures far 
different from the canonical double helix found primarily with DNA.   The classes of 
RNA secondary structures range from simple A-form duplex to single and multi-base 
bulges, mismatch loops, or three and four-stem junctions.  The presence of this 2′- 
hydroxyl introduces an extra hydrogen bonding site, which has potential for interactions 
with other RNA regions or surrounding water molecules.  Further, as DNA requires metal 
ions to stabilize its helical structure, the presence of the 2′-hydroxyl (in RNA) repulses 
metal ions within this region, thereby rendering alternative structural stability in forms of 
hairpins or loops.  Figure 1.8 illustrates an example of the secondary (2-dimensional) 
structure of a tRNA molecule. 
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Figure 1.6  The different configurations at the glycosyl bond for purines (represented by 
guanine) and pyrimidines (represented by cytosine). 
 
Other higher ordered nucleic acids are also known to exist.  These include triple 
helical and tetraplex structures.  Triplex structures can be formed with the requirements 
that the DNA or RNA strands are homopurine and homopyrimidine sequences under 
appropriate salt and pH conditions.  A-T triplexes can be formed under physiological pH, 
however C-G triplexes require protonation of the cytosine so that an additional H-
bonding interaction can be met (Figure 1.9).  Upon triplex formation, a third strand 
(triplex-forming oligonucleotide, or TFO) binds within the duplex major groove, in either 
parallel or antiparallel fashion to the purine strand, via Hoogsteen H-bonds.  TFOs that 
bind duplex in antiparallel fashion are typically ascribed to forming reverse-Hoogsteen 
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hydrogen bonds.  Parallel TFO binding primarily occurs with pyrimidine strands, forming 
a pyrimidine•purine•pyrimidine base triplet.  Antiparallel TFO binding mostly occurs 
with purine strands, forming a purine•purine•pyrimidine triplet.  Figure 1.9 depicts the 
H-bonding patterns of the different triplexes known to form.   
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Figure 1.7  Difference in RNA and DNA nucleotides.  DNA lacks the 2′-OH present in 
RNA, but possesses a 5-methyl group on the thymine base, absent in RNA. 
 
 Tetraplex structures consist of guanine tetrads that orient through eight H-bonding 
interactions.  Tetraplexes are predominant in G-rich sequences and can associate through 
two or four separate strands intermolecularly or through a single strand intramolecularly.  
Tetraplexes formed with two strands or less require unpaired stretches of DNA (usually 
thymine) which allow loop formation and resulting G-G proximities to be met.  Typical 
H-bonding patterns between guanine tetrads are depicted in Figure 1.10. 
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Figure 1.8  Secondary structure of yeast tRNA
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Figure 1.10  Hydrogen bonding patterns in DNA triplex. 
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Nucleic acid recognition by small molecules 
Vital to the transmission, expression, and conservation of genetic information, 
nucleic acids have obviously been a hot topic for research since the early days of its 
proposed configuration.  Small molecules, including both natural products and synthetic 
successes, that bind nucleic acids have been extensively examined with aims at ultimately 
understanding and achieving specific recognition such that gene therapy is a reality.  The 
forthcoming paragraphs focus on small molecules that are known to bind both DNA and 
RNA structures.  Particular focus of RNA binders will be on aminoglycosides.    
 
Figure 1.11 DNA binding can occur in either groove or between the base pairs 
(intercalation). 
 
 
Targeting DNA 
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 Interactions with DNA by small molecules can be either covalent or non-covalent.  
Covalent interactions with DNA can be represented by the popular drug cisplatin, which 
can form crosslinks between DNA strands via chloride substitution by the N7 of guanine 
bases.  However, the drawbacks to utilizing such drugs are the side effects accompanied 
with their administration, largely due to their non-specificity for cancer cells versus 
normal cells.  The majority of the focus on DNA recognition lies in noncovalent 
interactions, which can be divided further into two different classes, intercalation and 
groove binding (Figure 1.11).   
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Figure 1.12  Selected structures of compounds known for DNA intercalation. 
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Figure 1.13  Natural DNA minor groove binders netropsin and distamycin.   
 
 Intercalation involves the favorable stacking interactions of planar aromatic 
ligands within the base pairs of DNA (a model is shown in Figure 1.11).  The space 
displacement between the base pairs results in an overall elongation of the DNA helix, 
with partial unwinding at the intercalation site.  The general structure of intercalators 
consists of at least three fused six membered rings that match well with the planar surface 
of base pairs, maximizing the hydrophobic interactions.  Lerman first described 
intercalation with studies of proflavine.
14
  A vast number of DNA intercalators have been 
discovered since (Figure1.12).  These include such compounds as acridines (proflavine 
included), ethidium bromide, and anthraquinones to name a few.  Natural intercalators 
such as actinomycins and the anthracyclines daunomycin and doxorubicin have seen use 
as anticancer drugs.
15
  A number of intercalating compounds have been found to 
significantly stabilize triplex DNA structures.  These include such compounds as 
BePI
16,17
(benzo[e]pyridoindole) and coralyne.
18-21
  Helene has designed a potent triplex 
intercalating ligand, BQQ (6-[3-(dimethylamino)propyl]amino-11-
methoxybenzo[f]quino-[3,4-b]quinoxaline) which matches the crescent shape of the base 
triad in triplex DNA.
22
  The major drawback to intercalators, however, is their inability to 
discriminate between specific base sequences.  Moreover, due to their mode of binding, 
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the binding site size is limited to just a few base pairs.  An exception to this drawback is 
seen in the number of natural products that have multiple moieties, with different binding 
modes, within the same molecule (e.g., pluramycins).  These compounds shall be 
addressed in a later section. 
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Figure 1.14  Guanine NH2 repulsion of C-H in pyrroles prevent minor groove binding 
(left); imidazole nitrogens welcome the guanine NH2. 
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 A means for achieving sequence-specific DNA groove recognition has largely 
rested on the shoulders of the natural pyrrole-containing polyamides distamycin and 
netropsin (Figure 1.13).  These natural compounds have long been recognized as DNA 
minor groove binding agents with remarkable specificity for A-T rich regions of DNA (4-
5 base A/T base pairs).  The affinity of such compounds, through rigorous synthetic
23,24
 
and computer-based efforts,
25
 led to the design of oligopeptides similar to netropsin but 
with G-C specificity.  The key factor in achieving recognition of G/C relied on a H-
acceptor site for the 2-amino group of guanine.  It was believed that A/T specificity of the 
pyrroles in distamycin or netropsin was due to the unfavorable steric repulsion of the 
pyrrole C-H and 2-amino position of guanine (Figure 1.14).
26
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Figure 1.15  Hairpin polyamide of pyrroles/imidazole monomers with G/C recogntition 
properties.
27
 
 
Eventually it was rationalized that other factors, namely, van der Waals forces, 
and not just H-bonding sites, that dictate successful recognition of G/C base pairs.
25
  
Pioneering efforts by Dervan resulted in hairpin polyamides of pyrrole and imidazole 
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monomers that were capable of distinguishing the different DNA base pairs (Figure 
1.15).  The transition of the hairpin synthesis to the solid phase
28
 opened the door for 
more robust attempts to achieving stronger recognition patterns; though base pair 
specificity was met with pyrrole/imidazole pairs, specificity for A-T vs. T-A base pairs 
remained elusive, particularly at the hairpin terminus. 
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Figure 1.16  Selected structures of compounds that bind in the minor groove of B-DNA. 
 
 Other minor groove binding ligands include berenil,
29-31
  DAPI (4′,6-Diamidino-
2-phenylindole),
32-35
 and Wilson and Boykin’s furamidine derivatives36-39 are other well 
known DNA groove binders (Figure 1.16).  Like distamycin and netropsin, these ligands 
bind within A/T stretches of DNA.  The central feature in these minor groove binders is 
their crescent shape, which fits well with the pitch of the DNA minor groove.  Also, the 
presence of at least one positive charge is consistent feature of minor groove binders, 
complementing the high negative potential of the minor groove.  Hoechst 33258 (Figure 
1.16)  is another example of a minor groove binding ligand, and possesses similar 
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features to the aforementioned ligands.  A more in depth survey of its properties will be 
featured in the next chapter.   
 The DNA major groove has remained an elusive target by small molecules due to 
its greater width and lower negative potential compared to the minor groove.  It is a 
primary target for proteins and other DNA strands (TFOs), which can result in a triple 
helical structure.  However, a number of carbohydrate moieties have been shown to bind 
within the major groove, though the binding by such ligands also includes minor groove 
and intercalation modes.  An example of this is nogalamycin (Figure 1.12).  Therefore, 
the major groove binding is driven first by minor groove binding moieties and/or 
intercalating regions within the small molecule.  Such hybrid molecules will receive 
particular attention in a forthcoming chapter. 
 
Targeting RNA: Aminoglycosides 
 The origin of aminoglycoside antibiotics began with streptomycin sixty years 
ago.
40
 Isolated from Actinomyces griseus, streptomycin immediately found applications 
for the treatment against the tuberculosis-causing microorganism Mycobacterium 
tuberculosis.
41
 This was the second antibiotic (to penicillin) to be used clinically.   It was 
eventually shown to prevent protein synthesis,
42
 but its bactericidal properties were yet to 
be explained.  In 1959, it was proposed that ribosomes were the primary target for 
streptomycin.
43
  However, this was controversial, due to beliefs that membrane damage 
was the sole process.
44,45
  Davies and others were later able to show that streptomycin 
binds within the 30S subunit of the 70S ribosome,
46,47
 illustrating that indeed the 
mechanism of action was likely ribosome related.  Davies quickly thereafter showed 
 19 
 
resounding evidence that streptomycin disrupts the fidelity of translation between the 
ribosome and mRNA, producing proteins of inefficient function.
48
  It was proposed that 
this “flooding” of nonproductive proteins affects other cellular functions, which lead to 
cell death.  To this day, a complete understanding of the bactericidal effect is lacking, 
though much progress has been made.  The in vitro studies of the 1960s were punctuated 
with evidence of in vivo codon misreading by the late 1970s.
49
  Throughout the coming 
years, a number of aminoglycosides were discovered (Figure 1.17), with varying 
potencies for treating infections.  Therapeutic applications diminished due to the 
emergence of resistance to aminoglycosides by bacteria.  Coupled with adverse side 
effects such as renal and ototoxicity, aminoglycoside antibiotic applications toward 
infectious diseases were placed on the back burner to less harmful antibiotics such as -
lactams.  Only within the last decade has the area become increasingly intriguing again, 
due largely to chemical derivatization, a deeper understanding of resistance mechanisms, 
and structural information on aminoglycoside activity.  
 The binding site of aminoglycosides was ultimately discovered to be the 16S 
rRNA aminoacyl site (A-site) of the small ribosomal subunit (30S) in prokaryotic 
bacteria.
50
  Studies in the 1980s largely relied on enzymatic footprinting but advances in 
NMR and crystallographic techniques have vastly widened the views.  Due to structural 
elucidations of the complexes, both in solution and crystal form, there is a much clearer 
picture of the aminoglycoside-RNA interaction. 
 20 
 
OHO
HO
N
O
O
H2N
NH2
OH
O
OHO
O
NH2
HO
OH
H2N
R
HO
  R  
NH2   Neomycin
OH    Paromomycin
OHO
HO
N
O
O
H2N
NH2
OH
O
OHHO
R
HO
  R  
NH2   Neamine
OH    Paromamine
  R  
NH2   Ribostamycin
OHO
R1
R2
O
O
H2N
NH2
O
NH2
OHO
OH
OH
NH2
 R1    R2
OH   OH   Kanamycin A
OH   NH2  Kanamycin B
 H     NH2  Tobramycin
O
N
O
HO
H2N
NH2
O
NHR2
OHO CH3
N
OH
 R1    R2
CH3  CH3  Gentamicin C1
CH3   H     Gentamicin C2
 H      H       Gentamicin C1a
R1
HN
O
CHO
H3C
OH
O NHCH3
HO
HO
HO
OH
OH
O
H
N
NH2
HN
NH2
HN
O HO
Streptomycin
I
II
III
IV
I
I
I
I
II
II
II
II
III
III III
III
1'
2'
1
3
3''
1''
1'''
2'''
1'
2'
3
1
1''
3''
1'
2'
1
3
1''
2''
1
4
1'
2'
1''
2''
1
3
1'
2'
1''
2''
H
H
H
H
H
H
H
 
 
Figure 1.17  Representative chemical structures of aminoglycoside antibiotics. 
  
 21 
 
Novel Targets for Aminoglycosides 
 Over the past decade, several nucleic acid structures other than the 16S rRNA A-
site have been discovered as aminoglycoside targets.  Virtually all of these novel targets 
are RNA structures, and this infidelity of aminoglycosides for various RNA structures 
has been the subject of numerous reviews.
51-53
  Not only has a deeper understanding of 
RNA recognition been grasped, the list of nucleic acid structures that bind 
aminoglycosides has been expanded to include DNA and proteins.  Outlined below are 
the variety of targets, other than the 16S A-site, that have been discovered for their 
binding to aminoglycosides.  These include RNA targets such HIV-1 RNA, ribozymes, 
mRNA, and tRNA.  Novel DNA targets include both DNA and hybrid RNA/DNA 
duplexes and triplexes.  The new discovery of aminoglycoside binding to proteins such as 
the Anthrax lethal factor will also be addressed.
54
  The array of studies discussed in the 
forthcoming sections rely primarily on the techniques described above, so limited detail 
will be on experimental technique. 
 
HIV-1 RNA 
 RNA targets that play key roles in transcription of the HIV genome include the 
trans-activating region (TAR) and the Rev response element (RRE).  Both RNA regions 
are responsible for recognition of proteins that assist in transcription.  The RRE is 
responsible for binding the Rev protein.  This protein is responsible for facilitating the 
transport of HIV RNA out of the host cell nucleus without exposure to splicing agents.  
The prevention of splicing retains the complete HIV strand that is required for further 
replication of viral particles.  The HIV-1 Tat protein binds TAR RNA, a required 
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interaction for the efficient transcription of the full-length viral genome.  A more recently 
discovered HIV RNA target is the packaging region ( element), which is a site for RNA 
dimerization and nucleocapsid recognition, required events for the viral life cycle.  
Therefore, one can envision the potential that aminoglycoside-based recognition has in 
combating AIDS.   
 Among the aminoglycosides, neomycin B is most effective at inhibiting Rev 
protein recognition of RRE.  Quantitative studies of neomycin binding to constructs of 
RNA similar to the RRE decoding region gave strong indication of the necessity of non-
duplex RNA forms.
55
  By utilizing a fluorescent-labeled paromomycin structure for 
binding various constructs, Kd values for several aminoglycosides have been determined 
using a competition assay monitored by fluorescence.  Neomycin showed the strongest 
binding, with Kd values in the sub micromolar range.  The binding was shown to decrease 
as the number of non-canonical base pairs and/or bulges decreased.
55
 This finding agreed 
with earlier methods and painted a uniform picture of the structural requirements for high 
affinity binding by neomycin.  
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Figure 1.18.  Structure of a neomycin-neomycin dimer developed by Tor and 
coworkers.
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However, around this time Wong and coworkers, using SPR, demonstrated that up to 
three molecules may bind such constructs at one time, therefore suggesting more than one 
binding site.
56
 This phenomenon gained further support in later stopped-flow 
fluorescence studies.
57
 More recently, novel aminoglycoside-based ligands have been 
developed and exhibit enhanced binding to RRE.  Aminoglycoside dimers such as neo-
neo
58
 (Figure 1.18) have been shown to bind the RRE region nearly 20-fold stronger than 
monomeric neomycin, further suggesting a secondary binding site for neomycin (Figure 
1.19).
59
  An excellent review was recently reported incorporating such dimers and other 
novel RRE binders in fluorescence-based RRE binding assays.
60
 Aminoglycoside-
arginine conjugates have been shown to bind RRE with similar affinity to the Rev protein 
(Kd in the low nM range). Guanidinoglycosides, aminoglycoside derivatives replacing 
guanidines at amino positions, have been shown to inhibit HIV replication nearly 100 
times greater than parent aminoglycosides (Figure 1.20).
61
  
 TAR binding by aminoglycosides, like RRE, has received its share of attention as 
a potential anti-HIV area. The TAR element consists of the first 59 bases in the primary 
HIV-1 transcript, adopting a hairpin structure with a UCU bulge four base pairs below 
the loop of the hairpin.
62,63
  A construct of the TAR element is shown in Figure 1.21.
64
 
Neomycin has been found to be a non-competitive inhibitor of Tat by binding the lower 
stem of TAR and disrupting the conformation such that the neighboring site becomes 
inadequate for Tat recognition. 
65,66
 An interesting electron paramagnetic resonance study 
has suggested the possibility of a guanidinoneomycin binding at the site of Tat, in 
contrast to that of neomycin B.
64
 Aminoglycoside-arginine conjugates have been shown 
to also bind TAR, and with greater affinity than RRE (5 nM vs. 23 nM).
67-71
 A recently 
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developed peptide nucleic acid (PNA)-neamine conjugate has been shown to inhibit viral 
synthesis as well as hydrolyze the RRE target.
72
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Figure 1.19  Secondary structure of RRE construct indicating the two proposed binding 
sites of a neomycin-neomycin dimer
138
 based on monomeric neomycin binding studies.
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Figure 1.20.  Structures of guanidinoglycosides with potent HIV inhibition activity.
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 A more recently discovered RNA target in HIV is the  element, responsible for 
RNA dimerization and packaging, two necessary functions for viral perpetuation.
73
  Due 
to the youth of its discovery, little is known regarding the exact binding site within the 
large RNA.  Footprinting and spectroscopic results have indicated multiple binding sites 
for such aminoglycosides as neomycin,
74
 paromomycin, and guanidinoneomycin.
75,76
 
Significantly different results were obtained for a neomycin-neomycin dimer as well as a 
neomycin-acridine conjugate, insisting recognition differences that may potentially be 
exploited in future studies.
76
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Figure 1.21.  Secondary structure of a construct of the TAR element of HIV-1 found to 
bind aminoglycosides.
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Ribozymes 
Aminoglycoside antibiotics have been shown to bind preferentially to ribozymes 
and inhibit their activity.  Among these are the hammerhead, hairpin, RNase P, group I 
intron, and the hepatitis delta virus ribozymes.  In all cases, the cationic nature of 
aminoglycosides plays an important role.  Therefore, aminoglycosides such as neomycin, 
which possesses six amino groups, five of which are protonated at physiological pH, 
display the strongest binding to such ribozymes.  Most studies mentioned below therefore 
consider neomycin or neomycin derivatives. 
The hammerhead ribozyme is a small RNA that catalyzes specific RNA cleavage 
in the sugar-phosphate backbone.  The function of this RNA strongly relies on Mg
2+
 
placement to maintain structural integrity.   Aminoglycoside action in inhibition of 
hammerhead ribozyme function has been shown to involve displacement of these 
necessary Mg 
2+
 ions.
77
  Structural studies of the hammerhead ribozyme bound by 
neomycin have indicated that the charged ammonium groups of neomycin are at similar 
sites of divalent Mg 
2+
 ions.
78,79
  Moreover, neomycin has been shown to displace five 
Mg 
2+
 ions upon binding to the RNA, so all ammoniums in neomycin are essential for 
binding.  An increase in pH (above 8) has shown to significantly reduce the inhibition 
properties of neomycin, further validating the precept that charge is a definite 
requirement for strong binding.
77
  Modified aminoglycosides containing an extra amino 
group have shown that increased cationic charge results in increased binding and 
inhibition.
80
  However, the number of charges can go too far; dimeric 
aminoglycosides,
80,81
 possessing upwards of +10 charge, showed no profound increase in 
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activity, suggesting that discreet binding pockets are present and can be satisfied with 
approximately six well placed electrostatic interactions.
82
 
Like most ribozymes, the hepatitis  virus (HDV) ribozyme requires divalent 
cations and self-cleaves to generate a 2´, 3´-cyclic phosphate at the 5´ end and 3´ 
fragment containing a 5´-hydroxyl.
83
  Also characteristic among ribozymes in regards to 
neomycin binding and inhibitory activity, displacement of crucial Mg 
2+
 within the RNA 
is the most likely explanation.
84,85
  Footprinting experiments have indicated two binding 
sites for neomycin binding, one near the catalytic core and one at the end of stem IV.
85
  
The catalytic core binding is the probable cause for inhibitory activity, given the fact that 
other aminoglycosides bind the HDV ribozyme but show no inhibition,
85
 and that stem 
IV can be removed and catalytic activity is still maintained.   
 Neomycin has also been shown to inhibit hairpin ribozyme activity, but to a 
weaker extent than other catalytic RNA such as those mentioned above.
86
  However the 
aminoglycoside 5-epi-sisomicin (Figure 1.22) has shown reputable activity, with 
inhibition constants in the sub-micromolar range.  Interestingly, ribozyme cleavage is 
promoted with aminoglycosides in the absence of Mg
2+
.  The same observation was made 
with linear polyamines such as spermine,
86
 suggesting that the cleavage step is not 
necessarily dependent on charge and shape complementarity as it would seem to be with 
aminoglycosides.    
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Figure 1.22  Chemical structure of 5-epi-sisomicin. 
 
 Aminoglycosides are also known to inhibit group I intron splicing.
87
  Footprinting 
studies have indicated that neomycin, as it does with other ribozymes, most likely 
displaces metal ions to elicit its action in inhibiting splicing.
88
  Detailed mutational 
studies, coupled with molecular modeling, have shown that displacement of two Mg
2+
 
ions is required for inhibition.
89
 
 A more recently discovered ribozyme that binds neomycin, RNase P is 
responsible for the maturation at the 5´ end of all tRNA in both prokaryotes and 
eukaryotes.
90
  Bacterial RNase P consists of a small RNA and protein subunit, of which 
the RNA acts as the catalyst in the cleavage reaction.  Like the group 1 intron ribozyme, 
inhibition of activity by aminoglycosides such as neomycin is suggested to occur as a 
result of the displacement of two important Mg
2+
 ions.
91,92 ,93
 
 
tRNA 
 One may infer at this point that aminoglycosides bind to a variety of RNA, all of 
which play different roles biologically.  The list extends with evidence that 
aminoglycosides bind tRNA.
94-96
  Chemical and enzymatic footprinting analysis of 
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tRNA
Phe
 with such aminoglycosides as neomycin and dimeric neomycin has indicated 
that binding sites likely exist in duplex regions adjacent to loop or bulges as well as loops 
themselves.  Specific interactions include the anticodon stem and the junction of the TC 
and D loops.
95
  A more recent x-ray study has shown that neomycin’s primary binding 
site is in the major groove adjacent to the D loop (Figure 1.23), containing six potential 
hydrogen bond interactions.
96
  Comparisons of the neomycin-tRNA
Phe 
crystal structure 
with other tRNA
Phe
 crystal structures with either Pb
2+
 or Mg
2+
 indicate a stark 
resemblance to the placement of cations (the protonated amines of neomycin).  Thus, as 
ribozyme activity involves, the displacement of divalent metal ions likely plays a key role 
in neomycin binding.   
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Figure 1.23  Secondary structure of the aminoglycoside binding region of tRNA
Phe
.
 
 
Dashes indicate neomycin and dimeric neomycin interactions.
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mRNA 
 A number of aminoglycosides have been shown to specifically bind an RNA 
construct corresponding to the mRNA site for thymidylate synthase (TS).  Thymidylate 
synthase catalyzes the reductive methylation of 2´-deoxyuridine 5´-monophosphate 
(dUMP) to form the thymidine monophosphate, which is critical reaction within the DNA 
synthesis cycle.
97
  Thus, it has become a target for chemotherapeutic agents such as 5-
fluorouracil.  Among the RNA constructs known for TS binding is its own mRNA.  
Aminoglycoside binding to TS mRNA involves an internal CC bubble structure that 
coincidentally is thought to be important for efficient translation.
98
  Other than the TS 
mRNA construct, other structures containing an internal CC bubble were shown to attract 
aminoglycoside binding, validating a structural preference of aminoglycosides.
98
 
 
RNA triplex 
 Though it is the first triple-helical nucleic acid structure reported,
99
 the RNA 
triplex has received little attention when compared with other RNA structures or DNA 
triplexes (discussed below) for that matter.  Since a large number of important RNA 
targets consist of duplex motifs, the introduction of a third strand to the duplex, to form a 
triplex, has obvious implications for inhibiting protein function at their recognition sites.  
Likewise, single stranded RNA can be targeted by circular or foldback triplex forming 
oligonucleotides (TFOs), which intramolecularly form duplex structures.
100-103
 Triplex 
formation is limited to homopyrimidine or homopurine stretches, which in turn limit its 
therapeutic applicability.  Nevertheless, potential exists with knowledge of RNA primary 
sequence.  One example of an important RNA sequence for TFO targeting has been the 
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5´- noncoding region of hepatitis C viral RNA, which has shown to form a triple helical 
structure in the presence of Mg
2+
 and the polyamine spermidine.
104
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Figure 1.24  (left) Base pairing in a T•A•T triplex; grooves (from TFO binding in the 
major groove) are indicated; (right) Computer model of neomycin bound to the Watson-
Hoogsteen groove of a DNA triplex.
186
  
  
More recently aminoglycosides were shown to significantly stabilize RNA triplex 
structures.  Among the aminoglycosides, and as with many other RNA-binding studies, 
neomycin was found to be the most significant RNA triplex stabilizing 
aminoglycoside.
105
  More notably, neomycin was shown to be the most significant RNA 
triplex-stabilizing agent among all known ligands, with the exception of ellipticine.  
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Thus, another RNA structure was found to bind aminoglycosides, further emphasizing 
the binding infidelity of aminoglycosides. 
 
DNA triplex 
 The association of homopyrimidine•homopurine stretches of duplex DNA are 
known to be targets for triplex formation by major groove association of a TFO.
106
  TFO 
recognition of duplex DNA can be exploited in a variety of ways, such as by inducing 
transcription inhibition, site-directed mutagenesis, or recombination.  Another attractive 
feature of triplex DNA is the feature of H-DNA, an intramolecular-forming triplex, found 
in biological systems.  H-DNA formation is found within mirror repeats of 
homopyrimidine•homopurine stretches in plasmid DNA, in which triplex formation 
requires a negative supercoiling (dissociation of symmetrical duplex stretch with folding 
back of a single strand to form triplex).
107
  The constrained, bent DNA conformation that 
occurs upon H-DNA formation is often observed with regulatory proteins, therefore the 
formation of such structures may represent a form of molecular switch in controlling 
gene expression.  The targeting of triplex DNA is thus of obvious interest.  However, 
triplex formation is thermodynamically and kinetically less favorable than duplex-TFO 
dissociation.  Therefore, the driving force for utilizing TFO-based recognition for 
therapeutic purposes is the development or discovery of ligands that stabilize and 
kinetically favor the formation of triplex structures in a specific fashion. 
 Neomycin, among a series of aminoglycoside antibiotics studied, has been shown 
to significantly stabilize DNA triplexes.
105,108-110
  Neomycin was also shown to enhance 
the rate of TFO-duplex association.
105
  The binding and stabilization of DNA triplexes by 
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neomycin is unique among other triplex-stabilizing ligands in that no DNA duplex 
binding occurs. Molecular modeling has suggested neomycin binding within the Watson-
Hoogsteen groove, and that it is neomycin’s charge and shape complementarity that 
drives triplex recognition over duplex (Figure 1.24).
111
  All previously discovered 
triplex-stabilizing ligands also displayed some degree of duplex stabilization as well. 
Moreover, neomycin is the first groove binding ligand to exhibit DNA triplex 
stabilization (the absence of a fused, planar ring system eliminates the structural 
possibilities for intercalation).  This exciting finding widened the view that otherwise 
displayed RNA structures in regards to aminoglycoside recognition.  The list of nucleic 
acid structures that aminoglycosides bind, however, did not end with DNA triplex. 
 
DNA-RNA Hybrids 
 DNA/RNA hybrid duplexes are biologically relevant due to their recognition by 
such enzymes as RNase H and reverse transcriptase.
112,113
  Recognition of such structures 
by small molecules therefore has potential in antiviral applications. Earlier mutational 
studies indicated that genetic deactivation of the RNase H activity of HIV-1 reverse 
transcriptase (RT) results in non-infectious virus particles,
114
 thus the importance of 
RNase H is obvious.  Targeting crucial RNase H-based interactions is a pathway for 
developing anti-HIV agents.  It is even more attractive when considering that RNA/DNA 
hybrids formed during the reverse transcription process are not associated with a high 
mutation frequency, as RT
115
 and protease inhibitors
116-119
 (both AIDS therapeutic 
agents) are.   
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 Aminoglycosides were recently shown to bind DNA/RNA hybrids related to HIV-
1. 
120,121
 Using a combination of cleavage, calorimetric, and spectroscopic studies, 
paromomycin was shown to significantly stabilize octomeric hybrid duplexes with 
binding affinities up to 200-fold higher than the control DNA duplexes.
121
  Significant 
inhibition of cleavage by RNase was also observed.  A more recent study, involving 
hybrid duplexes that mimic RNase H substrates at both early and late stages of the 
reverse transcription process, has involved other aminoglycosides neomycin and 
ribostamycin.
120
  The key structural differences between these are the following (please 
refer to Figure 1.17. for structures): neomycin possesses an amine at the 6´ position (ring 
I), whereas paromomycin contains a hydroxyl group; ribostamycin is similar to 
neomycin, but lacks ring IV.  The activity of these three aminoglycosides were in the 
order: neomycin > paromomycin > ribostamycin.  The activity thus correlates with the 
amount of charge on each aminoglycoside (neomycin has 6 protonated amines, 
paromomycin has 5, and ribostamycin has 3.  Under these conditions (pH 6.0), the 3-
position amine (ring II) is protonated.  The correlation of charge with binding is a 
common theme in aminoglycoside binding, and emphasizes the potential problems in 
achieving binding specificity.  Nevertheless, the utilization of aminoglycosides to HIV-1 
based hybrid duplexes offers an exciting new area to explore in efforts to combat viral 
infections.   
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Figure 1.25  Computer generated models of neomycin binding to A-form DNA (left) 
compared with B-DNA (right).  Note the groove complementarity of neomycin with the 
A-DNA major groove as compared with the B-DNA groove. 
 
 DNA/RNA hybrid duplexes can be targeted by TFOs to form a hybrid triplex 
structure.  The TFO in hybrid triplex can consist of a DNA or RNA strand 
complementary to either strand of the duplex
122
 (consider the examples 
poly(rA)•2poly(dT) and 2poly(rA)•poly(dT) that have been shown to exist).123 As with 
small ligands that bind hybrid duplex, TFOs may produce similar results concerning the 
prevention of key biological events involving hybrid structures.  In fact, stable hybrid 
triplex formation has been shown to inhibit RNA polymerase,
122
 RNase,
124
 and DNase 
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I.
124
  However, the formation of such triplex structures requires molar salt concentrations.  
Recent studies have circumvented this requirement by introducing neomycin.  Neomycin 
was shown to induce the hybrid triplex structures poly(rA)•2poly(dT) and 
2poly(rA)•poly(dT) using a series of spectroscopic techniques.125  The induction and 
binding of this groove-binding ligand occurred at low micromolar neomycin 
concentrations and low millimolar sodium concentrations.  In concert with binding to 
hybrid duplex structures, a common theme started to emerge regarding the structural 
preference of aminoglycosides such as neomycin.  Not only does neomycin binding occur 
with complex RNA structures, but to triple helical DNA and hybrid duplexes and 
triplexes.  The emerging structural theme was A-form nucleic acids.   
 
A-form nucleic acids 
Recently competition dialysis was utilized to explore neomycin’s binding 
preference among a number of different nucleic acid structures.
126
  It was found that, as 
expected, neomycin binds RNA structures, including a 16S A-site construct and RNA 
duplexes and triplexes.  However, other non-RNA structures were found to bind 
neomycin.  These included not just DNA/RNA hybrids and DNA triplexes, but also 
tetraplex structures and poly(dG)•poly(dC) duplex.  The initial feeling from these 
experiments were that, as expected, neomycin’s promiscuity for binding different nucleic 
acid structures were not an exception to this assay.  However, a deeper investigation of 
the literature prompted an exciting discovery.  Though known for RNA, all “unexpected” 
structures that displayed binding in the competition assay have been shown to possess A-
like conformations.  For example, cations such as aminoglycosides have been shown to 
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induce the B-A transition in dG•dC rich sequences such as poly(dG)•poly(dC),127,128 and 
CD studies have shown tetraplexes to possess A-like conformations.
129
 These results 
unraveled the ties that held RNA structures together as the specific site for 
aminoglycoside recognition.  While not questioning the mode of action of 
aminoglycosides to rRNA, the chemical principles behind aminoglycoside-nucleic acid 
binding warrants concern. It is not just RNA, but A-like conformations of nucleic acids 
that aminoglycosides such as neomycin prefer to bind.  A clear representation of 
neomycin binding to an A-form structure, compared with B-DNA, is depicted in Figure 
1.25. 
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Figure 1.26  Structure of a Cu
2+
-Kanamycin complex with nucleic acid cleavage 
properties.
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Figure 1.27.   Oxidative cleavage of DNA by C 1H (top) or C 4H (bottom) pathways by 
Cu
2+
-aminoglycosides.
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Aminoglycosides as Cleaving Agents 
The hydroxyl groups in aminoglycosides have been exploited as metal donors in 
their complexation with copper. Such “metalloaminoglycosides” as Cu2+-kanamycin 
(Figure 1.26) has shown promising cleavage activity with both RNA and DNA.  
Efficient and specific cleavage of an RNA aptamer has been achieved at physiological 
pH and temperature by a Cu
2+
-kanamycin complex.
130
  The absence of cleavage of other 
RNA structures such as poly(C) and poly(rA)•poly(rU) confirmed the specificity of the 
kanamycin complex.  Because RNA binding is structure-specific and not sequence-
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specific, such structural recognition by these aminoglycoside complexes has advantages 
over artificial ribonucleases based on oligonucleotide-Lewis acid conjugates.  Further in 
vivo studies have indicated that targeted cleavage can occur at concentrations where 
aminoglycosides alone show translation inhibition.
130
 Cu
2+
-kanamycin complexes have 
also been shown to catalytically cleave DNA via oxidative (1.27) and hydrolytic 
pathways.
131,132
 Both Cu
2+
-kanamycin and Cu
2+
-neamine complexes were also shown to 
display a greater than million-fold rate enhancement of DNA cleavage, approaching that 
of enzymes.
131
 
 
Other aminoglycoside targets: the Anthrax Lethal Factor 
 A recent discovery out of Wong’s laboratory involves the inhibition of the 
Anthrax Lethal Factor protein, one of three plasmid-encoded proteins responsible for 
anthrax development.
54
  Among a library of 3000 compounds studied, neomycin was 
found as the most potent in inhibitory activity (Ki = 7 nM).  Interestingly, a further 
comparison of dimeric neomycin derivatives (see Figure 1.18) indicated neomycin was 
still the most potent, though dimeric aminoglycosides bind the 16S A-site more strongly.  
These interesting findings further illustrate the potential for utilizing aminoglycoside-
based structures for targeting not just RNA, but DNA and proteins as well.  As with the 
rest of the structural targets for neomycin, both charge and shape complementarity to the 
protease active site contributes to its binding.   
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CHAPTER 2 
 
DUAL RECOGNITION OF B-DNA BY NOVEL NEOMYCIN COJUGATES 
 
Introduction 
Neomycin represents the aminoglycoside family as a molecule with high affinity 
for a number of different nucleic acid structures.  Findings from our labs have lengthened 
the list of nucleic acids that neomycin is known for binding.  Initial studies of 
aminoglycoside-triplex DNA interactions found neomycin to be the first example of a 
groove binding ligand that significantly and specifically stabilizes triplex DNA over 
duplex DNA.
105,108
 An enhancement in triplex binding was later illustrated through the 
development of neomycin-intercalator conjugates.
109,110
 Together with RNA:DNA hybrid 
studies
133
 and competition dialysis experiments
126
 we eventually discovered that  
aminoglycoside affinity is not restricted to RNA, but nucleic acids that are known to 
adopt A-like conformations.   These exciting results led us to further explore neomycin’s 
utility in nucleic acid recognition by shifting focus on nucleic acids that adopt B-form 
conformations; namely, DNA.
134
  The successful targeting of the B -DNA major groove 
has been elusive.  The design of a ligand that specifically targets this groove could 
potentially inhibit protein interactions necessary for undesirable gene expression.  To this 
end, we envisioned neomycin’s delivery to the major groove by attaching it to a DNA 
minor groove binder. 
 In the delivery of neomycin to B-DNA, we opted for covalently linking neomycin 
with Hoechst 33258, a well known minor groove binding ligand with particular affinity 
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for A/T bases.  A number of research endeavors have utilized Hoechst 33258 derivatives 
for probing the DNA recognition principles that guide the observed binding by such 
minor groove binding ligands.  An iodinated phenol derivative of Hoechst 33258 has 
been shown to enhance ligand biodistribution into tumor cells.  The conjugation of 
Hoechst 33258 with other DNA-interactive moieties has also proven successful and 
display enhanced binding properties over Hoechst 33258 alone.  A porphyrin-Hoechst 
has been shown to significantly stabilize DNA oligomers.
135
 McLaughlin has shown that 
conjugation of Hoechst 33258 to DNA
136-139
 via a hexaethylene glycol phosphate linkage 
significantly enhance DNA stability up to 16 
o
C.
137
  Hairpin structures of polyamides 
containing pyrrole moieties have been covalently attached to Hoechst derivatives to result 
in minor groove binding ligands that specifically bind up to nine consecutive A/T base 
pairs.
140,141
  Polyamine-Hoechst conjugates, termed “microgonotropens,” were found to 
significantly enhance DNA stability and display significantly higher association constants 
when compared with Hoechst 33258 alone. 
142,143
  The polyamine tether of these 
conjugates was believed to extend from the minor groove and electrostatically interact 
with the lower strand phosphate regions and possibly major groove base contacts. 
 Since polyamines such as spermine and spermidine have been shown to bind 
within the DNA major groove, and recognizing neomycin’s polyamine nature, we 
embarked on an investigation of the potential for neomycin to bind within the major 
groove of DNA.  The potential exploitation of neomycin binding to the DNA major 
groove would thus be insightful for ultimately defining the atomic and molecular 
requirements for major groove recognition of DNA.   
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Design and Synthesis of Neomycin-Hoechst 33258 Conjugates 
Hoechst 33258 was chosen as the minor groove binder for conjugation with 
neomycin for two primary reasons: (1) Hoechst compounds significantly fluoresce upon 
sequence-specific (A/T base pairs stretches) DNA binding, allowing for equilibrium 
binding studies at low (nM) concentrations; (2) Ease of synthetic modification at the 
terminal phenol. Other minor groove-binding ligands lack such a combination.  For 
example, the fluorescence of polyamides is significantly lower and changes in 
fluorescence upon DNA binding are not significant.  Often fluorescence assays involve 
competition experiments with Hoechst compounds to monitor changes in the Hoechst 
signal.
141
 Secondly, ligands that do significantly fluoresce either lack terminal positions 
for straightforward chemical modification or are intercalators, lacking sequence 
specificity.   
For conjugation with Hoechst 33258, we opted for chemistry at the phenol 
position.  Conventional DNA binding studies with Hoechst derivatives have utilized this 
pathway, largely due to the ease of modification and the crucial role of the piperazine.  
The piperazine region of Hoechst 33258 plays an important role in its sequence 
specificity in binding to d(CGCGAATTCGCG)2 and d(CGCAAATTTGCG)2.  Largely 
characterized as an A-T rich binding ligand, Hoechst 33258 has been shown to bind a 
terminal G-C base pair adjacent to an A/T rich stretch.
144-146
   Crystal structures of the 
complex have indicated significant interaction of the bulky piperazine with the 
neighboring G-C base of an A-T stretch.  The interaction is electrostatic, due to the 
protonated terminal amine.  Such G-C recognition by piperazine has been observed with 
other DNA-interactive ligands.  A recent analysis of the terminal groups of minor groove 
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binding ligands, including Hoechst 33258, emphasizes the importance of the piperazine 
region in DNA recognition.
147
 Substitution with an N-dimethylaminopropylcarboxamide 
group has shown considerable binding with higher A/T specificity, lacking the terminal 
G-C base pair recognition and further illustrating the importance of piperazine in 
sequence specificity.
148
  Substitution with a piperidine moiety
149
 has indicated a lack in 
binding, also indicating the necessity for the terminal cationic ammonium group. 
In determining the linker between Hoechst 33258 and neomycin, we explored two 
extremes.  One involved a short linker with minimal number of atoms between the two 
binding moieties.  The other involved a longer and more flexible linkage.  Structures are 
shown in Figure 2.1.  Both choices were examined using molecular modeling 
(MacroModel) with d(CGCAAATTTGCG)2. The modeling was performed using Amber 
force field, water as solvent, and under constant dielectric conditions.  Structural 
minimizations converged on a gradient to within 0.02 kJ/mol.  For the short linker, we 
found that a pentane moiety separating the two reactive positions (of Hoechst and 
neomycin) gave the optimum binding without significant departure from either binding 
moiety within its respective groove (Figure 2.1, left).  In investigating the longer linker, 
we found hexaethylene glycol to be a suitable linker (Figure 2.1, right).  In examining 
this linker, considerable area separates the linker from both neomycin and Hoechst, 
though binding of these two remained intact.  Linkers longer than hexaethylene glycol 
induced considerable movement of neomycin from the groove.   
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Figure 2.1 Computer model of NH(10) (left) and NH(22) (right) binding to 
d(CGCAAATTTGCG)2.  The Hoechst region is shown in red, neomycin in green, and 
hexaethylene glycol linker in black.  DNA is in blue.  The modeling was performed using 
Amber force field, water as solvent, and under constant dielectric conditions.  Structural 
minimizations converged on a gradient to within 0.02 kJ/mol. Structures of the 
conjugates are displayed below their respective model.  Five of the six amines in 
neomycin were protonated, in agreement with NMR studies of neomycin.
150,151
 For all 
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conjugates, the number(s) in brackets (subscripted) denote the number of atoms 
separating the respective binding moiety and neomycin. 
 
Coincidentally the starting materials needed for developing this particular linker were 
available commercially.  Lastly, such choices in linker provide a stark contrasting 
comparison in terms of length and flexibility.  The higher entropic penalty in dual 
binding of NH(22) is apparent when considering the significantly greater conformational 
freedom in the hexaethylene glycol linker.  A close comparison of the model in Figure 
2.1 indicates a significant bend in the linker of NH(22), suggesting a somewhat 
constrained conformational requirement in delivering neomycin within the major groove.  
On the other hand, the shorter alkyl linkage in NH(10) is restricted to considerably less 
conformational possibilities, and yet the contacts of neomycin within the major groove, if 
considering all energy-feasible conformations of the linker, are not compromised to the 
degree that would be found in the hexaethylene glycol linker of NH(22).   
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Scheme 2.1  Synthetic scheme for the preparation of an electrophilic (isothiocyanate) 
derivative of neomycin. Reagents and conditions:  (i) di-tert-butyldicarbonate, NEt3, 
DMF, H2O, 91% (ii) 2,4,6-triisopropylbenzenesulfonyl chloride, pyridine, 71% (iii) 
aminoethanethiol, Na metal, EtOH, 76% (iv)  thiocarbonyldipyridone, CH2Cl2, DMAP, 
95%.  
 
The foundation of designing conjugates for dual-binding to nucleic acids is in our 
ability to prepare electrophilic derivatives of neomycin for the reaction with a 
nucleophilic DNA-interactive molecule.
152
 Utilizing reactions reported by Tor,
153
 the 
synthesis of an amino derivative of neomycin is accomplished:  Boc (t-butoxycarbonyl)-
protection of the six amino groups in neomycin sulfate followed by 5-TPS (2,4,6-
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triisopropylbenzenesulfonyl) derivatization at the 5-OH position and subsequent 
substitution of the 5-TPS by aminoethanethiol.  Further reaction of this “neo-amine” 
with TCDP (thiocarbonyldipyridone) results in the electrophilic isothiocyanate (Scheme 
2.1).  A thiourea connection between neomycin and a nucleophile may then prepared.  
Alternatively, an electrophilic agent can be reacted with the nucleophilic neomycin-
amine derivative to provide the desired conjugate.
110
 Using this technique, we have 
successfully prepared a number of neomycin conjugates with various interactive moieties 
(reported and unreported), from intercalators to triplex-forming 
oligonucleotides.
109,110,134,152,154
  The ability to prepare such derivatives opens the door 
widely for probing the effects of carbohydrates such as neomycin on different nucleic 
acid structures.      
Utilizing reported synthetic procedures for preparation of benzimidazole 
compounds such as Hoechst 33258, the initial task was to prepare a Hoechst 33258 
analog containing an appropriate amino-tethered linker at the phenol portion of the 
molecule.  Starting with commercially available p-cyanophenol 6, a Mitsunobu-type 
reaction with protected aminoalcohol (N-trifluoroacetamido protection of 5-
aminoalcohol)
155
 allowed for successful conversion of 7. The cyano group in compound 7 
was subsequently converted to its corresponding ethyl imidate ester using anhydrous HCl 
in absolute ethanol before coupling with 8 (prepared in 5 steps utilizing reported 
procedures)
149,156
  to give the desired Hoechst-linker component 9.  After trifluoroacetyl 
deprotection of 9, reaction with neomycin isothiocyanate 5 gave conjugate 11 after Boc-
deprotection of 10 using a 1:1 solution of CH2Cl2:trifluoroacetic acid and trace 
ethanedithiol.  Purity of 11 was checked using HPLC (gradient of acetonitrile in aqueous 
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0.1% TFA).  More often than not, the compound requires no further purification (prep 
LC), depending on the efficiency of the column chromatography separation of the Boc-
protected conjugate.  Characterization of 11 using MALDI-TOF mass spectrometry (M
+
), 
1
H NMR, and UV (max similar to Hoechst 33258) was done to validate the successful 
synthesis of conjugate 11. 
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Scheme 2.2  Reagents and Conditions:  (i) 5-trifluoroacetamido-1-pentanol, PPh3, DIAD, 
dioxane, r.t., 2h,  84%; (ii) (a) HCl(g), EtOH, 0 
o
C, quant.; (b) 2-(3,4-diaminophenyl)-6-
(1-methyl-4-piperazinyl)benzimidazole (8), HOAc, reflux, 4h, 38%; (b) K2CO3 in 5:2 
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MeOH:H2O, r.t., overnight, 94%; (iii) (a) isothiocyanate 5, pyridine, DMAP, 72%; (b) 
1:1 TFA:CH2Cl2, trace ethanedithiol, quant. 
 
UV Melting Study of NH(10) Binding to DNA 
 Due to neomycin’s significant enhancement on triplex DNA stability, initial 
experiments included triplex UV melting studies of our first conjugate, NH(10).  When 
mixed in a 2:1 ratio under appropriate salt conditions (150 mM KCl), poly(dT) can 
associate with poly(dA) to form a poly(dA)•2poly(dT) triplex.  Dissociation of the third 
poly(dT) strand from duplex poly(dA)•poly(dT) can be monitored with slow heating of 
the DNA sample accompanying UV absorbance measurements at 260 nm.  The “melting” 
of the triplex to duplex and single strand is represented by a hyperchromic transition in 
the absorbance vs. temperature profile, due to the loss of base stacking in the TFO.  A 
more pronounced transition at higher temperatures corresponds to duplex dissociation. 
Using first derivative analysis in the UV/Vis software provides the melting temperature 
(Tm), which represents the temperature where the helix is half dissociated.  Samples of 
nucleic acid in the presence of ligand may displays shifts in Tm values, indicating a 
destabilization (lower Tm than that in the absence of ligand) or stabilization (higher Tm 
than that in the absence of ligand).  The hyperchromism exhibited by the melting process 
is due to the loss of base stacking upon strand dissociation.  The observed UV absorbance 
of DNA accounts for interactions between the dipole transition moments (upon 
excitation) of the individual bases with the dipole moments of their nearest neighbors.  
Therefore, the absorbance depends not solely on the inherent transition moment of each 
base, which differs in both magnitude and direction with different bases, but also on the 
 50 
 
relative orientations of the neighboring bases.
157
  The end result is a shift in max for 
stacked bases vs. unstacked bases; stacked bases absorb less at 260 nm per nucleotide 
than unstacked (post-melting) bases. 
The thermal stability of poly(dA)•2poly(dT) in the presence of neomycin, 
Hoechst 33258, and NH(10) was first investigated.  It was found that the conjugate 
displays a marked effect on the stability of poly(dA)•poly(dT) duplex when compared to 
both neomycin (which is known to have no effect on the thermal stability of duplex 
DNA) and Hoechst 33258).   As depicted in Figure 2.2, the dissociation of duplex DNA 
in the presence of NH(10) occurs at a higher temperature (>95
o
 C) than that of DNA in the 
presence of Hoechst 33258 (86 
o
C) and neomycin (72 
o
C, unchanged when comparing to 
native duplex melting), suggesting that the interaction between NH(10) is stronger than 
those between the individual parent compounds.   Samples containing both neomycin and 
Hoechst 33258 displayed no difference in Tm from that observed with the individual 
molecules. It is important to note that clear triplex melting was not observed for 
poly(dA)•2poly(dT) in the presence of the conjugate NH(10) under these conditions (2M 
ligand). This suggests that duplex binding upon annealing prevents the third strand 
polypyrimidine from binding in the major groove.  Further support was found in a 
concentration-dependent melting study with NH(10), in which the melting transition is 
seen to gradually decrease (Figure 2.3). These results strongly supported the concept of 
dual groove-binding, where Hoechst 33258 rests in the minor groove while the tethered 
neomycin region docks within the major groove.   
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Figure 2.2.  UV melting profiles of poly(dA)•2poly(dT) with various ligands.  Samples 
of DNA (15 M) were mixed with ligand (2 M) in buffer (10 mM sodium cacodylate, 
0.5 mM EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow 
annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument software. 
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Figure 2.3.  UV melting profiles of poly(dA)•2poly(dT) with increasing concentrations 
of NH(10).  Samples of DNA (15 M) were mixed with ligand (0.5 to 1.25 M) in buffer 
(10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 to 
95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis 
using instrument software. 
 
Synthesis of NH(22) 
The reaction scheme for the preparation of Hoechst-HEG-amine derivative is 
depicted in Scheme 2.3.  A Mitsunobu reaction of hexaethylene glycol 12 with p-
cyanophenol was carried out according to a reported procedure.
139
 Tosylation of the 
terminal hydroxyl, azide substitution with subsequent reduction afforded the terminal 
amine, which was protected as a trifluoracetamide before forming the ethyl imidate ester 
(17) and coupling with 8.  Deprotection of 18 and reaction with neomycin isothiocyanate 
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(5) were done in similar fashion to the previous conjugate (Scheme 2.2).  
Characterization using NMR, UV absorbance, MALDI-MS confirmed product of 
significant purity (HPLC). 
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Scheme 2.3.  Reagents and conditions: (i) p-cyanophenol, PPh3, DIAD, dioxane, 51%; 
(ii) (a) TsCl, CH2Cl2, NEt3, 72%;  (b) NaN3, DMF, NaI, 86%; (c) H2, 10% Pd/C, EtOH, 
68%; (d) trifluoroacetic anhydride, CH2Cl2, pyridine, quant.; (iii) HCl(g), EtOH, quant.; 
(iv) 8, HOAc, 20%. 
 
  
 54 
 
OHO
HO
NO
O
RHN
NHR
OH
O
OHOO
NHR
OH
OH
RHN
NHR
S
N
H
S
(i) Neo-NCS, pyr., DMAP
(ii) TFA/CH2Cl2
19
N
N
N
H
N
N
HN
O
O
O
O
O
NH2
N
N
N
H
N
N
HN
O
O
O
O
N
H
20  R = Boc
21  R = H "NH(22)"
O
O
O
H
R
 
 
Scheme 2.4  Reagents and conditions: (i) pyridine, DMAP, 52%; (ii) 1:1 TFA:CH2Cl2, 
94% 
 
Comparison Binding Study of NH(10) vs. NH(22) 
 
Poly(dA)•2poly(dT) 
UV melting studies with poly(dA)•2poly(dT) were first done to analyze NH(22) 
binding.  As shown in Figure 2.4, substantial differences between NH(10) and NH(22) are 
apparent.  Given that Hoechst 33258 alone significantly stabilizes poly(dA)•poly(dT), it 
is likely the Hoechst moiety in the conjugates that drives the binding to DNA. The longer 
hexaethylene glycol linker in NH(22) therefore gives the neomycin region a larger region 
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for interaction with either DNA or solvent medium.  The observation that a slight 
decrease in Tm occurs for NH(22) when compared to Hoechst 33258 (Figure 2.3) suggests 
the longer and more flexible linker in effect diminishes the tandem binding contributions 
of each moiety.   
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Figure 2.4  UV melting profiles of poly(dA)•2poly(dT) with NH(10) and NH(22).  Samples 
of DNA (15 M) were mixed with ligand (2 M) in buffer (10 mM sodium cacodylate, 
0.5 mM EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow 
annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument software. 
 
Alternatively, NH(10), possessing a shorter, alkyl linker, greatly shifts the Tm when 
compared to Hoechst 33258 (greater than 11 
o
C).  The geometrical explanation likely lies 
with the (relatively) short linker docking the neomycin in good proximity within the 
major groove, with significantly less freedom than that envisioned with the longer and 
more flexible hexaethylene glycol linker.  The interactions of neomycin within the major 
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groove are driven by Hoechst binding (in NH(10)).  Also, as observed previously, both 
conjugates exhibited diminished triplex melting profiles, indicative of major groove 
binding and thus blockage of third strand binding to the duplex upon sample preparation 
(slow annealing from 95 
o
C) 
 
Oligomeric Duplexes 
 To test the effect of the conjugates on oligomeric DNA duplex stability, UV 
melting profiles of d(A)22•d(T)22  in the absence and presence of various ligands (Figure 
2.5), including conjugates NH(10) and NH(22), were gathered in similar fashion to that 
done with polymeric DNA.  A similar effect to that observed with poly(dA)•poly(dT) 
was observed.  Melting of d(A)22•d(T)22  alone gives a Tm of 51 
o
C, whereas in the 
presence of Hoechst 33258 the duplex transition occurs at 67 
o
C (Tm = 16 
o
C).  Both 
conjugates displayed a significant increase in Tm when compared to Hoechst 33258.  For 
NH(22), a Tm of 72 
o
C was observed.  However, the melting profile under these conditions 
(1 M duplex-1 DNA, 3 M ligand) for NH(22) was biphasic: a transition at 51 
o
C was 
observed, signifying the melting of unbound ligand.  Therefore, the saturation of DNA 
was not met with NH(22) under such conditions where both Hoechst 33258 and NH(10) 
display a monophasic transition (indicating saturation).  Such an observation is good 
indication of the diminished binding of the conjugate due to linker flexibility rendering a 
virtual competition for binding by the individual Hoechst and neomycin moieties.   
A comparison was then made with a self-complementary DNA duplex 
d(CGCAAATTTGCG)2 well known for Hoechst 33258 affinity.
158
 UV melting (Figure 
2.6) of the DNA with NH(22) showed similar effect to Hoechst 33258, with Tm = 14 
o
C, 
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much less than that with NH(10) (Tm = 25 
o
C).  The observed melting for the 12mer 
duplex was in excellent agreement with that reported.
158
  
As depicted in Figures 2.5 and 2.6, the UV melting profiles of oligomeric DNA 
such as d(A)22•d(T)22  and d(CGCAAATTTGCG)2 exhibit a relatively broad transition 
representing the dissociation of duplex structure to individual strands.  Early theoretical 
studies of polynucleotides used a one-dimensional Ising model to describe the melting 
nature of the duplex, where the sharpness of the transition was governed by two factors, 
namely, the enthalpy of the transition and the “helix interruption” constant, often referred 
to as the cooperativity factor .159  A broad transition could be a consequence of a small 
H in the melting process or a large  value.  For example, some 40 years ago, 
Applequist and Damle showed that the melting of the self-associated helix of poly(A) is 
characterized by a very broad transition between 0 
o
 and 90 
o
C.
160
  Although the H for 
the transition was found to be large, the value of  was large as well.  Thus, the melting 
was deemed non-cooperative.  In the present case, the broader transitions characterized 
by oligonucleotides are due not to non-cooperativity, since oligonucleotide melting 
transitions have classically been represented as an “all or none” event,160-162 but rather to 
the significantly lower H of dissociation due to the much smaller number of base pairs 
(and consequently less number of favorable base-stacking interactions) than 
polynucleotide duplexes such as poly(dA)•poly(dT).  Numerous examples are found in 
the literature that show H of melting increases with helical length, with a notable 
example being that of Breslauer, who elegantly demonstrated that DNA duplex structures 
can thermodynamically be considered a sum of their nearest-neighbor pairwise 
interactions.
163
   Perhaps Crothers
164
 simplifies it best in stating “The qualitative aspects 
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of the transition can be understood from simple free-energy arguments.  Since the 
nucleation process is less favorable than helix growth, and since nucleation must be 
performed to make each separate helical section, the free energy will be minimized by 
sharply restricting the number of helical sections, with increased average length with 
those that are present.  In the limit of an infinitely difficult nucleation process 
(corresponding to  = 0), boundaries between helix and coil would be suppressed 
entirely, and the system would show a phase transition from helix to coil at a discreet 
temperature.   Thus when is small but nonzero, a transition that is sharp but finite 
breadth results.”  In this particular case, Crothers uses the equation eG/RT to explain 
the cooperativity factor.  Crothers also notes an additional factor that contributes to the 
breadth of the melting transition of the oligomeric duplex lies with the presence of G-C 
base pairs, which are known to broaden transitions due to the propensity of G-C base 
pairs to melt at higher temperatures than A-T base pairs.
164
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Figure 2.5   UV melting profiles of d(A)22•d(T)22  with various ligands.  Samples of 
DNA (1 M in duplex) were mixed with ligand (3 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 6.8) before heating at 95 
o
C for 5 minutes 
and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating 
rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument 
software. 
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Figure 2.6 UV melting profiles of d(CGCAAATTTGCG)2 with various ligands.  
Samples of DNA (1 M in duplex) were mixed with ligand (1 M) in BPES buffer (6 
mM Na2HPO4, 2 mM NaHPO4, 1 mM EDTA, 185 mM NaCl, pH 7.0) before heating at 
95 
o
C for 5 minutes and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 
to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative 
analysis using instrument software. 
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Circular Dichroism Study 
We utilized circular dichroism (CD) spectroscopy to study the conformational 
changes, if any, in the poly(dA)•poly(dT) structure as well as in the Hoechst moiety of 
the conjugate.  Circular dichroism is the difference in absorption between left and right 
circularly polarized light.  The resulting spectrum of a sample exposed to circularly 
polarized light is in the wavelength region where chromophores absorb light.  Because 
chiral molecules have no plane of symmetry, the independent interactions of left- and 
right-handed photons of circularly polarized radiation with an asymmetrical environment 
will be different.  Therefore, chiral molecules such as nucleic acids have characteristic 
CD spectra.  Such spectra often can be used in identifying the adopted conformations of 
unknown nucleic acid structures or of those due to ligand binding.
126
  Numerous reports 
have explained binding-induced chirality of Hoechst 33258 by DNA, typically indicated 
by a change in CD signal at the max of Hoechst 33258 UV absorbance.
165,166
  The 
circular dichroism spectrum of Hoechst 33258 bound to DNA indicates an induced 
chirality of Hoechst 33258 as it conforms to maximize favorable contacts within the 
minor groove.  The resulting CD profile indicates a positive increase in CD signal in the 
Hoechst absorbance region (300-400 nm) and is a thus result of the absorbance of one 
direction of circularly polarized light over the other (clockwise vs. counter-clockwise).   
In our studies, we carried out titrations of ligand into a solution of DNA, with CD 
scans of the solution taken after appropriate equilibration times between ligand additions.  
The resulting scans were overlayed to compare the CD spectra at different ligand:DNA 
ratios (Figures 2.7-2.9).  We found that there is a significant change in the CD signal in 
the poly(dA)•poly(dT) region, which is represented by a negative band at 248 nm and a 
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positive band at 260 nm.  Also, in the region of 360 nm, there is an increasingly positive 
CD signal as ligand:DNA ratios are increased, indicative of Hoechst complexation with 
the DNA.  Such a signal would be absent if no interaction is occurring.  In all cases 
(Hoechst 33258, NH(10), and NH(22)), signals corresponding to Hoechst complexation 
were observed. 
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Figure 2.7  CD scans of poly(dA)•poly(dT) with increasing concentrations of Hoechst 
33258.  Samples of DNA (40 mM) were scanned from 400-210 nm after serial additions 
of concentrated ligand with stirring.  Peaks around 360 nm correspond to ligand-DNA 
complexation. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; 
T = 20 
o
C. 
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Figure 2.8  CD scans of poly(dA)•poly(dT) with increasing concentrations of NH(10).  
Samples of DNA (40 mM) were scanned from 400-210 nm after serial additions of 
concentrated ligand with stirring.  Peaks around 360 nm correspond to ligand-DNA 
complexation. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; 
T = 20 
o
C. 
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Figure 2.9 CD scans of poly(dA)•poly(dT) with increasing concentrations of NH(22).  
Samples of DNA (40 mM) were scanned from 400-210 nm after serial additions of 
concentrated ligand with stirring.  Peaks around 360 nm correspond to ligand-DNA 
complexation. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; 
T = 20 
o
C. 
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Figure 2.10  Fluorescence titration of NH(10) (left) and NH(22) (right) into 
poly(dA)•poly(dT).  Small aliquots of concentrated ligand were added to DNA (2 M) 
before fluorescence analysis (excitation at 345 nm, emission scanning from 370-600 nm 
at 1 nm/s; 4 nm slit width; T = 25 
o
C). Buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 150 mM KCl, pH 7.2. 
 
 
Fluorescence Study of NH(10) and NH(22) Binding  
 Upon binding to DNA, Hoechst 33258 exhibits a significant fluorescence 
enhancement,
167
 due presumably to the loss of solvent exposure upon snugly binding 
(van der Waals and H-bonding forces) within the DNA groove.
168
  An established DNA 
minor groove binder with A/T base pair specificity, Hoechst 33258 was discovered in the 
early 1990s to display multiple binding modes to polymeric DNA.
169
 Binding constants 
were found to be in the order of 10
8
 (M
-1
) for the sequence specific interaction (A/T 
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stretch of 4-5 base pairs). Fluorescence titrations of the novel conjugates, as well as 
Hoechst 33258, with poly(dA)•poly(dT) were carried out in similar fashion to that 
reported.
35,170,171
 The experiments typically consisted of titrations of fixed ligand (10 nM) 
with a concentrated DNA sample, with fluorescence emission scans gathered at each 
ligand:DNA ratio after the appropriate equilibration time.  The resulting binding isotherm 
could then be fit to a theoretical model, providing binding constants (Kb) for the 
respective ligands.  Because of multiple binding modes of Hoechst 33258 with polymeric 
DNA, with stoichiometries up to 2:1 for ligand:phosphate,
170
 titrations of low (nM) 
ligand concentration with DNA to yield low ligand:DNA ratios were carried out to 
simulate nearly independent-site binding characteristics.  In this approach, the low 
ligand:DNA exhibits a fluorescence signal corresponding to a sequence-specific binding 
event.  Thus, the resulting binding curve can be fit using an independent site model for 
tight binding, provided the binding site size, N, is known.  Once N is known, the DNA 
(b.p.) concentrations at each titration point can be divided by N to provide the binding 
site size that is necessary for determining binding constant data. 
  We determined stoichiometries of 9:1 for DNA (base pairs) binding to both NH(10) 
and NH(22) (Figure 2.10) by titrating concentrated ligand solutions into DNA and 
monitoring fluorescence changes.
172
 The differences in fluorescence at high ligand 
concentrations illustrate the differences in binding between the two conjugates.  The 
quenching of fluorescence of higher ligand concentrations (Figure 2.10, left) is due to 
aggregation of free ligand to bound ligand, and has been observed before with Hoechst 
33258.
169
  However, NH(22) fluorescence at high [NH(22)] gradually increases, a testament 
to weaker binding by neomycin; Neomycin’s freedom outside of the groove may prohibit 
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(free) Hoechst entry to bind bound Hoechst due to charge repulsion between the 
protonated Hoechst and multi-protonated neomycin and/or the glycol linker. 
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Figure 2.11  Fluorescence-detected binding of poly(dA)•poly(dT) + Ht 33258.  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 2.12  Fluorescence-detected binding of poly(dA)•poly(dT) + NH(22).  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 2.13  Fluorescence-detected binding of poly(dA)•poly(dT) + NH(10).  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 2.14  Fluorescence Job plot of Hoechst 33258 and d(CGCAAATTTGCG)2.  
Equimolar solutions (0.9 M) of both ligand and DNA were mixed in varying ratios and 
analyzed for fluorescence emission. Conditions: exc = 338 nm; slits = 2 nm; T = 20 
o
C; 
buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 180 mM NaCl, 2 mM Na2EDTA, pH 
7.0). 
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Figure 2.15  Fluorescence Job plot of NH(10) and d(CGCAAATTTGCG)2.  Equimolar 
solutions (0.9 M) of both ligand and DNA were mixed in varying ratios and analyzed 
for fluorescence emission. Conditions: exc = 338 nm; slits = 2 nm; T = 20 
o
C; buffer: 
BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 180 mM NaCl, 2 mM Na2EDTA, pH 7.0). 
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Figure 2.16   Fluorescence-detected binding of d(CGCAAATTTGCG) 2  + Ht33258. 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were prepared immediately after quantitation of both stock ligand and DNA 
solutions.  After sufficient mixing of solutions and equilibration time (30 minutes), each 
sample was analyzed for fluorescence emission over the 390-600 nm range. Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 
180 mM NaCl, 2 mM Na2EDTA, pH 7.0).  
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Figure 2.17  Fluorescence-detected binding of d(CGCAAATTTGCG) 2  + NH(10). 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were prepared immediately after quantitation of both stock ligand and DNA 
solutions.  After sufficient mixing of solutions and equilibration time (30 minutes), each 
sample was analyzed for fluorescence emission over the 390-600 nm range. Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 
180 mM NaCl, 2 mM Na2EDTA, pH 7.0).  
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Figure 2.18 Fluorescence-detected binding of d(CGCAAATTTGCG) 2  + NH(22). 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were prepared immediately after quantitation of both stock ligand and DNA 
solutions.  After sufficient mixing of solutions and equilibration time (30 minutes), each 
sample was analyzed for fluorescence emission over the 390-600 nm range. Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 
180 mM NaCl, 2 mM Na2EDTA, pH 7.0).  
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 poly(dA)•poly(dT)   A3T3 
conjugate K (x 107) N  K (x 107) 
Ht33258 11 + 1.0 10  18 + 5.0 
NH(10) 16 + 1.0 16  3.6 + 0.7 
NH(22) 3.4 + 0.9 16  0.5 + 0.3 
 
Table 2.1.  Fluorescence-based binding data for ligands studied.  Values for Kb were 
determined by nonlinear curve fitting of fluorescence titrations according to an 
independent site model using conditions similar to those reported. Values for N (binding 
site size) were either used as reported (Ht33258) or determined experimentally (Figure 
2.10). 
 
Results from fluorescence experiments with poly(dA)•poly(dT) are shown in 
Figure 2.11-13.  For both Hoechst 33258 and NH(10), a significant enhancement in 
fluorescence is observed.  However, a marked decrease in fluorescence change is 
noticeable for NH(22), likely due to reasons described above.  The observed binding 
constant for NH(10) was found to be slightly higher than Hoechst 33258 (1.1x10
8
 M
-1
, in 
close agreement (2.6x10
8
 M
-1
) to that observed previously), with a value of Kb = 1.6x10
8
 
M
-1
.  Binding data for NH(22) was approximately 3-fold lower than NH(10).  These results 
further corroborate the observed stabilization data (UV melting experiments) in the 
comparison of NH(10) versus NH(22).  The NH(10) conjugate is clearly a stronger binding 
agent than NH(22). 
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 The molecular modeling studies (Figure 2.1) clearly illustrated the potential for 
multiple interactions between the neomycin-Hoechst 33258 conjugates and 
d(CGCAAATTTGCG)2.  Furthermore, UV melting studies clearly indicated neomycin’s 
role in stabilizing the duplex to a larger degree than Hoechst 33258.  Whereas NH(10) 
stabilizes the DNA by nearly 11 
o
C higher than Hoechst 33258, NH(22) is less remarkable.  
We then found it necessary to study the binding further using isothermal fluorescence 
binding titrations.   
 Fluorescence titrations of d(CGCAAATTTGCG)2 with Hoechst 33258, NH(10), 
and NH(22) were done in similar fashion to that reported previously.  This duplex 
maintains the central A3T3 region of which Hoechst 33258 is known to bind in a 1:1 
fashion.  By conducting mixing curves (Job plots), where individual solutions of identical 
summed concentrations but at different [ligand]:[DNA] ratios were monitored by 
fluorescence, breaks at the 50:50 ratio clearly indicated a 1:1 stoichiometry of binding by 
Hoechst 33258 and the conjugates (Figure 2.14 and 2.15).  In obtaining the binding 
isotherms, individual samples of varying ligand:DNA ratios but with constant ligand 
concentration were analyzed for fluorescence in similar fashion to those done for 
polymeric DNA.  It is worth mentioning that single sample titrations, as done with 
polymeric DNA, gave less reliable results likely due to sample equilibration.  
Fluorescence scans and binding curves for both NH(10) and NH(22) are shown in Figure 
2.16 and 2.17.  Hoechst 33258 binding was found to be in good agreement with that 
reported previously.  However, NH(10) binding was clearly lower than Hoechst 33258 
(nearly six-fold, 3.6x10
7
 M
-1
) and NH(22) even less (nearly 40-fold, 5x10
6
 M
-1
). These 
results were quite surprising considering the aforementioned UV melting data.  However, 
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such a phenomenon has been observed recently with similar Hoechst-type molecules, 
emphasizing that association constants are temperature dependent, and that a direct 
correlation between enhanced thermal stability and increased binding affinity under 
isothermal conditions may not exist in many instances.
173
  One must, therefore, consider 
the binding of the ligand at elevated temperature and its effects compared with other 
ligands.  It is highly likely that at high temperatures NH(10) binding is stronger, possibly 
due do conformational changes in the DNA that favors stronger neomycin binding, than 
Hoechst 33258 alone.   
 Also apparent is the relationship of binding constant with DNA sequence.  NH(10) 
clearly displays stronger binding to poly(dA)•poly(dT) in both isothermal fluorescence 
and UV melting experiments.  A contrasting relationship between Tm and Kb are obvious 
with d(CGCAAATTTGCG)2.  The likely explanation for the lower Kb for NH(10) binding 
to this DNA is with the neighboring G/C basepairs that are less favorable binding 
domains for neomycin.  As illustrated in Figure 2.10, the conjugates prefer a site of nine 
A/T base pairs.  Therefore, the diminished binding site in (six base pairs, A3T3) may be 
the most plausible explanation for lower isothermal binding constants. 
 
Breaking up the A/T stretch: Study of d(CGCAAGCTTGCG)2 
 We found it interesting to probe the affinity of Hoechst 33258 and the novel 
neomycin conjugates for sequences in which the AnTn stretch is interrupted with a GC 
junction.   Hoechst 33258 has been shown in numerous reports to bind stretches of A/T 
from four to six base pairs in length.  Introduction of a G/C base pairs has been shown to 
significantly lower the binding of Hoechst 33258.  Therefore, by studying a sequence 
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containing the GC junction can provide deeper insight to neomycin’s role in binding.  For 
example, could neomycin binding perturb the DNA to accommodate Hoechst binding? 
To this end, we chose the DNA duplex d(CGCAAGCTTGCG)2 for study. 
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Figure 2.19  Fluorescence-detected binding curves of d(CGCAAGCTTGCG)2  binding 
to Hoechst 33258 (left) and NH(10) (right).  Individual samples of ligand (100 nM in 2 
mL) mixed with varying concentrations of DNA were prepared immediately after 
quantitation of both stock ligand and DNA solutions.  After sufficient mixing of solutions 
and equilibration time (30 minutes), each sample was analyzed for fluorescence emission 
over the 390-600 nm range. Conditions: exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: 
BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 180 mM NaCl, 2 mM Na2EDTA, pH 7.0).  
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Fluorescence titration experiments of d(CGCAAGCTTGCG)2 with Hoechst 
33258 and NH(10) were carried out in similar fashion to those with the central A3T3 
stretch.  In both cases, the observed Kb values were very similar, but significantly lower 
than that observed for d(CGCAAATTTGCG)2.  The binding is nearly 1000-fold lower 
for both Hoechst 33258 and NH(10) (Figure 2.18), validating previous accounts 
illustrating the strong binding preference of Hoechst ligands for AnTn regions of DNA.  
NH(10) appears slightly less attracted (1.5x10
5
 M
-1
) than Hoechst 33258 (3.7x10
5
 M
-1
) for 
DNA duplex. 
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Figure 2.20  UV melting profiles of d(CGCAAGCTTGCG)2 with various ligands.  
Samples of DNA (1 M in duplex) were mixed with ligand (1 M) in BPES buffer (6 
mM Na2HPO4, 2 mM NaHPO4, 1 mM EDTA, 185 mM NaCl, pH 7.0) before heating at 
95 
o
C for 5 minutes and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 
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to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined as the average of first 
derivative analysis (midpoint of transition) using instrument software. 
 
 However, UV melting experiments provided more interesting results.  Whereas 
Hoechst 33258 shows no effect on the Tm of the duplex, NH(10) exhibits a favorable 
binding interaction with this duplex, stabilizing the duplex with a Tm 5 
o
C higher than 
melting in the absence of ligand (Figure 2.20).  Therefore, neomycin’s role in binding to 
d(CGCAAGCTTGCG)2 (and quite possibly to the A3T3 analog given the high Tm 
versus Hoechst 33258) is clearly real.  Had no change in Tm occur, the question of 
neomycin’s activity in recognition of these oligomeric DNA remains unresolved, and 
likely attributed as a consequence of Hoechst 33258 localization within the minor groove 
only.  These results further support indications that binding constant and Tm data are 
not necessarily correlated.  NH(10) clearly exhibits binding to d(CGCAAGCTTGCG)2 in 
UV melting whereas Hoechst 33258 does not.  Yet, the observed equilibrium binding 
data indicate slightly less binding affinity for NH(10). 
 
The Potential for Targeting G-C rich DNA: Exploiting 
 Neomycin’s Preference for A-like Conformations 
 An earlier model (Figure 1.25) depicted neomycin’s structural complementarity 
with the A-form major groove.  Electrostatic potential maps of a GC rich DNA yield a 
somewhat obvious sign as to why such polyamines as neomycin can bind and induce B-A 
transitions in (continuous) G-rich stretches.  As shown in Figure 2.21, the major groove 
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of such DNA is largely negative, as opposed to that of DNA of either mixed base or A-T 
rich.   
  
 
Figure 2.21 Computer model of neomycin (left) and NH(10) (right) binding to 
d(GCGGGCCCGC)2.  The Hoechst 33258-DNA complex was extracted from pdb entry 
137d
174
 and further model building was done in MacroModel.  Energy minimization was 
carried out before and after linking the three binding moieties.  The surface potential 
rendering was accomplished by exporting the pdb file of the minimized structure into 
WebLabViewer Pro. 
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Thus, the attraction of the highly cationic neomycin (protonated amines give a +5 charge 
at physiological pH) to the negative potential in the major groove can be easily 
envisioned (Figure 2.21, left).  For this reason, there lies potential for utilizing neomycin 
and Hoechst to target sequences both G-rich in nature or stretches of DNA containing 
neighboring A-T and G-C stretches.  Figure 2.21 (right) depicts a model of NH(10) 
binding to d(GCGGGCCCGC)2.
174
  Further investigation of NH(10) with such DNA is 
warranted. 
 
 
Experimental Restrictions from Studying Hoechst-Related Compounds 
 
Isothermal titration calorimetry of DNA with Hoechst 33258  
and Neomycin-Hoechst 33358 conjugates 
 Initial studies of NH(10) and Hoechst 33258 binding to the 12mer duplex 
d(CGCAAATTTGCG)2 using isothermal titration calorimetry (ITC) were carried out.  
These efforts were to compare NH(10) binding to Hoechst 33258, and the procedure for 
doing so appeared straightforward given the extensive calorimetric studies reported by 
Haq and Chaires with the same ligand (Hoechst 33258) and DNA.  However, multiple 
attempts to reproduce ITC profiles of  Hoechst 33258 binding to d(CGCAAATTTGCG)2 
rendered the study unsuccessful.  All experimental data discussed below can be found in 
the Appendix. 
 The first attempts to gather reproducible binding isotherms and data strictly 
followed procedures in the recent publication.  The first experiment involved Hoechst 
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33258 titrated into a solution of d(CGCAAATTTGCG)2.  The ITC profile of this 
interaction looked very similar to that reported: a strong endothermic signal that gets 
weaker as ligand concentrations increase, ultimately becoming exothermic with apparent 
ligand saturation.  However, the correct binding profile required subtraction of the 
background signal, requiring a “blank” titration of ligand into buffer only.  To our initial 
surprise, a strong endothermic signal with gradual decrease to exothermic signal, as 
ligand concentrations increased, was the result.  Thus, the profiles of ligand-into-DNA 
and ligand-into-buffer looked very similar.  This was in contrast with that reported, which 
indicated a strong exothermic signal.   
 Further examination of the literature indicated a viable explanation for our 
observed titration signal for the ligand-into-buffer experiments.  A number of studies 
have indicated that Hoechst 33258 aggregates at low micromolar concentrations (approx. 
25 M).  Thus, as in our initial experiments (300 M Hoechst 33258) to exactly 
reproduce the recent calorimetry study, the concentrations of Hoechst 33258 were well 
above the minimum concentrations needed to avoid aggregation.  The observed ITC 
profile of ligand-into-buffer was envisioned to occur due to the following phenomena: (a) 
initial injection of concentrated ligand (300 M) into buffer results in a highly 
endothermic signal due to ligand-ligand dissociation upon dilution; (b) subsequent 
titration signal gradually become less endothermic due to exothermic contributions by 
free ligand (in the sample cell) binding to dissociated ligand (from titrant); (c) eventual 
exothermic signal due to increased ligand-ligand binding as a result of increased ligand 
concentration in the sample cell (past the minimum aggregation concentration).   
 83 
 
 The resulting binding isotherm, after ligand-into-buffer subtraction, indicated a 
complex pattern signal pattern which was unsuccessfully fit using the appropriate one-
site binding model in Origin 5.0 software provided with the instrument.  Again, this was 
in disagreement with that reported, which was shown to display a characteristic one-site 
binding pattern.  The culprit in yielding such a complex binding isotherm was attributed 
to the dynamic signal produced in the ligand-into-buffer titrations.  Therefore, efforts 
were made to combat these issues.  Particularly, lower salt concentrations, lower ligand 
concentrations, and a reverse titration (DNA into ligand) were all attempted to avoid 
ligand aggregation.  Numerous salt concentrations were attempted to no avail, as 
aggregation was still apparent.  Lower ligand (and thus, DNA) concentrations resulted in 
low binding signal, as characterized by a series of scattered points.  Finally, a reverse 
titration gave low signal, as the concentrations of DNA that were used also indicated 
significant aggregation, and resulted in a series of random points after data subtraction. 
 It should also be noted that a few attempts at analyzing NH(10) binding were also 
made at the beginning of the ITC study.  However, similar profiles to that of Hoechst 
33258 were observed, which prompted the experimental troubleshooting with Hoechst 
33258 only (to minimize use of the limited amounts of synthesized conjugate). 
 
Competition dialysis of Hoechst 33258 and NH(10) 
 A routine and powerful experiment utilized in our labs, among others, 
competition dialysis provides a straightforward answer to the question of binding affinity 
of one nucleic acid form over the other.  The technique involves a series of nucleic acids 
(DNA and RNA single strand, duplex, triplex, tetraplex, or other specific structures) that 
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are dialyzed against a constant (but in large mole excess) ligand concentration for a 
period of time (usually one day) to establish equilibrium.  The individual nucleic acid 
solutions can then be removed from their dialysis container and rinsed with detergent 
such as sodium dodecyl sulfate (SDS) to free up any bound ligand from its nucleic acid 
binding site.  Each sample of nucleic acid can then be analyzed via fluorescence to 
determine the concentration of free ligand found within.  This concentration corresponds 
to the bound ligand concentration (which is no longer bound due to SDS rinsing).  The 
result is a series of data relating bound concentrations to their respective nucleic acid 
form, which can be plotted in the form of nucleic acid versus bound ligand concentration 
to illustrate the binding preference of the ligand for one nucleic acid structure over others. 
 Competition dialysis has been used to determine the nucleic acid  preference for a 
number of small molecules.  The limiting factor in the technique is most visibly the 
requirement for a chromophore.  Hence, a neomycin study was impossible due to the lack 
thereof.  However, analysis of a neomycin-acridine conjugate, with comparison to other 
acridine derivatives, led our group to ultimately determine that neomycin preference is 
not just for RNA (as it is well-known to be), but for nucleic acids that are known to adopt 
A-form conformations (see Chapter 1 discussion).  Thus, the technique is very 
informative.   
 Initial binding experiments with NH(10) also involved competition dialysis 
experiments.  NH(10) was dialyzed against a series of nucleic acids and indicated a 
number of attractive binding structures.  However, efforts to reproduce the results 
suffered severely.  Like ITC experiments, further troubleshooting focused on Hoechst 
33258 to conserve NH(10).  At first sight, the observation that Hoechst 33258 binds 
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considerable to many plastics (except polystyrene) led to the acquisition of a polystyrene 
dialysis container.  This was envisioned to limit the possibilities of inconsistent amounts 
of Hoechst 33258 binding to the dialysis container, in turn altering nucleic acid binding 
results.  However, the problem in inconsistent data was not resolved.  Further 
experimentation of identical nucleic samples, up to three at a time, which were dialyzed 
against Hoechst 33258, resulted in inconsistent binding data: some samples indicated 
significant binding, while others shown none whatsoever.  Eventually, it was concluded 
that the infidelity of Hoechst 33258 binding to plastics was unavoidable, considering that 
the dialysis units and flotation device were all non-polystyrene plastics. The 
complications due to a combination of Hoechst 33258 binding to plastics and aggregation 
(and eventual precipitation, as mentioned in the experimental section) led us to abandon 
this technique altogether.  
 
Conclusion 
 We recently reported that neomycin affinity for nucleic acids includes structures 
known to adopt A-like conformations.  We have since endeavored to explore neomycin’s 
utility in binding to B-DNA to better understand the molecular forces that dictate binding 
within the DNA major groove.  From the current study of novel neomycin-Hoechst 
33258 conjugates designed for probing neomycin binding to B-DNA, the following 
conclusions can be drawn: (1)  NH(10) and NH(22) significantly enhance DNA stability.  
UV melting experiments with both polymeric and oligomeric DNA indicate significant 
shifts in Tm when compared with samples in the absence of ligand. (2) Triplex DNA 
inhibition by both NH(10) and NH(22) suggests dual groove binding.  UV melting 
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experiments of the conjugates under triplex-forming conditions indicate an inhibition of 
TFO binding, likely due to neomycin binding in the major groove.  Furthermore, 
viscosity experiments indicate neomycin (in NH(10) and NH(22)) binding on B-DNA 
involves a groove binding mode. (3) The binding mode for Hoechst to DNA is the same in 
all ligands studied.  Circular dichroism experiments indicate similar spectral patterns for 
poly(dA)•poly(dT) when titrated with either Hoechst 33258, NH(10), or NH(22).  (4) The 
optimal binding site for the conjugates includes a contiguous stretch of nine A-T base 
pairs.  Fluorescence titrations indicated base pair:ligand ratios of 9:1 for both NH(10) and 
NH(22).  A higher binding constant for NH(10) with poly(dA)•poly(dT) than Hoechst 
33258 was also observed.  The importance of the extended A/T site for strong binding 
was further illustrated in studies with both shorter A/T stretches and interrupted A/T 
stretches.  NH(10) binding to d(CGCAAATTTGCG)2 exhibited lower binding affinities 
than Hoechst 33258.  For both Hoechst 33258 and NH(10), Kb values were significantly 
less (but nearly equal) for the A2GCT2 duplex than for the A3T3 duplex.  (5) Neomycin’s 
role in the dual binding process is not necessarily Hoechst-driven.   UV melting 
experiments with NH(10) indicate a stabilization of the shortened A/T binding site as well 
as the interrupted (G/C) binding site.  Hoechst 33258 in such cases indicate a diminished 
effect on such DNA.  (6) The linker between Hoechst and neomycin plays an important 
role in delivering both binding moieties to the grooves.  Both UV melting and 
fluorescence data indicate significant enhancement of DNA binding for NH(10) over 
NH(22).  Molecular modeling indicates a more constrained tandem interaction between the 
two moieties due to the decreased freedom of the long and flexible hexaethylene glycol 
linker.  Altogether, these results further illustrate NH(10) not only as a remarkable DNA 
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binder but as a probe to better understand the molecular requirements for successful dual 
groove recognition of B-DNA. 
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CHAPTER 3 
 
TRIPLE RECOGNITION OF B-DNA 
Introduction 
Targeting genes with small molecules has gradually become a reality in medicine, 
owing to a deeper understanding of the mechanisms of cancer formation and growth.   
For example, the action of drugs such as anthracyclines and acridines (both DNA 
intercalators) involves the binding and stabilization of ternary complexes of DNA and 
with DNA topoisomerases, a phenomenon unknown until recently.
175-178
 The 
understanding of recognition in nonspecific and DNA sequence-specific binding modes is 
crucial to defining the principles for consistent development of gene-regulatory drugs.  
The minor groove is perhaps the most studied of the potential recognition sites of 
DNA by small molecules over the past decade, largely due to the pioneering work by 
Dervan’s group.23 Exploiting solid phase synthesis techniques for preparation of 
polyamides based on distamycin and netropsin, Dervan ultimately set forth rules for base 
pairing recognition centralized on tandem interactions between imidazole and/or pyrrole 
pairs formed via polyamide dimers or hairpin structures.
179,180
 Promising features of such 
polyamides, because of their high binding affinities to B-DNA, are their ability to 
compete with specific protein-DNA binding.
181-186
 The inhibition is not limited to minor 
groove binding transcription factors, but the polyamide binding may also succeed at 
“locking” DNA into its B-form such that major groove binding proteins may fail in its 
task to distort the B-DNA conformation upon its binding.
181
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Gene regulation by small molecules is driven by the development of ligands that 
bind unique stretches of DNA.  Extending beyond the conventional polyamide hairpins 
and bis(benzimidazoles) for recognition of up to six base pairs, current research has 
uncovered a few remarkable conjugates that have been shown to recognize longer 
stretches of DNA.  For example, head-to-head hairpin polyamide dimers have been 
shown to recognize DNA from ten to twelve base pairs in length.
187
 Utilizing the ability 
of pyrrole/imidazole or hydroxypyrrole/pyrrole
188
 pairs to discriminate base pair 
recognition, Dervan has shown that 5’-TGGCATACCA-3’, 5’-TGGCATTACCA-3’, and 
5’-TGGCATATACCA-3’ can bind hairpin dimers (Figure 3.1) at subnanomolar 
concentrations. 
187
 Moreover, the 10 base pair site is discriminated by 25- and 140-fold 
over the 11 and 12 base pair sites.when a central ethyl spacer is present between the 
branching diamide (Figure 3.1, n = 2).   
 
 
 
Figure 3.1.  Hairpin dimer developed in Dervan’s laboratory shown to bind 10-12 bp’s of 
DNA. 
187
 
 
Another well studied minor groove binding structural motif is the 
bis(benzimidazole), originating from the early discoveries of compounds such as Hoechst 
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33258 to bind DNA.
167,189
 These benzimidazoles are known for their potential to poison 
DNA topoisomerases or to stabilize complexes of DNA-topoisomerases that ultimately 
result in strand cleavage.
190
 Numerous reports on benzimidazoles exist, ranging from 
tris(benzimidazoles)
191,192
 to furamidine-benzimidazole
37,193,194
 structures, as well as 
conjugates with distamycin (among other polyamides),
140,141
 polyamines
195
 (including our 
work with neomycin-conjugated Hoechst 33258),
134
 and intercalators.  Minor groove 
binder-polyamine conjugates have prospects for dual binding of DNA, by binding both 
minor groove and major groove (polyamine) in tandem.  Bruice has coined the term 
“microgonotropens” as fluorescent conjugates that bind DNA, whose sequence is largely 
defined by the minor groove binding agent (such as distamycin or Hoechst 33258), while 
a tethered polyamine non-specifically interacts with phosphate anions nearing the major 
groove.
140,141,143,195,196
 Our own work has uncovered a major groove-interacting structure 
in neomycin, when conjugated with the minor groove-binding Hoechst 33258.
134
 
A number of natural products have been shown to possess structures characteristic 
of both groove-binding and intercalation.  Selected examples (Figure 3.2) include 
rebeccamycin (indolocarbazole family), nogalamycin (anthracycline family), altromycin 
(pluramycin family), and mithramycin (aureolic acid family).  Some include an additional 
elecrophilic moiety capable of alkylating DNA.  Furthermore, the majority have been 
shown to display multiple DNA binding modes.  For example, nogalamycin has been 
recently reported to thread DNA, exhibiting intercalation by the central chromophore, 
with saccharide regions extending from both ends to bind both major and minor grooves. 
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Figure 3.2.  Structures of naturally occurring intercalator-groove binder hybrids that bind 
DNA. 
 
 From its discovery as a DNA triplex stabilizing agent, we have since utilized 
neomycin for probing nucleic acid recognition in a variety of pathways.  By utilizing 
synthetic neomycin intermediates for its covalent attachment with intercalators 
(pyrene,
110
 BQQ
109
) and groove binders (Hoechst 33258,
134
 DNA
197
), we have shown an 
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increased binding affinity for both A-form (or A-like)
126
 and B-form nucleic acids.
134
  We 
extend the recognition potential by combining neomycin and both intercalating and minor 
groove-binding moieties in one molecule.  Outlined in the forthcoming article are 
advancements towards multi-recognition of DNA by the successful design, synthesis, and 
binding studies of a novel neomycin-pyrene-Hoechst 33258 “conjugate,” termed 
“NHP(22,18).” Utilizing a number of spectroscopic techniques, NHP(22,18) is found to 
significantly bind DNA over parent ligands (Hoechst 33258, neomycin, and NH(22)). 
NH(22) is a novel Neomcyin-Hoechst 33258 conjugate that is separated by a hexaethylene 
glycol linkage, nearly identical to that between Neomycin and Hoechst in NHP(22,18).  
Comparisons were also made with novel conjugates Hoechst-pyrene-amine (HP(13); a 
precursor to NHP(22,18) lacking the neomycin moiety) and a neomycin-pyrene conjugate 
(NP(18)), which maintains an identical linkage between the neomycin and pyrene moieties 
to that in NHP(22,18).  Viscometry data suggesting intercalation (by the pyrene moiety) is 
also presented.  Together, the results support, to our knowledge, the first example of a 
triple-recognition agent designed for targeting DNA.   
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Figure 3.3  Structures of novel conjugates used in this study.  For all conjugates, the 
number(s) in brackets (subscripted) denote the number of atoms separating the respective 
binding moiety and neomycin. 
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Design and synthesis of triple recognition agent 
Modeling 
As imaginable when viewing the DNA structure, to place the key binding 
moieties in separate areas would require a linker with significant length and flexibility.  
Regarding this, we opted for designing the conjugate based on a novel neomycin-Hoechst 
33258 conjugate, NH(22), which maintains a hexaethylene glycol linkage between the two 
binding moieties.  Though NH(22) binding to DNA was shown to be weaker than NH(10), 
we chose the to maintain the hexaethylene glycol spacer for NHP(22,18) for a number of 
reasons: (a) the linker is long enough to accommodate binding from all three moieties 
when spaced evenly along the hexaethylene glycol chain (see Figure 3.3), (b) direct 
comparisons can be made with NH(22) to isolate pyrene’s effect on DNA binding, (c) due 
to both pyrene and Hoechst binding, the freedom of neomycin for outside solvent 
interactions is diminished when compared with the neomycin moiety in NH(22), and (d) 
the commercial availability of (terminal) diamines spaced with di- and tri-ethylene 
glycols fit conveniently with the synthetic design, not only with NHP(22,18), but with 
NP(18) (see Figure 3.3).  Lastly, (e) molecular modeling of NHP(22,18) indicated a virtually 
ideal fit with such distances between the binding moieties.    
Pyrene is a popular fluorescence tag for studying or identifying biochemical 
processes in vitro.  The intense fluorescence upon exposure to UV allows for sensitive 
measurements at nanomolar concentrations.  Various studies have indicated that pyrene 
intercalates DNA, yet the strength and selectivity of binding is significantly weaker than 
many well known DNA intercalators.  The ease of its synthetic incorporation into 
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biomolecules largely accounts for its popularity in biochemistry, and is the primary 
reason for choice in these studies.   
 
 
 
Figure 3.4  Computer model of NHP(22,18) binding to d(CGCAAATTTGCG)2.  The 
Hoechst 33258-DNA complex was extracted from pdb entry 296d
145
 and further model 
building was done in MacroModel.  Energy minimization was carried out before and after 
linking the three binding moieties.  The surface potential rendering was accomplished by 
exporting the pdb file of the minimized structure into WebLabViewer Pro. 
 
In modeling the triple-recognition agent, we first docked the three binding 
moieties in their respective areas: Hoechst in its routine minor groove A/T stretch (as 
gathered from pdb entry 296d),
145
 neomycin in the nearby major groove, and 
 96 
 
aminopyrene two base pairs above the terminal hydroxyl group of Hoechst 33258.  In 
docking neomycin, the 5-OH of the ribose ring was directed toward the minor groove, as 
would be required if covalently linked to a minor groove binding ligand.  Furthermore, 
the amino position of aminopyrene was directed out of the minor groove, as it would 
when conjugated to the Hoechst moiety. After structural minimization, the linker, based 
on hexaethylene glycol, was constructed to connect the three binding moieties.  The 
structure was further minimized to provide the renderings in Figure 3.4. 
Inspection of the model of NHP(22,18) with d(CGCAAATTTGCG)2 clearly 
indicates a snug fit of Hoechst within the DNA minor groove and significant H-binding 
sites between neomycin and specific bases, as well as with the strands that line the major 
groove.  A clear increase in the base pair distance is also noticeable in the pyrene 
intercalation site.  The resulting picture is somewhat of a “clamp” on the DNA structure.   
 
Synthesis of NHP(22,18) and Control Ligands 
Given the success of neomycin conjugates prepared by our group we rationalized 
that the number of recognition elements could be extended. The key step in the formation 
of NHP(22,18) involves the placement of a central 2
o
 amino group within the linker that 
could be reacted with pyrenebutyric acid succinimide ester to form an amide-linked 
pyrene intermediate.  The terminal 1
o
 amino position, after bis(benzimidazole) formation 
to give an Hoechst 33258-pyrene derivative, can be deprotected and reacted with an 
electrophilic neomycin derivative (neomycin isothiocyanate) to provide the N-Boc 
protected compound 29.    
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Scheme 3.1  Preparation of HP(13).  Reagents and conditions: (i) p-cyanophenol, PPh3, 
DIAD, dioxane, 78%; (ii) 24, DMF, NaI, 61%; (iii) 5, DMAP, DMF, 65%; (iv)  (a) 8, 
HOAc, EtOH, 41%; (b) K2CO3, MeOH, H2O, 94%. 
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Scheme 3.2  Preparation of triple recognition agent NHP(22,18). Reagents and conditions: 
(i) pyridine, DMAP, 52%; (ii) 1:1 TFA:CH2Cl2, quant. 
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Monotosylation of triethylene glycol using published procedures to provide 22 
and subsequent coupling with p-cyanophenol using Mitsunobu conditions afforded 23 in 
good yields. Tosylate substitution with a mono-protected diamine 24 under basic 
conditions provided intermediate 25.  Reaction of the secondary amine of 25 with pyrene 
succinimide ester 26, followed by standard coupling with 8 in an ethanol/acetic acid 
mixture provided the desired Hoechst-pyrene-amine (HP(13)) after subsequent 
trifluoroacetyl removal at the terminal amine (Scheme 3.1).  Deprotection of the 
trifluoroacetyl group using K2CO3 in methanol/water afforded the Hoechst 33258-
pyrene-amine 28.  Reaction of 28 with neomycin isothiocyanate 5, followed by NH-Boc 
deprotection of coupled product 29 gives the desired triple recognition agent 30 (Scheme 
3.2) as a trifluoroacetate salt. 
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Scheme 3.3 Synthesis of NP(18).  Reagents and conditions: (i) (a) pyrenebutyric acid, 
TSTU, DMF, NEt3, 64%; (b) TFA/CH2Cl2, 96%; (ii) (a) neomycin isothiocyanate 5, 
pyridine, 62%; (b) 1:1 TFA:CH2Cl2, ethanedithiol, 96%. 
Traditionally, modifications at the phenol hydroxy group of Hoechst 33258 have 
been carried out prior to benzimidazole formation.  Therefore functional groups within 
the linker (at the phenol OH position) must be stable to anhydrous HCl, which is used to 
convert the p-cyanol position to a reactive imidate ester for coupling with 1,2-
diaminobenzenes to provide the benzimidazole.  Conveniently, the pyrene-amide 
intermediate, formed before benzimidazole formation, is stable to such acidic conditions, 
as well as in a later step where base is used to deprotect the terminal trifluoroacetyl group 
on the amine. 
A novel neomycin-pyrene conjugate (NP(18)) was also prepared for comparison 
studies. NP(18) maintains the identical linkage between neomycin and Hoechst 33258.  
The synthetic route is outlined in Scheme 3.3.  For its preparation, monoprotected 
diamine 24 was first reacted with pyrene succinimide ester 26 before trifluoroacetyl 
deprotection and reaction of amine 31 with neomycin isothiocyanate 5.  N-Boc 
deprotection of 32 in CH2Cl2/TFA mixture afforded compound 33 (NP(18)) as the 
trifluoroacetate salt.  
 
Melting Studies with Various Conjugates 
The thermal stability of poly(dA)•poly(dT) in the presence of various ligands was 
first studied by UV melting analysis (Figure 3.5).  In addition to NH(22), NHP(22,18), and 
Hoechst 33258, additional comparisons were made with a novel neomycin-pyrene 
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conjugate (NP(18)) and Hoechst-pyrene-amine (HP(13)), which is a precursor to NHP(22,18) 
synthesis. A comparison including HP(13) allows a direct analysis of neomycin’s (in 
NHP(22,18)) effect on DNA stability.  A more detailed study of the binding effect by 
NHP(22,18) was also achieved with melting experiments consisting of a combination of 
individual ligands (e.g., NH(22) + aminopyrene in the same solution, and so forth).  When 
compared with NH(22) and Hoechst 33258, a noticeable shift in the Tm is lacking for 
NHP(22,18).  As indicated in Table 3.1, Tm values for NH(22) and Hoechst 33258, and 
combinations containing these ligands (see Figure 3.5) remain in a similar range (Tm = 
15 
o
C), while NHP(22,18) melts exhibited a less significant shift in Tm (Tm = 10
o
C).  This 
unanticipated result prompted studies of the NHP(22,18)-DNA complex by other melting 
methods, most notably differential scanning calorimetry (DSC).  DSC is often used to 
monitor the dissociation of DNA strands, providing valuable Tm and H values for the 
association/dissociation process.   
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Figure 3.5  UV melting profiles of poly(dA)•poly(dT) with various ligands.  Samples of 
DNA (15 M) were mixed with ligand (2 M) in buffer (10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow 
annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument software. 
 
 
compound Tm21 Tm21 
None 72 0 
Neomycin 72 0 
Hoechst 33258 86 14 
aminopyrene 73 1 
NP(18) 78 6 
NH(22) 86 14 
HP(13) 78 6 
NHP(22,18) 82 10 
NH(22) + aminopyrene 87 15 
HP(13) + neomycin 81 9 
NP(18) + Hoechst 33258 85 13 
 
Table 3.1 Tm data for poly(dA)•poly(dT) melting in the presence of indicated ligands.  
Samples containing DNA (15 M) and ligand (2 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis. 
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Figure 3.6  DSC profiles of 100 M poly(dA)•poly(dT) alone (left) and in the presence 
of 8 M NH(10) (right).  Buffer conditions were identical to that in UV melting 
experiments.  Samples were heated at a rate of 0.5 
o
/min.  Values for Tm and H were 
determined using Origin 7.0 software provided with the instrument. 
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Figure 3.7 DSC profiles of 100 M poly(dA)•poly(dT) with increasing concentrations of 
NHP(22,18).  Top left: 1 M NHP(22,18); Top right: 4 M NHP(22,18); Bottom: 8 M 
NHP(22,18). Buffer conditions were identical to that in UV melting experiments.  Samples 
were heated at a rate of 0.5 
o
/min.  Values for Tm and H were determined using Origin 
7.0 software provided with the instrument. 
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Figure 3.8  UV melting profiles of poly(dAdT)2 with various ligands.  Samples of DNA 
(20 M) were mixed with ligand (3 M) in buffer (10 mM sodium cacodylate, 0.5 mM 
EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow annealing 
to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm 
values were determined by first derivative analysis using instrument software. 
 
 
 
 
 
 
 
 
 
 106 
 
compound Tm21 Tm21 
None 66 0 
Neomycin 66 0 
Hoechst 33258 75 9 
aminopyrene 65 -1 
NP(18) 66 0 
NH(22) 76 10 
HP(13) 74 8 
NHP(22,18) 82 16 
NH(22) + aminopyrene 77 11 
HP(13) + neomycin 72 6 
NP(18) + Hoechst 33258 74 8 
 
Table 3.2 Tm data for poly(dAdT)2 melting in the presence of indicated ligands.  Samples 
containing DNA (20 M) and ligand (3 M) in buffer (10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes before slow 
annealing to room temperature before UV melting analysis (monitored at 260 nm from 
20-95 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis. 
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Figure 3.9   UV melting profiles of dA22•dT22 with various ligands.  Samples of DNA (1 
M in duplex) were mixed with ligand (3 M) in buffer (10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 6.8) before heating at 95 
o
C for 5 minutes and slow 
annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument software. 
 
compound Tm21 Tm21 
None 51 0 
Neomycin 51 0 
Hoechst 33258 72 21 
aminopyrene 50 -1 
NP(18) 53 2 
NH(22) 72* 21* 
HP(13) 64* 13* 
NHP(22,18) 85 34 
NH(22) + aminopyrene 73 22 
HP(13) + neomycin 61* 10* 
NP(18) + Hoechst 33258 69 18 
 
Table 3.3 Tm data for dA22•dT22 melting in the presence of indicated ligands.  Samples 
containing DNA (1 M in duplex) and ligand (3 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-95 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis. *indicates a biphasic transition observed in the melts, with an earlier 
transition corresponding to unbound DNA duplex melting. 
 
DSC profiles were first gathered for the NH(10)-poly(dA)•poly(dT) complex, and 
were in excellent agreement with Tm values determined in UV melting experiments 
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(Figures 3.6 and 3.7).  Furthermore, the H of duplex dissociation in the absence of 
ligand (value) was somewhat smaller than when NH(10) is present (value).  The difference 
between these two values represents the DH of ligand binding to the DNA.  DSC data 
gathered for the NHP(22,18)- poly(dA)•poly(dT) complex gave a much different result.  
The relatively sharp peak corresponding to duplex melting, otherwise present in DNA 
alone, becomes virtually absent even up to temperatures as high as 110 
o
C.  Intermediate 
concentrations (less than saturating conditions) indicate melting of unbound DNA (at 72 
o
C) with one important difference from that of DNA melting with no ligand present: H 
values at the Tm were significantly lower.  It was then concluded that the Tm for 
NHP(22,18)-bound DNA was above that observable in DSC (and UV) experiments.  These 
results, gathered after melting experiments done with shorter DNA oligomers (discussed 
below), struck a chord with what we initially observed, namely, lower Tm values than 
anticipated for NHP(22,18) in UV melting experiments. 
Pyrene has been shown to prefer alternating A-T base pairs over homologous 
steps upon intercalation of DNA.  It was therefore of interest to explore the effect of 
NHP(22,18) on the polymer duplex poly(dAdT)2.  Furthermore, more convincing UV 
melting profiles indicating an enhancement in binding by NHP(22,18) over other ligands 
was needed.  UV melting analysis with poly(dAdT)2 was done in similar fashion to 
poly(dA)•poly(dT).  NHP(22,18) was found to exhibit a significantly larger Tm (16 
o
C) 
under the conditions employed than that found for other ligands (Figure 3.8), including 
NP(18) and HP(13).  This further illustrates the contributions of both Hoechst and neomycin 
toward pyrene binding, a phenomenon unobserved for NP(18) and less significant for 
HP(13).  Lastly, the direct comparison of NHP(22,18) with control samples containing a 
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combination of lower-order conjugates and individual ligand (Figure 3.8 and Table 3.2), 
essentially providing all three binders in the DNA sample (e.g., NP(18) + Hoechst 33258), 
further illustrates the importance of covlalently linking the three moieties in order to 
achieve optimal recognition. 
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Figure 3.10  UV melting profiles of dA22•dT22 with NHP(22,18).  Samples of DNA (1 M 
in duplex) were mixed with ligand (0, 1, 2, and 3 M from left to right) in buffer (10 mM 
sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 6.8) before heating at 95 
o
C for 5 
minutes and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at 
heating rate of 0.2 
o
/min.  Tm values were determined as the average of first derivative 
analysis (midpoint of transition) using instrument software. 
 
 To test the effect of the conjugates on oligomeric DNA duplex stability, UV 
melting profiles of d(A)22•d(T)22  in the absence and presence of various ligands were 
gathered in similar fashion to that done with polymeric DNA (Figure 3.9).  A much more 
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significant and noticeable shift in the Tm for d(A)22•d(T)22  with NHP(22,18) was apparent.  
When compared with other ligands, such as Hoechst 33258, NH(22), NP(18), and HP(13), the 
triple-binding agent NHP(22,18) hailed as the strongest stabilizer of this DNA oligomer, 
with a Tm = 24 oC.  A concentration-dependent melting study (Figure 3.10) illustrates 
the gradual shift in Tm values as ligand concentrations are increased, with Tm values up 
to 32 
o
C at 3 M ligand concentrations.  These results indicate a clear distinction in 
binding effect for NHP(22,18), as solutions containing a combination of individual ligands 
(NH(22) + aminoypyrene; neomycin + HP(13); NP(18) + Hoechst 33258) exhibited 
significantly lower Tm values (see Figure 3.9 and Table 3.3). 
 
[NHP(22,18)] Tm21 Tm21 rdb 
0 50 0 0 
1 M 60 10 0.05 
2 M 74 24 0.09 
3 M 82 32 0.14 
 
Table 3.4 Tm data for dA22•dT22 melting in the presence of indicated NHP(22,18) 
concentrations.  Samples containing DNA (1 M in duplex) and ligand (3 M) in buffer 
(10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C 
for 5 minutes before slow annealing to room temperature before UV melting analysis 
(monitored at 260 nm from 20-95 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were 
determined by first derivative analysis. 
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Figure 3.11  UV melting profiles of d(CGCAAATTTGCG)2 with various ligands.  
Samples of DNA (1 M in duplex) were mixed with ligand (1 M) in BPES buffer (6 
mM Na2HPO4, 2 mM NaHPO4, 1 mM EDTA, 185 mM NaCl, pH 7.0) before heating at 
95 
o
C for 5 minutes and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 
to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative 
analysis using instrument software. 
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compound Tm21 Tm21 
None 54 0 
Neomycin 54 0 
Hoechst 33258 68 14 
aminopyrene 54 0 
NH(22) 72 18 
HP(13) 62 8 
NHP(22,18) 71 17 
NH(22) + aminopyrene 69 15 
HP(13) + neomycin 56 2 
NP(18) + Hoechst 33258 68 14 
 
Table 3.5 Tm data for d(CGCAAATTTGCG)2 melting in the presence of indicated 
ligands.  Samples containing DNA (1 M in duplex) and ligand (1 M) in buffer (6 mM 
Na2HPO4, 2 mM NaHPO4, 1 mM EDTA, 185 mM NaCl, pH 7.0 were heated at 95 
o
C for 
5 minutes before slow annealing to room temperature before UV melting analysis 
(monitored at 260 nm from 20-95 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were 
determined by first derivative analysis. 
 
UV Melting profiles with d(CGCAAATTTGCG)2 with NHP(22,18) exhibited 
similar results to that seen with Hoechst 33258, NH(22), and HP(13) (Figure 3.11).  These 
findings highlight the importance of an extended stretch of A-T base pairs.  Neomycin 
dimers have been shown to bind DNA duplexes of A-T bases stronger than G-C; such 
may be the case here.  Furthermore, fluorescence titrations have indicated that the novel 
neomycin conjugates reported here prefer A/T stretches of 9 base pairs.  Therefore the 
central A3T3 region in d(CGCAAATTTGCG)2 may be less favorable than DNA 
oligomers such as dA22•dT22.  Melting data (above) with such DNA supports this.  As 
such, experiments with control ligands as a combination of all three binders, as done with 
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dA22•dT22 and polymeric DNA, exhibited similar melting profiles as the individual 
ligands themselves (Figure 3.11 and Table 3.5). 
 
Fluorescence Binding Study 
poly(dA)• poly(dT) 
Fluorescence titrations of NHP(22,18) binding to DNA were carried out in a similar 
manner to that reported in the previous chapter.  For comparison, binding data for NH(22) 
and NH(10), as well as Hoechst 33258 are made. In our experiments with Hoechst 33258, 
the value of N = 10 was used, as established in the literature.  Separate experiments, in 
which constant [DNA] was titrated with concentrated ligand to provide values of n 
(number of base pairs per ligand), were carried out and used for determining N.  It has 
been shown that N = 2(n-1).
198
  As indicated by a break in the fluorescence signal when 
plotted against varying DNA(b.p.)/ligand ratios, values of n = 9 for both conjugates 
NH(22) and NHP(22,18) were observed (Figures 3.12 and 3.13).  This value is reasonable 
due to the presence of the neomycin moiety, which likely extends beyond the Hoechst 
binding site and/or perturbs the DNA environment to exclude binding further down the 
DNA lattice.  In the case for NHP(22,18), one would anticipate the binding site to be larger 
than NH(22), due to pyrene intercalation.  However, the freedom of the hexaethylene 
glycol-neomycin arm of NH(22) potentially extends further than that in NHP(22,18), due to a 
“locking in” of the Hoechst and pyrene moieties to their preferred binding areas, 
restricting the reach of the neomycin arm relative to that in NH(22).   
 Binding curves depicting the ligand:DNA interaction is represented by the 
NHP(22,18)-DNA titration data shown in Figure 3.14-3.17.  For all ligands, as with 
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NHP(22,18), fluorescence enhancement upon increasing [DNA] was observed.  All curves, 
as suggested above, could be successfully curve-fit to provide binding constants for each 
ligand.  Resulting binding data are shown in Table 3.6.  Similar to that reported,
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Hoechst 33258 binding is approx. 1x10
8
 M
-1
.  Binding of the neomycin-Hoechst 33258 
conjugate possessing the hexaethylene glycol linker (NH(22)) exhibited markedly less 
binding affinity (Kb = 0.6x10
8
 M
-1
) than the other conjugates, including Hoechst 33258.  
The “triple recognition” agent, NHP(22,18), displayed the highest binding affinity (2.2x10
8
 
M
-1
) of all the ligands, including NH(10) (1.6x10
8
 M
-1
), which has been shown to 
significantly stabilize poly(dA)•poly(dT) over Hoechst 33258.  We therefore believe that 
NHP(22,18) binding affinity to poly(dA)•poly(dT) can be partially attributed to pyrene 
intercalation. 
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Figure 3.12  Fluorescence titration of NHP(22,18) into poly(dA)•poly(dT).  Small aliquots 
of concentrated ligand were added to DNA (2 M) before fluorescence analysis 
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(excitation at 345 nm, emission scanning from 370-600 nm at 1 nm/s; 4 nm slit width; T 
= 25 
o
C). Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 3.13  Fluorescence titration of NH(22) into poly(dA)•poly(dT).  Small aliquots of 
concentrated ligand were added to DNA (2 M) before fluorescence analysis (excitation 
at 345 nm, emission scanning from 370-600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C). 
Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 3.14  Fluorescence-detected binding of NHP(22,18) to poly(dA)•poly(dT).  Small 
aliquots (1.5 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2.5 mL 
of 10 nM) before fluorescence analysis (excitation at 345 nm, emission scanning from 
370-600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C). Buffer: 10 mM sodium cacodylate, 
0.5 mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 3.15  Fluorescence-detected binding of poly(dA)•poly(dT) + Ht 33258.  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 3.16  Fluorescence-detected binding of poly(dA)•poly(dT) + NH(22).  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
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Figure 3.17  Fluorescence-detected binding of poly(dA)•poly(dT) + NH(10).  Small 
aliquots (1 to 20 L) of DNA (200 M bp-1) were added to a solution of ligand (2 mL of 
10 nM) before fluorescence analysis (excitation at 338 nm, emission scanning from 390-
600 nm at 1 nm/s; 4 nm slit width; T = 25 
o
C); Buffer: 10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, pH 7.2. 
 
d(CGCAAATTTGCG)2 
 Figures 3.18-3.21 depict the binding isotherms gathered for the conjugates with 
d(CGCAAATTTGCG)2.  Surprisingly, the binding of the neomycin conjugates were all 
found to be significantly less than that found with Hoechst 33258 (1.8x10
8
 M
-1
; 
comparable with reported values of 3x10
8
 M
-1
).
158,170
  The logical explanation is that the 
binding site of six A/T base pairs (AAATTT) is not as preferred for binding as a site a 
few base pairs longer.  As indicated in Figures 3.12 and 3.13, NHP(22,18) and NH(22) 
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prefer a longer A/T stretch (9 base pairs) than what is possessed in 
d(CGCCAAATTTGCG)2.   
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Figure 3.18  Fluorescence-detected binding of NHP(22,18) with d(CGCAAATTTGCG)2. 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were analyzed for fluorescence emission over a 390-600 nm range. Conditions: exc 
= 345 nm; slits = 6 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 180 
mM NaCl, 2 mM Na2EDTA, pH 7.0). 
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Figure 3.19  Fluorescence-detected binding of Ht33258 with d(CGCAAATTTGCG)2. 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were analyzed for fluorescence emission over a 390-600 nm range. Conditions: exc 
= 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 180 
mM NaCl, 2 mM Na2EDTA, pH 7.0). 
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Figure 3.20  Fluorescence-detected binding of NH(22) with d(CGCAAATTTGCG)2. 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were analyzed for fluorescence emission over a 390-600 nm range.  Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 
180 mM NaCl, 2 mM Na2EDTA, pH 7.0).  
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Figure 3.21  Fluorescence-detected binding of NH(10) with d(CGCAAATTTGCG)2. 
Individual samples of ligand (100 nM in 2 mL) mixed with varying concentrations of 
DNA were analyzed for fluorescence emission over a 390-600 nm range.  Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: BPES (6 mM Na2HPO4, 2 mM NaH2PO4, 
180 mM NaCl, 2 mM Na2EDTA, pH 7.0). 
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 Poly(dA)•poly(dT)   A3T3 
conjugate K (x 107) N  K (x 107) 
Ht33258 11 + 1.0 10  18 + 5.0 
NH(22) 3.4 + 0.9 16  0.5 + 0.3 
NHP(22,18) 22 + 6.0 16  3.5 + 1.2 
 
Table 3.6  Fluorescence-based binding data for ligands studied.  Values for Kb were 
determined by nonlinear curve fitting of fluorescence titrations according to an 
independent site model using conditions similar to those reported. Values for N (binding 
site size) were either used as reported (Ht33258) or determined experimentally (see 
Methods). 
 
Circular dichroism Study 
We utilized circular dichroism (CD) spectroscopy to study the changes, if any, in 
the poly(dA)poly(dT) structure as well as in the Hoechst moiety of the conjugate.  
Numerous reports have explained binding-induced chirality of Hoechst 33258 by DNA, 
typically indicated by a change in CD signal at the max of Hoechst 33258 UV 
absorbance.
165,166
  In our studies, we carried out titrations of ligand into a solution of 
DNA, with CD scans of the solution taken after appropriate equilibration times between 
ligand additions.  The resulting scans were overlayed to compare the CD spectra at 
different ligand:DNA ratios (Figures 3.22-3.26).  We found that there is a significant 
change in the CD signal in the poly(dA)•poly(dT) region, which is represented by a 
negative band at 248 nm and a positive band at 260 nm.  Also, in the region of 360 nm, 
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there is an increasingly positive CD signal as ligand:DNA ratios are increased, indicative 
of Hoechst complexation with the DNA.  Such a signal would be absent if no interaction 
is occurring. Interestingly, peaks characteristic of pyrene absorption appear to overlap 
with the Hoechst region, suggesting changes in the pyrene environment upon exposure to 
DNA.  Therefore, these results were the first evidence that both Hoechst and pyrene 
binding to the poly(dA)•poly(dT) duplex is occurring.  Control experiments with NP(18) 
and HP(13) were also carried out for comparison.  As shown in Figure 3.24, no significant 
change in CD signal was observed when poly(dA)•poly(dT) was titrated with NP(18), 
indicating little interaction of the ligand within the duplex and supporting the 
insignificant duplex stabilization observed in UV melting studies.  The conjugate HP(13) 
indicated a marked change of CD intensity within the Hoechst region.  However, no 
overlap with the pyrene region is apparent, suggesting that the overlapping pyrene signal 
seen with HP(13) is a consequence of dual neomycin and Hoechst binding within the 
duplex.  Thus, the influence of pyrene intercalation is only achievable with the assistance 
of tandem neomycin and Hoechst binding.  CD titrations of poly(dA)•poly(dT) with 
aminopyrene were not carried due to the assumption that no observable interaction would 
be indicated, simply due to the observation that NP(18) showed no binding (Figure 3.24).  
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Figure 3.22 Circular dichroism of poly(dA)•poly(dT) complexed with Hoechst 33258.  
Small aliquots of concentrated ligand (200 M) were titrated into a solution of DNA (30 
M) before equilibration and scanning from 400-210 nm.  Peaks around 360 nm 
correspond to ligand-DNA complexation. Buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 150 mM KCl, pH 7.2; T = 20 
o
C. 
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Figure 3.23  Circular dichroism of poly(dA)•poly(dT) complexed with NH(22).  Small 
aliquots of concentrated ligand (200 M) were titrated into a solution of DNA (30 M) 
before equilibration and scanning from 400-210 nm.  Peaks around 360 nm correspond to 
ligand-DNA complexation. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM 
KCl, pH 7.2; T = 20 
o
C. 
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Figure 3.24  Circular dichroism of poly(dA)•poly(dT) with increasing concentrations of 
NP(18).  Small aliquots of concentrated ligand (200 M) were titrated into a solution of 
DNA (30 M) before equilibration and scanning from 400-210 nm.  Buffer: 10 mM 
sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; T = 20 
o
C. 
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Figure 3.25  Circular dichroism of poly(dA)•poly(dT) complexed with NHP(22,18).  Small 
aliquots of concentrated ligand (200 M) were titrated into a solution of DNA (30 M) 
before equilibration and scanning from 450-210 nm.  Hoechst and pyrene complexation 
is indicated by the increase in signal from 400-320 nm, whereas evidence of DNA 
binding can be observed by changes in the 300-210 nm region.  Solutions were in 10 mM 
sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; T = ambient. 
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Figure 3.26 CD Scans of poly(dA)•poly(dT) complexed with HP(13).  Small aliquots of 
concentrated ligand (200 M) were titrated into a solution of DNA (30 M) before 
equilibration and scanning from 450-210 nm.  Hoechst and pyrene complexation is 
indicated by the increase in signal from 400-320 nm, whereas evidence of DNA binding 
can be observed by changes in the 300-210 nm region.  Solutions were in 10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; T = ambient. 
 
Viscometric Titrations Suggest Intercalation by Pyrene Moiety 
The experimental results gathered at this point led us to consider a multi-
recognition process for NHP(22,18).  Equilibrium binding data indicated an enhanced 
binding over both NH(22) (which contains a near-identical linker to NHP(22,18)) and NH(10), 
which was previously shown to significantly bind DNA better than Hoechst 33258.   
Circular dichroism results (Figure 3.25) suggested Hoechst and pyrene interaction.  
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However, we deemed it a requirement to confirm pyrene intercalation by a more reliable 
method in viscometric analysis.   
Viscometry has long been utilized for investigating ligand-substrate binding 
modes, particularly to confirm intercalation events. Intercalation of nucleic acids results 
in an increase in the helical length, because of space displacement between the base pairs 
by the ligand.  Nucleic acids of appropriate length are rod-like, so an increase in helical 
length results in an increase in solution viscosity.
199
 Thus, we carried out viscometric 
titrations of neomycin, Hoechst 33258, NH(22), and NHP(22,18) with poly(dA)•poly(dT) 
(Figure 3.27). The results were, at first, unanticipated since groove binding molecules 
such as Hoechst 33258 with DNA display little changes in intrinsic solution viscosity.  In 
all cases except Hoechst 33258, the DNA solution viscosity decreased when ligand was 
added.  The most marked decrease was with NH(22), whereas NHP(22,18) was clearly 
higher. Similar to that observed before,
111,200
 the decrease in viscosity can be attributed to 
groove binding, which, in contrast to intercalation, can shorten the helix by compaction.  
This compacting of DNA is clearly a result of neomycin interaction, further corroborating 
neomycin’s role in the multi-recognition process.  However, the binding degree of 
NHP(22,18) can be extended further. 
  By subtracting the results of NH(22)-DNA binding from NHP(22,18)-DNA binding 
in the viscosity experiments, the effect of the pyrene moiety in NHP(22,18) on the DNA can 
be ascertained.  A closer look-by this consideration-clears the view somewhat.  By 
overlaying the subtracted data (NHP(22,18) minus NH(22), Figure 3.28), a clear 
resemblance to theoretical intercalation is observed for the pyrene moiety in NHP(22,18). 
Therefore, there is a clear correlation of NHP(22,18) with intercalation of 
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poly(dA)•poly(dT). The slightly lower value can be attributed to intercalation occurring 
less periodically within the DNA lattice due to the large binding site size (versus a simple 
intercalator that would intercalate every three base pairs).  Furthermore, the mere 
observation of viscosity decrease, as seen in other accounts, confirms neomycin binding.  
Lastly, multiple spectroscopic experiments have conveyed the Hoechst moiety’s presence 
in DNA binding.  Thus, convincing evidence, from a combination of analytical 
techniques, gives strong candidacy for a DNA triple-recognition agent in NHP(22,18). 
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Figure 3.27  Viscometric analysis of poly(dA)•poly(dT) with various ligands:  Small 
aliquots of ligand (200 M) were titrated into a solution of DNA (100 M) and 
corresponding flow times were recorded in triplicate with deviation less than 0.1 second.  
Error bars for each titration point are included.  Buffer:  10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, 1 mM MgCl2, pH 7.2; T = 27 + 0.05 
o
C. 
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Figure 3.28 Subtracted viscosity data to convey pyrene effect on solution viscosity:  
Small aliquots of ligand (200 M) were titrated into a solution of poly(dA)•poly(dT) (100 
M) and corresponding flow times were recorded in triplicate with deviation less than 0.1 
second.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, 1 mM 
MgCl2, pH 7.2; T = 27 + 0.05 
o
C. 
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Figure 3.29  Viscometric analysis of poly(dAdT)2 with various ligands:  Small aliquots 
of ligand (200 M) were titrated into a solution of DNA (100 M) and corresponding 
flow times were recorded in triplicate with deviation less than 0.1 second.  Error bars for 
each titration point are included.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, 
150 mM KCl, 1 mM MgCl2, pH 7.2; T = 27 + 0.05 
o
C. 
 
 Further viscometric analysis of alternating A/T base pair intercalation was done 
using poly(dAdT)2.  Unlike that seen with poly(dA)•poly(dT), the viscosity of 
poly(dAdT)2 solutions were found to increase upon titration of NHP(22,18) (Figure 3.29), 
suggesting an intercalating mode of binding by pyrene.  Also, as illustrated in Figure 
3.29, NH(22) titrations resulted in decreased solution viscosity.  At higher ligand 
concentrations, solution viscosity significantly dropped in both NHP(22,18) and NH(22) 
experiments.  Such a phenomenon might be explained by an increase in neomycin 
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binding along the DNA grooves, significantly compacting the DNA as mentioned above.  
The difference in viscometry profiles between the two polymeric DNAs can be a result of 
stronger pyrene intercalation between the A-T steps in poly(dAdT)2, stronger neomycin 
binding to poly(dA)•poly(dT), or a combination of both.  All in all, these studies clearly 
illustrate neomycin’s and pyrene’s role in the DNA binding event.  Multiple 
spectroscopic experiments have conveyed the Hoechst moiety’s presence in DNA 
binding.  Thus, convincing evidence, from a combination of analytical techniques, gives 
strong candidacy for a DNA triple-recognition agent in NHP(22,18). 
 
Triple Recognition of Triplex DNA 
TFO recognition of duplex DNA (to form a triplex) can be exploited to disrupt a 
variety of crucial or undesired biological processes.  Furthermore, H-DNA, an 
intramolecular-forming triplex found in biological systems, makes the triplex an 
important target of study.  For example, the constrained, bent DNA conformation that 
occurs upon H-DNA formation is often observed with regulatory proteins, therefore the 
formation of such structures may represent a form of molecular switch in controlling 
gene expression. 
  However, triplex formation is thermodynamically and kinetically less favorable 
than duplex-TFO dissociation.  Therefore, the driving force for utilizing TFO-based 
recognition for therapeutic purposes is the development or discovery of ligands that 
stabilize and kinetically favor the formation of triplex structures in a specific fashion. 
Thus, we recognized that triple recognition of DNA triplex was also of interest.  Due to 
neomycin’s record as a significant DNA triplex stabilizing agent, the idea that both 
pyrene and/or Hoechst can be delivered to its respective target was not an exaggerated 
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one.  Furthermore, a more detailed picture of the structural requirements for recognition 
may be possible given that a significant contribution by Hoechst is made in stabilizing the 
triplex (Hoechst 33258 destabilizes DNA triplex at low concentrations).  Lastly, it is 
feasible to envision a stronger binding preference for triplex (compared to duplex) by 
NHP(22,18) due to decreased entropic penalties associated with linker conformation, as the 
orientation of the triplex groove for neomycin binding relative to the minor groove (for 
Hoechst binding) requires a less strained linker conformation than that associated with 
dual duplex groove binding.  A molecular model depicting the complexation of NHP(22,18) 
with a DNA triplex is depicted in Figure 3.30.  A comparision with duplex binding is 
also illustrated (Figure 3.30, right). 
     
 
 
Figure 3.30  (left) Computer model of NHP(22,18) binding to DNA triplex.  The third 
strand TFO is shown in red, duplex in blue; NHP(22,18) is depicted in spacefill fashion.  
(right) Model of NH(22) binding to duplex.  The modeling was performed using Amber 
force field, water as solvent, and under constant dielectric conditions.  Structural 
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minimizations converged on a gradient to within 0.02 kJ/mol. Structures of the 
conjugates are displayed below their respective model.  Five of the six amines in 
neomycin were protonated, in agreement with NMR studies of neomycin,
150,151
 
 
In studying the DNA triplex-binding properties of both NHP(22,18) (compound 30) 
and NP(18) (compound 33), UV melting profiles of poly(dA)•2poly(dT) with varying 
concentrations of NHP(22,18) were gathered using similar protocols to that with other 
neomycin conjugates.  Significant shifts in triplex Tm are observed at low ligand 
concentrations (from 0.2 to 3 M) of NHP(22,18) (Figure 3.31).  A considerable shift in 
duplex melting can also be seen (Figure 3.31), although the effect of NHP(22,18) on duplex 
is small when compared with the effect on triplex melting (Figure 3.32).  Table 3.7 
provides all data for the triplex and duplex Tm data for NHP(22,18) experiments. 
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Figure 3.31 Poly(dA)•2poly(dT) melting in the presence of indicated NHP(22,18) 
concentrations.  Samples containing DNA (15 M) and ligand in buffer (10 mM sodium 
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cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.).  Values for Tm were determined by first 
derivative analysis. 
 
 
 
 
[NHP(22,18)] in M Tm32 Tm32 Tm21 Tm21 
0.2 41 7 76 4 
0.75 58 24 86 14 
1 60 26 87 15 
2 88* 54 88 16 
3 92* 58 92 20 
 
Table 3.7 Tm data for poly(dA)•2poly(dT) melting in the presence of indicated NHP(22,18) 
concentrations.  Samples containing DNA (15 M) and ligand in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis. *A merge of triplex melting with duplex melting (31 transition) 
was observed at higher concentrations of NHP(22,18). 
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Figure 3.32 Comparison plot of duplex versus triplex Tm for poly(dA)•2poly(dT) 
melting in the presence of varying concentrations NHP(22,18).  (rdb = ratio of drug to DNA 
in base pairs).  Samples containing DNA (15 M) and ligand in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). 
 
 
A comparison of triplex melting was then made with the neomycin-pyrene 
conjugate (NP(18), compound 33).  A noticeable shift in triplex Tm is apparent with NP(18) 
(Figure 3.33).  Table 3.8 depicts the Tm values for triplex and duplex melting in the 
presence of various concentrations of NP(18).  However, the stabilization by NP(18), which 
lacks the Hoechst moiety, is somewhat lower than NHP(22,18) at identical concentrations.  
As shown in Table 3.9 and Figure 3.34, significant increases in Tm for both triplex and 
duplex when NHP(22,18) is compared with NP(18) (Tm represents the subtracted Tm 
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values, NHP(22,18) minus NP(18)). The Tm reaches saturation a NHP(22,18) concentrations of 
2 M, as indicated by the plateau around Tm = 40 
o
C in Figure 3.34.  The large Tm for 
duplex melting in the comparison can be due to no observable changes in duplex Tm 
exhibited by NP(18) at all concentrations studied (Table 3.8).  Nevertheless, the triplex 
stabilization is enhanced when Tm comparisons are made with neomycin alone 
(consider 2 M ligand, where neomycin at this concentration exhibits a 3 oC shift in 
triplex Tm; both NP(18) and NHP(22,18) effects are much greater, with Tm = 14 
o
C for 
NP(18) and Tm = 54 
o
C for NHP(22,18)). 
 The triple recognition of triplex DNA, however, is incomplete in this study 
without considering the effect of the Hoechst 33258 moiety.  As shown in Figure 3.35, 
there is an apparent destabilization of the triplex by Hoechst 33258 (Tm = 6 
o
C at rdb = 
0.13), indicating an unfavorable effect of Hoechst 33258 binding within the minor 
groove.  When conjugated with neomycin, Hoechst binding delivers neomycin to (or 
within proximity of) the major groove such that third strand association (triplex 
formation) is squandered.  This is indicated by an absence of the triplex transition in the 
melting profile of poly(dA)•2poly(dT) with NH(22) (Figure 3.35, left).  In contrast, there 
is a significant increase in stabilization of the triplex when a Hoechst 33258 moiety is 
conjugated with both neomycin and pyrene.  As stated above, there is an enhanced triplex 
stabilization by NP(18), yet not to the degree of enhancement observable with NHP(22,18) 
(Tm = 54 
o
C for NHP(22,18) vs. Tm = 14 
o
C for NP(18) at rdb = 0.13).   In fact, Hoechst 
33258 binding in the minor groove disrupts NP(18) binding to the triplex, as evident in a 
diminished Tm (Tm = -2 
o
C at rdb = 0.13; Figure 3.35 and Table 3.10).  Hence, one may 
deduce that the observed stabilization of poly(dA)•2poly(dT) by NHP(22,18) comprises of 
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contributions of neomycin and pyrene binding as well as Hoechst 33258, the latter of 
which is a direct consequence of dual neomycin and pyrene binding.   
In the case of the polymeric DNA melting in Figure 3.31, the relatively broad 
transition is due to the formation of polymorphic structures as heating occurs. 
201
  The 
triple-recognition conjugate (NHP(22,18)) most likely binds and induces complex structures 
as DNA melting proceeds.  This is in contrast with that observed with NP(18), as a more 
cooperative transition is observed (Figure 3.33).  The broader transitions in NHP(22,18) 
melts reflect the more complex binding properties of such conjugates possessing multiple 
binding moieties. 
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Figure 3.33 Poly(dA)•2poly(dT) melting in the presence of indicated NHP(22,18) 
concentrations.  Samples containing DNA (15 M) and ligand in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.).  Values for Tm were determined by first 
derivative analysis. 
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[NP(18)] in M Tm32 Tm32 Tm21 Tm21 
0.2 36 2 72 0 
0.75 41 7 72 0 
1 43 9 72 0 
2 48 14 72 0 
3 52 18 72 0 
 
Table 3.8 Tm data for poly(dA)•2poly(dT) melting in the presence of indicated NP(18) 
concentrations.  Samples containing DNA (15 M) and ligand in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis.  
 
  
[ligand] in M 
Tm32 
(NHP(22,18)-NP(18)) 
Tm21 
(NHP(22,18)-NP(18)) 
0.2 5 4 
0.75 17 14 
1 17 15 
2 40 16 
3 40 20 
 
Table 3.9 Comparison of NHP(22,18) versus NP(18) on the Tm for poly(dA)•2poly(dT) 
melting at indicated ligand concentrations.  Samples containing DNA (15 M) and ligand 
in buffer (10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated 
at 95 
o
C for 5 minutes before slow annealing to room temperature before UV melting 
analysis (monitored at 260 nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). Values for 
Tm were determined by first derivative analysis.  
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Figure 3.34 Comparison plot of NHP(22,18) versus NP(18) on triplex Tm for 
poly(dA)•2poly(dT) melting in the presence of varying concentrations.  (rdb = ratio of 
drug to DNA in base pairs). Samples containing DNA (15 M) and ligand in buffer (10 
mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 
5 minutes before slow annealing to room temperature before UV melting analysis 
(monitored at 260 nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.).  
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Figure 3.35 UV melting comparison of poly(dA)•2poly(dT) with various ligands. 
Samples containing DNA (15 M) and ligand (2 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). Values for Tm were determined by first 
derivative analysis. 
 
compound Tm32 Tm32 
None 34 0 
Neomycin 37 3 
Hoechst 33258 28 -6 
aminopyrene 38 4 
NP(18) 48 14 
NH(22) n.o. n.o. 
HP(13) 43 9 
NHP(22,18) 88 54 
NH(22) + aminopyrene 37 3 
HP(13) + neomycin 41 7 
NP(18) + Hoechst 33258 32 32 
 
Table 3.10 Tm data for poly(dA)•2poly(dT) melting in the presence of indicated ligands.  
Samples containing triplex DNA (15 M) and ligand (2 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2) were heated at 95 
o
C for 5 minutes 
before slow annealing to room temperature before UV melting analysis (monitored at 260 
nm from 20-98 
o
C at a heating rate of 0.2 
o
/min.). For NH(22), no distinguishable 
transition was observed (n.o. = not observed).  Data for Hoechst 33258 and NH(22) 
samples taken from Figures 2.2 and 2.4.  Values for Tm were determined by first 
derivative analysis. 
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Figure 3.36   UV melting profiles of dA22•(dT22)2  with various ligands.  Samples of 
DNA (1 M in triplex) were mixed with ligand (0 to 2 M) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 6.8) before heating at 95 
o
C for 5 minutes 
and slow annealing to 10 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating 
rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument 
software. 
 
 UV melting experiments were also carried out with an oligomeric triplex 
dA22•(dT22)2 to test the effect of NHP(22,18) on shorter A/T rich triplexes.  At 150 mM 
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KCl, the UV transition representing triplex melting for dA22•(dT22)2 cannot be observed.  
However, when mixed with appropriate triplex-stabilizing ligand, a melting transition 
corresponding to triplex dissociation can be observed.  As indicated in Figure 3.36, a 
noticeable triplex transition appears at relatively low NHP(22,18) concentrations (1 and 2 
M).  As with other oligomeric DNA, the transition appears somewhat broader than that 
with polymeric DNA, for reasons mentioned earlier in the text.  Nevertheless, there is a 
clear indication of triplex stabilization, as apparent in the appearance and increase in 
triplex melting transition, with Tm values ranging up to 18 oC (if considering Tm = 10 
o
C, the minimum temperature analyzed in the study).  
To further investigate the role of Hoechst binding (NHP(22,18)) to triplex DNA, CD 
titrations of NHP(22,18) into poly(dA)•2poly(dT) were carried out in similar fashion to 
those with duplex poly(dA)•poly(dT).   Like that observed with duplex DNA, as 
concentrations of NHP(22,18) increased, significant changes in the Hoechst absorption 
region (around 350 nm) are noticeable (Figure 3.37).  Due to the similarity with 
poly(dA)•poly(dT) CD spectra in this region (positive increases in signal from 320 to 400 
nm, with a maxima around 350 nm), a minor groove binding mode can be attributed to 
Hoechst in binding to triplex DNA.  Therefore, the overall binding of NHP(22,18) can be 
triple in nature: neomycin binding in the Watson-Hoogsteen groove of the triplex, pyrene 
intercalating within the neighboring base pairs, and Hoechst in the local minor groove.  
Circular dichroism experiments with NP(18) (Figure 3.38) indicate a distinctive change in 
the DNA region (220-300 nm), supporting DNA binding, but clearly different in the 
region from 300-450 nm due to the absence of the minor groove binding by Hoechst. 
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Figure 3.37 Circular dichroism of poly(dA)•2poly(dT) complexed with NHP(22,18).  Small 
aliquots of concentrated ligand (200 M) were titrated into a solution of DNA (30 M) 
before equilibration and scanning from 450-210 nm.  Hoechst complexation is indicated 
by the increase in signal from 400-320 nm, whereas evidence of DNA binding can be 
observed by changes in the 300-210 nm region.  Solutions were in 10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; T = ambient. 
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Figure 3.38 Circular dichroism of poly(dA)•2poly(dT) complexed with NP(18).  Small 
aliquots of concentrated ligand (200 M) were titrated into a solution of DNA (30 M) 
before equilibration and scanning from 400-210 nm.  Solutions were in 10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2; T = ambient. 
 
 Analysis of triplex binding by Hoechst 33258, NHP(22,18), and NP(18) was also 
carried out using fluorescence spectroscopy.  We envisioned a similar protocol to that 
implemented for duplex poly(dA)•poly(dT) studies, however the conditions used for 
duplex involved low ligand and DNA concentrations (nM).  Due to triplex instabilities, 
competing dissociation to duplex would thus hinder accurate determinations of affinity 
constants.  To this end, we increased concentrations of ligand to 100 nM, therefore  
requiring concentrations of triplex to be in the low micromolar range, ensuring the 
presence of triplex upon its dilution from a concentrated (500 M) solution to that in the 
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sample cuvette (containing ligand).  Futhermore, the addition of Mg
2+ 
(1 mM) ensured 
triplex stability.    
Binding curves depicting the ligand:triplex interaction for Hoechst 33258, 
NHP(22,18), and NP(18) are shown in Figure 3.39-3.40.  For both Hoecsht 33258 and 
NHP(22,18), fluorescence enhancement upon increasing [DNA] was observed.  The curves, 
as suggested above, could be successfully curve-fit to provide binding constants for each 
ligand.   Surprisingly, the binding of Hoechst 33258 (5.9x10
6
 M
-1
) is slightly higher than 
NHP(22,18) (2.4x10
6
 M
-1
).  These results indicate Hoechst 33258 binding the triplex, and 
are somewhat unanticipated due to the observed destabilization of triplex in UV melting 
experiments.  A possible explanation for the observed binding is that Hoechst 33258 
binding to the duplex shifts the equilibrium to favor further triplex dissociation (to duplex 
and single strand), giving rise to more favorable duplex binding domains.  Total triplex 
formation requires molar salt concentrations; a certain population of duplex is therefore 
present in the experimental salt conditions, 150 mM KCl, 1 mM MgCl2.  An obvious 
concern is that lower binding affinity (10
6
 M
-1
) than typical Hoechst binding to duplex 
(10
8 
M
-1
).  However, the elevated concentrations (to micromolar) give complications in 
accurately determining Kb, as [ligand] should be in low nM range (1/Kb).  These 
conditions could not be met due to reasons mentioned above. 
In the titration of NP(18) with triplex DNA, there is an apparent decrease in pyrene 
emission as DNA is added.  Unfortunately, the binding data in the titration could not be 
reliably fit.  However, the scans provide critical evidence of pyrene interaction with the 
DNA.  The observed quenching of fluorescence by pyrene upon intercalation of DNA is 
due to a photoinduced electron transfer mechanism between the fluorophore and the 
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DNA base.  The first unambiguous evidence for electron transfer between an excited 
pyrene molecule and a nucleic acid base was shown by O’Connor et al.,202 and was later 
supported by Netzel
203
 and Manoharan.
204
  In contrast, intercalators of DNA that exhibit 
fluorescence enhancement upon binding undergo a separate phenomenon.  A case study 
is ethidium bromide, a classic DNA interacalator.  The increase in fluorescence of 
ethidium upon DNA intercalation is due to the loss of proton transfer from its excited 
state to bulk aqueous media when embedded between base pairs, in turn reducing the rate 
of proton transfer and consequently exhibiting an increase in fluorescence quantum 
yield.
205
  A specific example of this phenomenon is Hoechst minor groove binding, 
which upon deep interaction with the narrow minor groove and results in minimized 
exposure to the aqueous media.   
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Figure 3.39  Fluorescence-detected binding of poly(dA)•2poly(dT)  + Hoechst 33258. 
Small aliquots of DNA (500 M stock) were titrated into a solution of ligand (100 nM in 
1.5 mL) and analyzed for fluorescence emission over the 390-600 nm range. Conditions: 
exc = 338 nm; slits = 4 nm; T = 20 
o
C; buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 150 mM KCl, 1 mM MgCl2, pH 7.2. 
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Figure 3.40  Fluorescence-detected binding of poly(dA)•2poly(dT)  + NHP(22,18).  Small 
aliquots of DNA (500 M stock) were titrated into a solution of ligand (100 nM in 1.5 
mL) and analyzed for fluorescence emission over the 390-600 nm range. Conditions: exc 
= 345 nm; slits = 4 nm; T = 20 
o
C; buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 
150 mM KCl, 1 mM MgCl2, pH 7.2 
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Figure 3.41  Fluorescence-detected binding of poly(dA)•2poly(dT) + NP(18).  Small 
aliquots of DNA (75 M stock) were titrated into a solution of ligand (100 M in 1.5 
mL) and analyzed for fluorescence emission over the 390-600 nm range. Conditions: exc 
= 343 nm; slits = 2 nm; T = 20 
o
C; buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 
150 mM KCl, 1 mM MgCl2, pH 7.2 
 
 Viscometry was also utilized in studying the interactions of NHP(22,18) with 
poly(dA)•2poly(dT).  For comparison, both NH(22) and neomycin were included.   As 
depicted in Figure 3.42, a noticeable decrease in poly(dA)•2poly(dT) solution viscosity 
is apparent when increasing aliquots of NHP(22,18) are added.  Surprisingly, the viscosity 
of NHP(22,18)-triplex solutions decrease significantly when compared with both neomycin 
and NH(22).  This phenomenon contrasts with that observed with duplex 
poly(dA)•poly(dT).   A viable explanation for this observation could be that the 
neomycin interaction in NHP(22,18) is much stronger at such concentrations, when 
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compared with neomycin or NH(22), due to the high affinity binding of the Hoechst 
moiety in the minor groove.  Thus, neomycin is effectively delivered to the triplex groove 
efficiently.  Because of the strong interaction of neomycin with the DNA triplex, as 
observed in numerous reports from our labs, the mode of binding of NHP(22,18) to triplex 
DNA, in regards to the neomycin moiety, is quite different from that with duplex DNA, 
with which neomycin alone has significantly lower affinity.   
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Figure 3.42 Viscometric analysis of poly(dA)•2poly(dT) with various ligands:  Small 
aliquots of ligand (200 M) were titrated into a solution of DNA (100 M) and 
corresponding flow times were recorded in triplicate with deviation less than 0.1 second.  
Error bars for each titration point are included.  Buffer:  10 mM sodium cacodylate, 0.5 
mM EDTA, 150 mM KCl, 1 mM MgCl2, pH 7.2; T = 27 + 0.05 
o
C. 
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Serendipitous preparation of a novel 
neomycin-neomycin-Hoechst 33258 conjugate 
  
 Prior to development of the novel triple-recognition agent NHP(22,18), a synthetic 
pathway in developing alternative neomycin-Hoechst 33258 conjugates possessing a 
central 2
o
 amine within the linker had a surprising ending at the final conjugation step 
(Hoechst-diamine derivative with neomycin isothiocyanate).   Originally, it was 
envisioned that the successful development of a Hoechst derivative containing a diamine 
linker, separated by ethylene glycol spacers, would render the 2
o
 amine unreactive (due to 
electron withdrawing by the nearby oxygen atoms).  We found this not to be the case, 
however, when equivalents of the diamine derivative were mixed with neomycin 
isothiocyanate (Scheme 3.4).  The end result was a novel neomycin-neomycin-Hoechst 
conjugate (37, Scheme 3.5).  A limited amount of research was devoted to this compound 
due to the limited amounts prepared and the somewhat disappointing results initially 
obtained (stabilization of DNA was approximately equal to that of other neomycin-
Hoechst conjugates; see data in Appendix).  However, recent analysis has found 
neomycin-neomycin dimers to exhibit strong preference for B-DNA, most likely in the 
major groove.
154
  Therefore compound 37 represents a novel ligand for targeting duplex 
DNA sequence specifically (due to the attached Hoechst moiety), pending further 
biophysical analysis.  A computer-generated model of compound 37 bound to an A-T 
rich 10mer duplex is depicted in Figure 3.43. 
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Scheme 3.4  Sythesis of Hoechst-diamine: (a) 22, PPh3, DIAD, dioxane, 78%; (b) 24, 
K2CO3, NaI, DMF, 61%; (c) (i) trifluoroacetic anhydride, pyridine, NEt3, 58%; (d) (i) 
HCl(g), MeOH, quant. (ii) 8, MeOH, HOAc, 28%. 
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Scheme 3.5  Synthesis of Neomycin-Neomycin-Hoechst conjugate: (a) 5, pyridine, 
DMAP, 45%; (b) 36, TFA/CH2Cl2, trace ethanedithiol, 85%. 
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Figure 3.43 Computer model of compound 37 bound to d(A)10•d(T)10 duplex.  The 
modeling was performed using Amber force field, water as solvent, and under constant 
dielectric conditions.  Structural minimizations converged on a gradient to within 0.02 
kJ/mol. Structures of the conjugates are displayed below their respective model.  Five of 
the six amines in neomycin were protonated, in agreement with NMR studies of 
neomycin,
150,151
 
 
Conclusion 
We recently reported that neomycin affinity for nucleic acids includes structures 
known to adopt A-like conformations.  We have since endeavored to explore neomycin’s 
utility in binding to B-DNA to better understand the molecular forces that dictate binding 
within the DNA major groove.  Specifically, a progression from dual recognition to triple 
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recognition has been explored by including an intercalating region (pyrene) within the 
central spacer separating Hoechst 33258 and neomycin.  From the current study of the 
novel triple recognition agent NHP(22,18) the following conclusions can be drawn: (1) 
NHP(22,18) significantly enhances DNA stability.  UV melting experiments with both 
polymeric and oligomeric DNA indicate significant shifts in Tm when compared with 
samples in the absence of ligand.  The shifts were significantly greater than control 
ligands NP(18) and HP(13), indicating contributions by all three binding regions.  DSC 
experiments indicate a significant drop in H of duplex melting at the unbound Tm, 
indicating complexation Tm at a higher temperature (above the limits of instrumental 
conditions).  (2) NHP(22,18) binds stronger to B-DNA than Hoechst 33258 and other 
conjugates studied.  Fluorescence binding studies with NHP(22,18) indicates higher binding 
affinity than Hoechst 33258, NH(10), and NH(22) with poly(dA)•poly(dT).  (3) The binding 
mode for Hoechst to DNA is the same in all ligands studied.  Circular dichroism 
experiments indicate similar spectral patterns for poly(dA)•poly(dT) when titrated with 
either Hoechst 33258 or other Hoechst-neomycin conjugates.  (4) The optimal binding 
site for the conjugates includes a contiguous stretch of nine A-T base pairs.  Fluorescence 
titrations indicated base pair:ligand ratios of 9:1 for NHP(22,18).  A higher binding constant 
for NH(10) with poly(dA)•poly(dT) than Hoechst 33258 was also observed.  The 
importance of the extended A/T site for strong binding was further illustrated in studies 
with both shorter A/T stretches and interrupted A/T stretches.  NHP(22,18) binding to 
d(CGCAAATTTGCG)2 exhibited ten-fold lower binding affinity than Hoechst 33258. 
Yet, comparisons with d(CGCAAGCTTGCG)2 indicate a value for Kb greater than that 
observed with NH(10) or Hoechst 33258.  Such increase in binding can thus be attributed 
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to intercalation by the pyrene moiety.   (5)  Pyrene intercalation is apparent using 
viscometric techniques.  Comparison analysis of NHP(22,18) with NH(22), Hoechst 33258, 
and neomycin indicate an increase in solution viscosity when pyrene (in NHP(22,18)) is 
present, a phenomenon consistent with DNA intercalation.  (6) NHP(22,18) also stabilizes 
triplex DNA. UV melting experiments of the conjugates under triplex-forming conditions 
indicate a significantly higher Tm than that seen with neomycin or other control ligands 
(NP(18), HP(13)). Altogether, these results further illustrate NHP(22,18) not only as a 
remarkable DNA binder but as a probe to better understand the molecular requirements 
for multi-recognition of B-DNA. 
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CHAPTER 4 
DUAL RECOGNITION OF RNA DUPLEX 
Introduction 
Small molecules that bind the DNA minor groove have been noticed for quite 
some time.  A number of compounds based on the natural product distamycin have been 
prepared synthetically and shown to significantly and selectively bind discriminate base 
pair stretches of DNA.
23
  The central responsibility for DNA affinity is the structural 
features of such small molecules; the crescent shape of the ligand matches the pitch of the 
DNA helix, snugly fitting within the minor groove to distribute various favorable 
contacts with the DNA bases.  DNA groove binding by small molecules is almost 
exclusively limited to the minor groove.   Selective recognition of the major groove has 
remained elusive. 
 Like DNA major groove-binders, small organic molecules that bind duplex RNA 
grooves are virtually absent when compared with those of DNA minor groove studies.  
This can be largely attributed to its youth in research focus, since it has only recently 
been realized as a viable target for therapeutic purposes.
206
  The few that are known are 
ubiquitous in structural preference.
82
  For example, aminoglycoside antibiotics are known 
bind a variety of RNA structures.
56,65,78,80,84,88,207-210
  Besides more complex structures, 
there is clear evidence supporting duplex binding by aminoglycosides in the RNA major 
groove.
210,211
  Therefore, it is RNA minor groove interactions by small molecules that is 
least well known.  Schimmel has provided the lone examples of minor groove-
recognizing molecules, comprised of peptides up to 28 amino acids in length.
212
  Yet, this 
pushes the concept of “small” molecule binding.  The structural features of the RNA 
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minor groove may likely be the reason for the shortage of ligands in this area of 
molecular recognition. The RNA duplex maintains an A-form conformation, which is 
characterized by a wide, shallow minor groove and a pinched, deep major groove. 
Therefore, the snug fit in the minor groove, otherwise accomplished with B-form DNA 
due to its characteristic narrow, deep minor groove, is absent. Progress in ligand design 
primarily has focused on small molecule synthesis, which coincidentally has seen 
promise in DNA minor groove applications. The known duplex RNA binders are more 
synthetically challenging due to their size and complex structure.  A structural scaffold 
for groove recognition in duplex RNA is therefore lacking when compared to duplex 
DNA. 
 To expand our understanding of the requirements for duplex RNA binding, a 
number of research endeavors have been initiated. Organic cations such as berenil
31
 and 
DAPI (4´,6-diamidino-2-phenylindole)
34
 have displayed significant RNA duplex 
stabilization. However, DNA affinity by these ligands are also observed.  Interestingly, 
the mode of binding of ligands such as berenil to RNA is different from DNA binding.  
Berenil intercalates the RNA duplex, while binding to DNA is in a groove binding 
fashion.
31
  The different modes of binding by such molecules therefore offers some 
optimism in achieving selective binding of RNA duplex over DNA duplex by modifying 
the molecular structure.  Wilson envisioned such possibilities over a decade ago,
213
 which 
led to the development of several bipiperidine derivatives that showed significant affinity 
for duplex RNA over duplex DNA.
214
  Several of the more rigid organic cations of this 
bipiperidine series were likened to aminoglycoside antibiotics, which are well known for 
RNA binding.  An extended approach involves the conjugation of known RNA binders, 
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like peptides or aminoglycosides, to simple intercalators.
153,215
  Intercalation is largely 
non-nucleic acid specific (there are limited exceptions), so the  
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delivery of the conjugated ligand (e.g., groove binder) is potentially accomplished with 
both DNA and RNA.  However, it is the selectivity of the conjugated moiety that drives 
the structural or sequence selectivity.  An example of this comes from the natural product 
actinomycin D, which is known to intercalate DNA and rest its peptide appendages in a 
sequence selective fashion within the minor groove.
216,217
  Selected examples of 
synthetically achieved RNA intercalator-groove binder conjugates are an acridine-
spermine derivative (known for its potency toward Tat-TAR inhibition),
218
  an ethidium-
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arginine conjugate (an active TAR RNA binder),
215
  and a neomycin-acridine conjugate, 
(a potent Rev-RRE complex inhibitor).
153
  Beal’s group has developed a library of 
peptide-acridine conjugates with promising RNA structural selectivity for binding.
219,220
  
Based on work by groups such as Wilson’s involving threading intercalators,221 Beal has 
shown that dual groove recognition of RNA duplexes can be achieved by attaching 
peptides at both ends of intercalators such as acridine.  Yet these binding events require 
local opening of the RNA double helix, so the recognition may lie within duplex areas 
adjacent to bulges or loops, where such and opening is available for threading to occur.
219
 
Nevertheless, such groove recognition is insightful for the development of more structure 
specific RNA binding ligands for therapeutic applications. 
 Research in our laboratories focuses on the utility of neomycin, an 
aminoglycoside antibiotic, for nucleic acid recognition beyond its natural RNA target, the 
aminoacyl site of the 16S subunit of bacterial rRNA, and other more recently discovered 
RNA targets.  Within the past few years, our work has extended the list of structures that 
neomycin bind, namely triplex DNA
105,108
 and RNA,
105
 and DNA/RNA hybrids.
125
 These 
efforts led us to strongly support the idea that neomycin does not bind to RNA alone, but 
rather nucleic acid structures that are known for adopting an A-like conformation.
126
 We 
have since shown that neomycin can bind B-form DNA structures by covalently attaching 
it to a DNA minor groove-binder (Hoechst 33258).
134
 Most recently, we have found that 
dimers of neomycin bind DNA duplexes, with particular affection towards A/T base 
pairs.
154
    
The extended recognition by novel neomycin-based conjugates is indebted to 
recent developments in the synthetic derivitization of neomycin.  These new synthetic 
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approaches, as reported by Tor
153
 and our group,
152
 allow for the functionalization of 
neomycin for covalent conjugation with other nucleic acid-active molecules.  We have 
successfully prepared conjugates of neomycin with intercalating
109,110
 and groove binding 
molecules, including DNA.
134,152
  With such tools in hand, we are able to probe the 
recognition elements of a variety of ligands with a variety of nucleic acid targets, both 
known and unknown.  The present focus, as projected in this article, is on the recognition 
of duplex RNA groove. 
Based on the postulate that RNA recognition is similar to protein recognition (due 
to RNA’s ability to form complex tertiary structures),51 achieving specific structural 
recognition is the key forward step.  This contrasts DNA recognition, which generally 
involves sequence specific recognition of a simpler helical motif.  A good example of a 
molecule that supports these generalizations is Hoechst 33258.  Though known primarily 
for its affinity for A/T stretches in the minor groove of DNA, Hoechst 33258 has been 
shown to bind a number of RNA structures, including TAR RNA,
222
 thymidylate 
synthase mRNA,
223
 and human telomerase RNA.
224
  The binding site in each of these 
RNA is of different sequence, suggesting that there is a common structural invitation for 
Hoechst 33258 binding.  We investigate this premise further by testing NH(10) with 
duplex RNA.  As previously mentioned, we have shown that this conjugate binds DNA, 
most likely in both minor (Hoechst 33258 moiety) and major (neomycin moiety) grooves, 
and significantly stabilizes the B-DNA structure when compared to Hoechst 33258 
alone.
134
   Therefore, we anticipated similar binding to RNA duplex, given that neomycin 
is firmly established as an RNA major groove binding ligand.  The concern was whether 
the Hoechst 33258 moiety of the conjugate would display any binding properties, since 
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its known RNA interactions are few, and consistently involve bubble or loop structures.  
However, as supported in the forthcoming pages, we found that Hoechst 33258 binds 
duplex RNA when conjugated with neomycin.  Interestingly, Hoechst 33258 alone 
appears to show no effect under these conditions.  These findings are exciting when 
considering the absence of dual groove recognition of RNA duplexes (not involving 
intercalation) in the literature.   Also, the requirement for local unwinding or adjacent 
bulge structures, as with threading ligands, is diminished.  Therefore, ligands such as 
these potentially have applications for biological RNA duplex targeting.
225
  Lastly, these 
results lay a foundation for future studies with otherwise non-RNA binding ligands with 
potential for defining recognition principals in an otherwise mysterious area of nucleic 
acid recognition. 
 
UV Melting study of NH(10) with poly(rA)•poly(rU) 
The thermal stability of poly(rA)•poly(rU)in the presence of neomycin, Hoechst 
33258, and the neomycin-Hoechst 33258 conjugate (termed NH(10)) was first studied by 
thermal denaturation monitored by UV absorbance (Figure 4.1).  Neomycin, as expected, 
was found to increase the Tm of the duplex, with a Tm of 13 
o
C.  Hoechst 33258 showed 
no increase in Tm.  The conjugate, NH(10), considerably precipitated the RNA, obvious to 
the naked eye as well as by observing the little change in UV absorbance upon sample 
heating.  Therefore, we were only able to gather relatively clean melting profiles by 
immediate UV melting analysis upon sample preparation. Close inspection of Figure 4.1 
reveals a small amount of precipitation (small fluctuations in absorbance) even under 
these conditions.  The resulting profiles, however, indicate a significant increase in the 
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Tm, with a change of over 30 
o
C.  Simple comparison of Tm values strongly suggests that 
Hoechst binding is present in the conjugate.  Interestingly, there is no observed 
stabilization by Hoechst 33258 alone, meaning that there is a requirement for neomycin’s 
presence to effect any binding by the bis(benzimidazole) derivative.  Therefore, both 
neomycin and Hoechst bind in tandem to significantly stabilize poly(rA)•poly(rU), much 
more effectively than neomycin alone.  These exciting results prompted us to investigate 
this newly discovered neomycin-induced Hoechst binding in further detail with other 
techniques. 
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Figure 4.1.  UV Melting of poly(rA)•poly(rU) alone and in the presence of neomycin and 
NH(10).  [RNA] = 20 M; [ligand] = 6 M; Buffer: 10 mM PIPES, 1 mM EDTA, 100 
mM NaCl, pH 7.0.   
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Circular Dichroism of NH(10) and Neomycin Binding to poly(rA)•poly(rU) 
We utilized circular dichroism (CD) spectroscopy to study the changes, if any, in 
the RNA duplex structure as well as in the Hoechst moiety of the conjugate.  Numerous 
reports have explained binding-induced chirality of Hoechst 33258 by DNA, typically 
indicated by a change in CD signal at the max of Hoechst 33258 UV absorbance.
165,166
  In 
our studies, we carried out titrations of ligand into a solution of RNA, with CD scans of 
the solution taken after appropriate equilibration times between ligand additions.  The 
resulting scans were overlayed to compare the CD spectra at different ligand:RNA ratios 
(Figure 4.2).  We found that there is a significant change in the CD signal in the 
poly(rA)•poly(rU) region, which is represented by a negative band at 245 nm and a 
positive band at 265 nm.  Also, in the region of 345 nm, there is an increasingly negative 
CD signal as ligand:RNA ratios increased, indicative of Hoechst complexation with the 
RNA.  Such a signal would be absent if no interaction is occurring. For neomycin 
titrations, significantly less change in CD signal is apparent (Figure 4.3). Therefore, 
these results further support Hoechst binding to the poly(rA)•poly(rU)duplex is 
occurring. As was observed with other experiments, small changes in the CD spectra 
occurred when Hoechst 33258 was mixed with poly(rA)•poly(rU).  
Hoechst 33258 and Hoechst conjugates, when bound to DNA, are characterized 
by an increased positive ellipticity as bound concentrations of ligand are increased.  A 
contrasting phenomenon is found with RNA duplex, as Hoechst binding is represented by 
an enhanced negative ellipticity in the region of Hoechst absorbance (300-400 nm).  A 
comparison of the models of NH(10) bound to RNA duplex (see later section) indicates a 
distinct difference in Hoechst conformation when bound within the minor groove.  Such 
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distinct CD signals illustrate the subtle differences between the location of favorable 
interactions within the DNA vs. the RNA minor groove. 
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Figure 4.2 CD-detected binding of poly(rA)•poly(rU) and NH(10).  Small aliquots of 
concentrated ligand (300 M) were added to a solution of  RNA (40 M) with stirring 
before scanning sample from 400 to 220 nm; Buffer 10 mM PIPES, 1 mM EDTA, 100 
mM NaCl, pH 7.0. 
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Figure 4.3  CD-detected binding of poly(rA)•poly(rU) with neomycin (left) and Hoechst 
33258 (right).  Small aliquots of concentrated ligand (300 M) were added to a solution 
of  RNA (40 M) with stirring before scanning sample from 400 to 220 nm; Buffer 10 
mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
 
 The binding exhibited by the Hoechst moiety (in NH1) within the minor 
groove of the RNA duplex is characterized by a negative induced CD signal within the 
Hoechst absorption region (around 340 nm; see Figure).  The signal is virtually the mirror 
image of the induced CD signal observed when Hoechst is bound to DNA duplex (as 
seen in previous figures where DNA binding is studied).  The negative CD signal in the 
absorption region is a rarely observed phenomenon, as many DNA binding ligands 
exhibit a positive signal in their absorption regions, particularly with those designated as 
minor groove binding (refs).  However, the observed negative signal exhibited in the 
Hoechst absorption region when NH1 is mixed with RNA duplex does not discount the 
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observed signal as that representing a minor groove binding mode.  For example, there 
are distinct cases where the induced CD signal is negative for ligands that bind DNA in 
the minor groove, albeit in an orientation opposite that of the overall dipole moment of 
the groove.  For example, it has been shown that adducts of benzo[a]pyrene-7,8-
dihydrodiol-9,10-epoxide at the N-2 of guanine exhibit a stereochemical-dependent 
relationship with the sign of the CD signal arising from ligand binding.
226,227
  This 
induced CD signal (often termed ICD) was found to be negative when the benzylic 10-
position was in the S-configuration, whereas the corresponding enantiomer exhibited a 
positive ICD.  It is the stereochemistry at this benzylic position that has been found to 
influence the orientation of the long axis of the pyrenyl moiety toward the 3’ or 5’ end of 
the modified DNA oligomer.
228
  More importantly, using a combination of spectroscopic 
and NMR techniques, all stereoisomers with variation only at the benzylic 10-position 
were found to exhibit similar modes of binding.
228-231
  
Experiments that have traditionally pinpointed the orientation of the ligand along 
the groove have included linear dichroism (LD).  Whether the orientation of the Hoechst 
moiety in RNA duplex binding is in a similar orientation may be resolved by LD 
experiments, and should be thus examined in due course.  However, to date, the 
observation of a negatively induced CD signal for ligand-RNA duplex binding is lacking, 
preventing a direct correlation of binding orientation within the different minor groove 
environments of DNA and RNA duplexes. 
We further investigated the CD spectrum of the NH(10)-poly(rA)•poly(rU)complex 
by carrying out CD melting experiments.  These allow us not only to confirm Tm results 
obtained from UV melting studies, but also to monitor any conformational changes in a 
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temperature dependent fashion.  Since poly(rA)•poly(rU)is capable of forming complex 
structures when heated, it is likely these structures will be represented by changes in their 
CD spectra. Figure 4.4 clearly indicates a single melting transition of 
poly(rA)•poly(rU)alone. In the presence of ligand, we found that CD changes in the 
poly(rA)•poly(rU)region primarily occurred at temperatures around that in the absence of 
ligand (Figure 4.5a).  However, when the CD values of the ligand-complex at increasing 
temperatures are compared, there is a clear transition at higher temperatures (similar to 
that observed in UV melting), confirming the melting of the complex and “freeing up” of 
the bound ligand (Figure 4.5b).  These results strongly suggest that alternative structures 
are formed upon heating, likely attractive to the ligand since CD values are still virtually 
unchanged at temperatures where RNA duplex melting has occurred (as supported by the 
CD melting profile of the RNA region at 245 nm, Fig. 4b). Job analysis using UV 
absorbance indicates RNA triplex formation at elevated temperatures (2:1 
poly(rU):poly(rA) mixtures exhibit an absorbance minimum), further validating this 
assumption. These phenomena were observed both in the absence (Figure 4.6) and 
presence of NH(10) (Figure 4.7).  We combat this issue in a later section by examining 
ligand binding to a shorter RNA duplex, thus eliminating any confusion as to what 
structural transition is being observed. 
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Figure 4.4. CD detected melting of poly(rA)•poly(rU) at 266 nm: [RNA] = 60 M; 
[NH(10)] = 15 M; Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
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Figure 4.5. CD detected melting of poly(rA)•poly(rU) + NH(10) monitored at 266 nm (A) 
and 342 nm (B). [RNA] = 60 M; [NH(10)] = 15 M; Buffer: 10 mM PIPES, 1 mM 
EDTA, 100 mM NaCl, pH 7.0.  The CD at 266 nm represents RNA conformational 
changes, whereas 342 nm represents NH-1 (complexed with RNA) conformational 
changes. 
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Figure 4.6.  UV Job Plots of poly(rA)•poly(rU) at 20 oC, 50 oC, and 70 oC.  Samples of 
equimolar (40 M) solutions of poly(rA) and poly(rU) were mixed in varying ratios and 
analyzed for UV absorbance. Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 
7.0. 
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Figure 4.7.  UV Job Plots of poly(rA)•poly(rU) and NH(10) (6 M) at 20 
o
C, 50 
o
C, and 
70 
o
C.  Samples of equimolar (40 M) solutions of poly(rA) and poly(rU) containing 
NH(10) (6 M)were mixed in varying ratios and analyzed for UV absorbance. Buffer: 10 
mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
 
Fluorescence Study of NH(10) Binding to poly(rA)•poly(rU) 
Numerous studies have used fluorescence spectroscopy to study Hoechst 33258 
binding.
170,173,195,232
  Typically, upon interaction with DNA, the fluorescence of 
Hoechst 33258 is greatly enhanced due to binding.  There are a limited number of 
accounts where Hoechst 33258 fluorescence changes (increases or decreases) in the 
presence of RNA, indicating ligand binding.  We found it crucial to further confirm 
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Hoechst binding (in the conjugate NH(10)) to poly(rA)•poly(rU)by conducting 
fluorescence titrations of both Hoechst 33258 and NH(10) with poly(rA)•poly(rU).  
Similar to protocols found in the literature, a solution of ligand was titrated with a 
concentrated solution of nucleic acid.  The resulting fluorescence emission spectrum 
was recorded after each titration and equilibration, and data from a single emission 
wavelength can be fit, depending on whether fluorescence saturation is reached and 
single binding sites are present.  We found that the fluorescence of NH(10) is greatly 
enhanced upon additions of poly(rA)•poly(rU)(Figure 4.8), whereas in the case of 
Hoechst 33258, no change is observed.  Therefore, the Hoechst moiety in the 
conjugate (NH(10)) binds poly(rA)•poly(rU), likely in a similar mode to that of DNA.  
In the case of Hoechst 33258 alone, the absence of fluorescence change strongly 
suggests that no binding is occurring.   Due to an absence in fluorescence saturation, 
we were unfortunately unable to establish any useful binding data.  Nonetheless, these 
experiments provide a distinct qualitative picture as to whether RNA duplex binding 
is present in the Hoechst moiety of the conjugate. 
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Figure 4.8.  Fluorescence emission scans of NH(10) titration with poly(rA)•poly(rU).  
Small aliquots of a concentrated solution of RNA (543 M) were titrated into a solution 
of NH(10) (2 mL of 333 nM) and mixed well before excitation at 342 nm.  [RNA] ranged 
from 0.36 to 32 M. Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
 
 
Isothermal Titration Calorimetry of NH(10) Binding to poly(rA)•poly(rU) 
Isothermal titration calorimetry reveals identical stoichiometries of binding, as 
well as a greater than 10-fold increase in binding by the NH(10) conjugate when compared 
with neomycin.  The intriguing results of UV and CD experiments prompted us to 
investigate the binding of NH(10) using isothermal titration calorimetry (ITC).  The ITC 
experiments typically involved 10 L injections of ligand solution into a sample chamber 
containing RNA, of which resulted in a heat burst curve for each injection, corresponding 
to the heat (given or taken) from the interaction between ligand and RNA.  For Hoechst 
33258 alone, little binding was observed, as indicated by heat burst curves similar to 
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drug-into-buffer titrations (Figure 4.9).  Neomycin titrated into duplex poly(rA)•poly(rU) 
displayed considerable binding (fit using Origin 5.0 software), with a binding constant of 
1.2x10
6
 M
-1
 (Figure 4.10a).   Using the same conditions for conjugate NH(10) (except for 
a lower ligand concentration due to early saturation in the isotherm due to stronger 
binding by NH(10)), the binding constant K = 1.6x10
7
 M
-1
, a greater than 10-fold increase 
over neomycin alone binding to poly(rA)•poly(rU)(Figure 4.10b).  Also, the H of 
binding is 9 kcal lower for NH(10) (-15.9 kcal/mol) than for neomycin (-6.9 kcal/mol).  In 
both cases, the binding stoichiometries are virtually the same, about 5 base pairs per 
ligand.  These results provide support that the presence of the Hoechst moiety in the 
conjugate results in an increased affinity for the RNA duplex, and that the interaction 
likely involves both grooves of the duplex.  Had the binding of the Hoechst moiety 
extended further up the polymeric lattice, the binding site size would be larger than 
neomycin.  We clearly see this is not the case.  Also, it is unlikely that binding within the 
same groove is occurring, due to the size and composition of the linker between the two 
binding groups (as if they could fold together to bind a site of ~5 base pairs).  Thus, dual 
groove binding by the conjugate is likely responsible for the observed signal in these 
experiments. All thermodynamic data gathered from ITC experiments are listed in Table 
4.1. 
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Figure 4.9  ITC profile of Hoechst 33258 and poly(rA)•poly(rU).  Injections of ligand 
(40x5 L of 100 M) into 40 M RNA were made at 20oC. Buffer: 10 mM PIPES, 1 mM 
EDTA, 100 mM NaCl, pH 7.0. 
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Figure 4.10   ITC of Neomycin and NH(10) binding to poly(rA)•poly(rU):  (A) Neomycin 
(10 L injections of 150 M) titrated into 40 M RNA and (B) NH(10)(10 L injections 
of 100 M) titrated into 40 RNA.  Heat burst curves generated from binding were 
processed and curve fit using Origin 5.0. Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM 
NaCl, pH 7.0. 
 
Compound N (base pairs) K (x 10
6
 M
-1
) H (kcal/mol) S (kcal/mol) 
Neomycin 5.4 1.2 + 0.2 -6.9 + 0.2 1.2 
NH(10) 4.6 15.9 + 3.0 -15.9 + 0.2 -6.2 
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Table 4.1  ITC generated thermodynamic data for neomycin and NH(10) binding to 
poly(rA)•poly(rU) duplex. 
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Figure 4.11 Viscometric analysis of poly(rA)•poly(rU) with various ligands.  Small 
aliquots of ligand (500 M) were titrated into a solution of RNA (100 M) and 
corresponding flow times were recorded in triplicate with deviation less than 0.1 second.  
Buffer:  10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
 
Viscosity Studies with NH(10) 
 The experimental results gathered at this point led us to conclude that neomycin 
is most likely the driving interaction, but that is not neomycin alone.  The Hoechst 33258 
moiety must be involved with the binding. UV melting profiles, CD, fluorescence, and 
ITC titration experimental results easily convey this. Given the substantial evidence by 
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other experiments that Hoechst-RNA binding was indeed occurring, it was of great 
interest to substantiate the mode of binding using viscometry.  Hoechst 33258 has been 
known to intercalate non-B-form nucleic acid structures,
233,234
 so we rationalized that this 
may be the case (if indeed our stoichiometry results from ITC were unreliable). 
Viscometry has long been utilized for investigating ligand-substrate binding modes, 
particularly to confirm intercalation events. Intercalation of nucleic acids results in an 
increase in the helical length due to space displacement between the base pairs by the 
ligand.  Nucleic acids of appropriate length are rod-like, so an increase in helical length 
results in an increase in solution viscosity.
199
  Thus, we carried out viscometric titrations 
of neomycin, Hoechst 33258, and NH(10) with poly(rA)•poly(rU) (Figure 4.11). Our 
results were quite interesting.  Neomycin displayed characteristic strong groove binding, 
with a decrease in viscosity (most likely due to a compacting of the RNA structure, 
contrasting that of intercalation, which increases viscosity due to elongating of the rod-
like nucleic acid structure).  Such a decrease in viscosity has been observed before, 
particularly with aminoglycoside interactions.
111,200
  Hoechst 33258, in accordance with 
other experiments, showed no change in the poly(rA)•poly(rU) solution viscosity.  NH(10) 
displayed even more decrease in solution viscosity when compared to neomycin, 
suggesting stronger groove binding and shortening of RNA.  Being the standard seal for 
determining intercalation interactions, these viscometry results lead us to strongly suggest 
that binding of the Hoechst 33258 moiety is not of an intercalative nature.  Since 
aminoglycosides are widely considered to bind the major groove of RNA, these results 
support a strong candidacy for a dual recognition agent in NH(10), with interactions 
covering both major and minor groove of duplex RNA.  However, one may consider that 
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due to dual groove binding, the helical shortening would be offset, and thus the observed 
viscosity would be virtually unchanged.  Yet, since both ITC and CD titrations suggest 
identical stoichiometries of interaction (neomycin vs. NH(10)), it is easy to consider a 
dual-groove binding nature.    Therefore, the a plausible explanation for viscosity 
decreases may rely on a cooperative binding mode by NH(10), where initial binding 
induces stronger interaction of NH(10) than that of neomycin alone.   Still, the structural 
elucidation of the NH(10)-RNA interaction is warranted to validate the proposed binding 
mode using the current experimental data.   
 There are a number of examples where NMR is used to investigate the 
complexation of Hoechst 33258 and similar bis(benzimidazoles) with DNA.
196,235-250
  
There are also accounts of analogous RNA duplexes (as studied below) of which 
extensive NMR data has been gathered (though not with Hoechst 33258).
251,252
  Efforts to 
study such conjugates as NH(10) in binding to both DNA and RNA duplex were of great 
importance, and would be be satisfactory in confirming the actual binding site of Hoechst 
in the RNA interaction (or neomycin in the DNA interaction).  For studying the 
interaction, similar to that reported, aromatic proton shifts corresponding to the Hoechst 
region are clearly distinguishable, and can be easily detected for binding interactions by 
observing peak shifts in this region when DNA or RNA is present.  Furthermore, the 
specific interaction can be elucidated given that the high field proton shifts for the 
nucleobases are resolved.  Both approaches have seen success, therefore future 
experiments using NMR should provide reliable results.  However, such NMR 
experiments require significant amounts of material (both ligand and DNA) and very 
powerful NMR instruments.  We were thus limited in both areas, though with the success 
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in the synthesis and further knowledge and experience in the methods, successful 
approaches may be met in the near future. 
 
Recognition of Oligomeric RNA Duplexes 
To test whether or not the neomycin-Hoechst 33258 conjugate could bind and 
stabilize smaller sequences of RNA, we turned our attention to the self-complementary 
duplexes r(CGCAAAUUUGCG)2 and r(CGCAAGCUUGCG)2. Due to the enhanced 
stabilization of d(CGCAAATTTGCG)2 by NH(10) over Hoechst 33258, it was exciting to 
ponder whether the conjugate (NH(10)) would display enhanced stabilization of the RNA 
analog.  Furthermore, the requirement for an A/U stretch was also probed by carrying out 
comparison experiments with a GC junction in place of the central AU junction of 
r(CGCAAAUUUGCG)2.    
 
UV Melting Study of NH(10) binding 
For a clear comparison of each ligand’s effect on the thermal stability, we 
prepared samples of r(CGCAAAUUUGCG)2 individually in the presence of neomycin, 
Hoechst 33258, and NH(10).  Also, a solution of r(CGCAAAUUUGCG)2 in the presence 
of both neomycin and Hoechst 33258 was prepared.  Such a comparison could indicate 
whether neomycin binding induces a conformational preference in the duplex for Hoechst 
33258 to bind.  This indeed was not the case.  We found that NH(10) significantly 
enhances the Tm of the RNA duplex (Tm = 11 
o
C, Figure 4.12). Neomycin displayed a 
slightly less shift in the Tm (Tm = 4 
o
C), whereas Hoechst 33258 slightly destabilized the 
duplex Tm (Figure 4.13).  The mixture of neomycin and Hoechst 33258 resulted in a Tm 
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in between those obtained with neomycin and Hoechst 33258 alone (Figure 4.14). 
Additional UV melting experiments of NH(10) and neomycin with 
r(CGCAAGCUUGCG)2 indicated a slight stabilizing effect by NH-1, though not much 
greater than neomycin alone (2 degrees higher, Figure 4.15).  Therefore, the conjugation 
of Hoechst 33258 with neomycin is necessary for Hoechst binding, and the binding for 
AnUn stretches are significantly more favorable than G/C containing sequences. 
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Figure 4.12 UV Melting of r(CGCAAAUUUGCG)2  alone and in the presence of NH(10). 
[RNA] = 2 M duplex-1; [ligand] = 4 M; Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM 
NaCl, pH 7.0. 
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Figure 4.13 UV Melting of r(CGCAAAUUUGCG)2 + Hoechst 33258.  [RNA] = 2 M 
duplex
-1
; [ligand] = 4 M; Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
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Figure 4.14 UV Melting of r(CGCAAAUUUGCG)2 + Hoechst 33258 + neomycin.  
[RNA] = 2 M duplex-1; [ligand] = 4 M; Buffer: 10 mM PIPES, 1 mM EDTA, 100 mM 
NaCl, pH 7.0. 
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Figure 4.15   UV Melting of r(CGCAAGCUUGCG)2  alone and in the presence of 
NH(10). [RNA] = 2 M duplex
-1
; [ligand] = 4 M; Buffer: 10 mM PIPES, 1 mM EDTA, 
100 mM NaCl, pH 7.0. 
 
Fluorescence Studies with NH(10) 
Fluorescence titration experiments further corroborated a sequence specificity of 
NH(10) for the A3U3 stretch (Figure 4.16)  As with poly(rA)•poly(rU), fluorescence of 
NH-1 is enhanced upon mixing with the 12mer RNA duplexes.  Fluorescence mixing 
curves indicated clear 1:1 binding for NH(10) in both r(CGCAAAUUUGCG)2 and 
r(CGCAAGCUUGCG)2 (Figures 4.18 and 4.19).  Therefore, equilibrium titrations of 
RNA into NH(10) could be fit to a one site binding model to give Kb values of 6.5+1.6x10
6
 
M
-1
 and 1.2+0.3x10
6
 M
-1
 for r(CGCAAAUUUGCG)2 and r(CGCAAGCUUGCG)2, 
respectively.  As expected, Hoechst 33258 alone displayed no fluorescence increase upon 
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mixing with RNA.  Moreover, the fluorescence was observed to slightly decrease, as 
illustrated in a fluorescence Job plot of Hoechst 33258 with r(CGCAAAUUUGCG)2 
(Figure 4.20). 
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Figure 4.16 Fluorescence titration of r(CGCAAAUUUGCG)2 into NH(10):  A 2 mL 
solution of NH(10) (1 M) was scanned after successive addition of small aliquots of a 
concentrated RNA duplex solution (40 or 60 M) and sufficient mixing.  Excitation: 342 
nm; Emission: 390-600 nm; slits: 4 nm; Buffer: PIPES10 (10 mM PIPES, 1 mM EDTA, 
100 mM NaCl, pH 7.0); T = 25 
o
C. 
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Figure 4.17   Fluorescence titration of r(CGCAAGCUUGCG)2 (left) into NH(10):  A 2 
mL solution of NH(10) (1 M) was scanned after successive addition of small aliquots of a 
concentrated RNA duplex solution (40 or 60 M) and sufficient mixing.  Excitation: 342 
nm; Emission: 390-600 nm; slits: 4 nm; Buffer: PIPES10 (10 mM PIPES, 1 mM EDTA, 
100 mM NaCl, pH 7.0); T = 25 
o
C. 
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Figure 4.18  Fluorescence mixing curve of r(CGCAAAUUUGCG)2 + NH(10).  Individual 
solutions of 1 M ligand and 1 M RNA (duplex-1) were mixed in varying ratios to a 
total volume of 1.5 mL and analyzed for fluorescence. Excitation: 342 nm; Emission: 
390-600 nm; slits: 4 nm; Buffer: PIPES10 (10 mM PIPES, 1 mM EDTA, 100 mM NaCl, 
pH 7.0); T = 25 
o
C. 
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Figure 4.19  Fluorescence mixing curve of r(CGCAAGCUUGCG)2 + NH(10).  Individual 
solutions of 1 M ligand and 1 M RNA (duplex-1) were mixed in varying ratios to a 
total volume of 1.5 mL and analyzed for fluorescence. Excitation: 342 nm; Emission: 
390-600 nm; slits: 4 nm; Buffer: PIPES10 (10 mM PIPES, 1 mM EDTA, 100 mM NaCl, 
pH 7.0); T = 25 
o
C. 
 
0
2 10
5
4 10
5
400 450 500 550 600
E
m
is
s
io
n

 
0
1 10
5
2 10
5
3 10
5
4 10
5
0 50 100
E
m
is
s
io
n
% Ht 33258
 
Figure 4.20  Fluorescence mixing curve of r(CGCAAAUUUGCG)2 + Hoechst 33258.  
Individual solutions of 1 M ligand and 1 M RNA (duplex-1) were mixed in varying 
ratios to a total volume of 1.5 mL and analyzed for fluorescence. Excitation: 338 nm; 
Emission: 390-600 nm; slits: 4 nm; Buffer: PIPES10 (10 mM PIPES, 1 mM EDTA, 100 
mM NaCl, pH 7.0); T = 25 
o
C. 
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These results further illustrate that NH(10) is not only a potent DNA duplex 
binding molecule, but a potent RNA duplex binding molecule as well.  Furthermore, a 
specificity of Hoechst for A/U base pairs exists, potentially due to a similar phenomenon 
that explains A/T base specificity in DNA. 
 
Modeling Study of NH(10)-RNA Recognition 
 
 RNA duplexes adopt an A-form conformation.  The A-form family of nucleic 
acids consist of right-handed, antiparallel double helices which possess a shallow, but 
wide, minor groove and a deep, narrow major groove, which are largely the result of the 
approximately 4 angstrom displacement of the base pairs. This largely contrasts with B-
DNA, which maintains a narrow, deep minor groove and a wide, shallow major groove. 
The number of base pairs per helical turn is 11 for A-DNA, whereas B-DNA maintains 
one less per turn.  The ~30
o
 reduction in helical twist is also a characteristic of A-form 
when comparing to B-form. The rise per base pair can be nearly one angstrom less than 
B-DNA, and the base pair inclination is much greater in A-form (between approximately 
10 
o
-20 
o
, compared to 0 
o
 for B-DNA.  Typically, B-form DNA is associated with sugar 
puckering of C2-endo, while A-form consists of C3-endo conformation (Figure 4.21), 
which give rise to ~1 angstrom difference in the phosphate-phosphate separations 
between each conformation. The C3-endo is the more stable conformation due to the 
presence of the C2-hydroxyl. 
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Figure 4.21  Sugar pucker differences in RNA (left) and DNA (right).  RNA adopts a 
C3-endo conformation, which exposes the bases (labeled in blue for clarity) and 
increases the  interstrand phosphate-phosphate distances between the minor groove.  
DNA maintains a C2-endo conformation, forming a deeper and narrower (shorter 
phosphate-phosphate distance) minor groove. 
 
Hoechst 33258 binding: DNA vs. RNA 
The driving force of the Hoechst-nucleic acid interaction is isohelicity.
25
  Like 
distamycin and netropsin-based ligands, the crescent molecular shape of 
bis(benzimidazoles) such as Hoechst 33258 matches well the pitch of the DNA minor 
groove.  The forces driving the interaction are a combination of van der Waals 
interactions, hydrogen-bonding, and electrostatic (ammonium group of the terminal 
piperazine ring).  Hydrogen bonding has typically been observed between the imidazole 
NH and either thymine 02 or adenine N3 positions within A/T base pair 
stretches.
145,146,168,250,253,254
  Molecular modeling of Hoechst 33258 with 
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d(CGCAAATTTGCG)2 indicated such interactions (Figure 4.22).  The recognition of 
DNA, however, does not rely solely on the number and type of hydrogen bonding 
contacts.  Numerous studies have indicated that the sequence specificity of such crescent 
shaped ligands is dominated by van der Waals interactions between the ligand the groove 
walls and floor.
26,255,256
  
 
 
Figure 4.22 Hydrogen bonding interactions of Hoechst 33258 and 
d(CGCAAATTTGCG)2 extracted  from pdb entry 296d.  The bar lining the sequence 
(left) represents the binding site.  Numbers over dashed lines represent the H-bond 
distances. 
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Figure 4.23  Hydrogen bonding interactions of Hoechst 33258  and 
r(CGCAAAUUUGCG)2.  The DNA coordinates were extracted from pdb entry 1al5.  
The bar lining the sequence (left) represents the binding site.  Numbers over dashed lines 
represent the H-bond distances. 
 
Molecular modeling of Hoechst 33258 docked in the minor groove of RNA 
analog r(CGCAAAUUUGCG)2, as with DNA,  indicates a number of hydrogen bonding 
interactions can potentially occur (Figure 4.23).  Yet experimental evidence suggests that 
no significant interactions between Hoechst 33258 and RNA duplex (polymeric and 
oligomeric) occur (our work and others).
214
  RNA, adopting the A-form conformation, 
possesses a minor groove much wider than that observed for B-DNA.  Therefore the tight 
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fit, that occurs with ligands such as Hoechst 33258 and B-DNA, is absent in RNA duplex 
(Figure 4.24). Nonetheless, Hoechst 33258 has been shown to bind bulge and loop-
containing RNA duplexes, primarily the bubble regions.
222-224
  Little has been 
investigated as to the molecular contacts, so geometrical considerations are general at the 
least.  One can, however, deduce that H-bonding can play a role in this recognition, given 
the number of H-bonding sites in the ligand and the absence of geometry similar to the B-
DNA minor groove that encourages favorable van der Waals interactions. 
 
 
 
Figure 4.24.  Computer model of Hoechst 33258 binding in the minor groove of 
d(CGCAAATTTGCG)2 (left) and  r(CGCAAAUUUGCG)2 (right).  NH(10) binding: 
DNA vs. RNA 
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Similar to Hoechst 33258 alone, the Hoechst moiety in NH(10) can be shown to 
display similar contacts with the DNA minor groove (Figure 4.25).  Close inspection of 
the molecular model of the NH(10)-d(CGCAAATTTGCG)2 complex indicates a fit 
between the benzimidazoles region and groove walls (Figure 4.26, left) similar to that of 
Hoechst 33258.  The neomycin moiety is observed to also display a number of hydrogen 
bonding interactions within the major groove.  The dual nature of binding portrayed by 
the conjugate is supported experimentally with observations that enhanced stabilization 
of DNA occurs when compared with Hoechst 33258 alone.
134
  Furthermore, the major 
groove interactions may explain previous observations that third strand binding by a 
triplex forming oligonucleotide in the duplex major groove (to form a DNA triplex) is not 
observed under normal triplex-forming conditions with the conjugate (NH(10)) present.
134
 
Contrasting DNA and small molecules that are limited to binding its minor 
groove, small molecules known for binding RNA are cationic in nature (e.g., 
aminoglycosides such as neomycin) and thus bind in the RNA major groove.  The larger 
negative potential
257
 in the major groove draws more attention than the minor groove in 
RNA.  Moreover, a number of groups have established aminoglycosides as binding 
within the RNA major groove.
200,210,258
  In the present research, we have modeled NH(10) 
for binding r(CGCAAAUUUGCG)2, with neomycin docked within the major groove and 
the Hoechst region rested within the minor groove of the central A3U3 stretch (Figure 
4.26, right). The hydrogen bonding pattern of the Hoechst region in NH(10) with the RNA 
duplex is similar to the corresponding DNA d(CGCAAATTTGCG)2 (Figure 4.27). Yet 
the snugness of fit within the minor groove does not impress like that with the DNA 
minor groove.  The observed interaction is likely driven by the neomycin moiety.  This is 
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supported by equilibrium binding data indicating binding constants in the 10
6
 (M
-1
) range 
in RNA binding (observed for neomycin in ITC experiments), contrasting that of Hoechst 
33258 with DNA, which renders binding constants two orders of magnitude greater. 
 
 
 
Figure 4.25  Hydrogen bonding interactions of the Hoechst moiety of NH(10)  and 
d(CGCAAATTTGCG)2.  The DNA coordinates were extracted from pdb entry 296d.  
The bar lining the sequence (left) represents the binding site.  Numbers over dashed lines 
represent the H-bond distances. 
 
 200 
 
Furthermore, the lack of favorable van der Waals interactions is conceivable by 
observing the low quantum yield in fluorescence measurements (Figures 4.8, 4.16, 4.17) 
when compared with DNA.  Had DNA-like groove interactions occurred, fluorescence 
due to Hoechst binding should be more enhanced due to diminished solvent exposure. A 
clear conformational difference in the Hoechst moiety can be observed in the spacefill 
models shown in Figure 4.28. 
 
  
 
Figure 4.26  Computer models of NH(10) binding to d(CGCAAATTTGCG)2 (left) and its 
RNA analog r(CGCAAAUUUGCG)2 (right).  
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DNA binding: Hoechst 33258 vs. NH(10) 
A comparison of Hoechst 33258 vs. NH(10) minor groove interactions can be 
made by observing the H-bonding interactions depicted in Figures 4.23 and 4.24.  In 
viewing the model of the NH(10)-DNA complex (Figure 4.26, left), the substituted phenol 
region of the Hoechst moiety appears somewhat tugged out of the groove, possibly due to 
neomycin exhibiting favorable interactions within the major groove.  Also, the H-
bonding distances for NH-1 are slightly larger than that observed with Hoechst 33258 
alone. Experimental evidence supports an increased stabilization of DNA duplex by 
NH(10) over Hoechst 33258 alone, suggesting neomycin’s role in binding.
134
  Though the 
snug fit within the minor groove is somewhat diminished in NH(10), the favorable contacts 
of neomycin counteract the discreet loss in optimal binding geometry of the Hoechst 
moiety.   
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Figure 4.27 Hydrogen bonding interactions of the Hoechst moiety of NH(10) and 
r(CGCAAAUUUGCG)2.  The DNA coordinates were extracted from pdb entry 1al5.  
The bar lining the sequence (left) represents the binding site.  Numbers over dashed lines 
represent the H-bond distances. 
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RNA binding: Hoechst 33258 vs. NH(10) 
Hoechst 33258 binding to the minor groove of RNA seems probable in the current 
modeling studies.  Similar H-bonding contacts are observed both with the Hoechst 
moiety of NH(10) and with DNA.  However, various experiments clearly convey that the 
RNA duplex binding effect elicited by the ligand is minimal, if at all.  In agreement with 
reported accounts of isohelicity dominating the high binding affinity and specificity, 
Hoechst 33258 simply does not optimally match the pitch of the RNA minor groove, and 
therefore van der Waals contacts otherwise present in DNA interactions are significantly 
diminished.  If one were to consider the modeling of Hoechst 33258 with RNA to be 
fully reliable, the fact that H-bonding interactions are displayed between Hoechst 33258 
and RNA, then the postulate that van der Waals interactions dominate binding is further 
supported by the presented research. 
 
 
Figure 4.28  Geometrical differences in NH-1 when binding DNA (left) and RNA 
(right).  Structures are taken from models described in Figure 4.26.  Hoechst is shown in 
black, neomycin in green, and the linker between the two moeities is depicted in red. 
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 Various techniques described in this paper support, by conjugation of a Hoechst 
33258-based derivative with neomycin, favorable interactions between Hoechst and the 
RNA minor groove, a phenomenon unobserved with Hoechst 33258 alone.  The 
conjugate, with neomycin binding in the major groove, places the Hoechst moiety in 
good proximity to the minor groove, where the theoretical H-bonding interactions could 
be a reality (Figure 4.26, right). 
 
Sequence Specificity of Hoechst 33258 for DNA 
Numerous accounts have found that the recognition of DNA minor groove by 
small molecules relies on the van der Waals interactions between the ligand and 2-
deoxyribose walls of the minor groove. 
26,255,256
   The primary sites largely involve A/T 
sequences, which are narrower than G/C base pairs.  The H-bonding patterns that occur 
are considered a consequence of localization of the ligand within the groove.  Dervan’s 
rules for base pair recognition,
27
 specifically G/C base pairs, rely on the avoidance of 
steric hindrance between the 3 position C-H in pyrroles and the 2-amino of guanine by 
utilizing imidazole groups, whose nitrogen can act as H-bond acceptors.
26
  Therefore, 
recognition by hydrogen bonds signify a role in the sequence recognition process, albeit a 
consequence of the snug fit of the crescent shaped distamycin-based ligands to the width 
and pitch of the minor groove.  Hoechst 33258 has been shown on multiple occasions to 
bind a A/T stretches of 4-5 base pairs.
145,146,168,250,253,254
  Disruption of the stretch with a 
G-C pair significantly alters the binding, a consequence of the unfavorable steric clash 
between the guanine NH2 (at the 2 position) and the N-H of the imidazole.   
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Figure 4.29  Close up view of the imidazole N-H repulsion by 2-position NH2 in 
guanine.  NH-NH distance was calculated as 2.7 Angstroms. 
 
Sequence Specificity of NH(10) for RNA 
The preference for the A3U3 stretch in the RNA duplex r(CGCAAGCUUGCG)2 is also 
observed in a comparison with r(CGCAAGCUUGCG)2.  The diminished binding affinity 
(Figure 4.18) may be due to steric clash between imidazole NH and the 2-amino group in 
guanine.  Upon replacement of the central AU junction in the A3U3 RNA with GC, 
molecular modeling of the RNA complexed with NH(10), upon minimization, indicates a 
~30
o
 rotation of the benzimidazole on the piperazine side (Figure 4.29).  The 
benzimidazole on the phenol side does not indicate significant rotation, likely because of 
the proximity of the guanine NH2 to the imidazole, which is pulled slightly out of the 
groove by neomycin’s multiple contacts in the major groove. Consequently, fluorescence 
studies show that binding is nearly 6 times greater when the central GC is replaced with 
AU.  The observation that binding is still great (K ~10
6
) with the A2GCU2 duplex can be 
attributed to interactions imposed by neomycin, an infidel in RNA binding.
126
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Probing the groove environment of  
Hoechst binding: DNA vs. RNA 
A report by Jin and Breslauer has indicated that Hoechst 33258 exhibits a Stokes 
shift () upon complexation with DNA similar to that of free ligand in an approximately 
60% dioxane (aqueous) solution.
259
  Supported by other spectroscopic measurements, it 
was concluded that such a phenomenon was a viable measure of the microenvironment in 
which Hoechst 33258 complexation occurs (the minor groove).  Thus, the correlation 
with bulk solvent properties suggests that the Hoechst-minor groove environment was 
more nonpolar than aqueous in nature.   
For further evaluation of the minor groove environmental differences upon NH(10) 
binding with DNA and RNA duplex, an examination of the fluorescence excitation and 
emission spectra of NH(10) in the absence and presence of DNA and RNA was carried 
out.  A comparison was then made with aqueous solutions of NH(10) containing varying 
ratios of miscible organic solvent (1,4-dioxane).  In these experiments, the observed 
Stokes shift (the difference in wavenumber between excitation and emission spectra) can 
be directly associated with minor groove polarity of the Hoechst-DNA or Hoechst-RNA 
complex.  A smaller Stokes shift corresponds with a more nonpolar ligand environment, 
as observed by comparing with Stokes shift values gathered in solvent systems of varying 
polarity.  Thus, the Stokes shift of a ligand such as NH(10) with DNA vs. RNA may vary 
according to the local groove environment in which Hoechst binds.   
 Figure 4.30 depicts the excitation and emission spectra of NH(10) as a free ligand 
in both working buffers (cacodylate for DNA experiments; PIPES for RNA experiments) 
and in the presence of 1 M duplex (either d(CGCAAATTTGCG)2 or its RNA analog 
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r(CGCAAAUUUGCG)2). There is a clear difference in the Stokes shift for free ligand 
when compared to that complexed with either DNA or RNA duplex (see Table 4.2 for 
values) by simple observation of the closeness of the excitation and emission spectra for 
the complex and the increased distance of the maxima in free ligand solutions (Figure 
4.30).  Thus, the microenvironment of NH(10) for both DNA and RNA complexation is 
more organic in nature than that of the free ligand.  Additional experiments of NH(10) in 
solutions of varying dioxane content illustrate the general trend of solvent polarity vs. 
Stokes shift, in similar agreement to that reported with Hoechst 33258.  The noticeable 
difference between the mixture experiments and those of free ligand in buffer are most 
likely due to the buffers used (mixing experiments were done using deionized water only, 
as done previously). Furthermore, when comparing the Stokes shift for NH(10) binding to 
DNA versus RNA, a much smaller value for DNA suggests a much more nonpolar 
microenvironment for NH(10) binding to DNA than binding to RNA.  Such observation is 
plausible  (if one considers Hoechst binding in the RNA minor groove) given that the 
minor groove in A-form conformations (RNA duplex) is much shallower and wider than 
the B-form (DNA) minor groove, and therefore more exposed to bulk solvent.  While 
these results do not directly confirm Hoechst binding in the minor groove, they correlate 
with the current knowledge of the groove differences in duplex DNA and duplex RNA. 
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Figure 4.30  Fluorescence excitation and emission scans of NH(10) in the absence and 
presence of d(CGCAAATTTGCG)2 and r(CGCAAAUUUGCG)2 and in mixed solvent 
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(dioxane/water) conditions.   Conditions: [NH(10)] = 100 nM; [nucleic acid] = 1 M; 
buffers for DNA experiments: 10 mM sodium cacodylate, .5 mM EDTA, pH 7.2; for 
RNA experiments: 10 mM PIPES, 100 mM NaCl, 1 mM EDTA, pH 7.0; slits = 4 nm for 
emission, 8 nm for excitation; T = ambient. 
 
System exc. emiss.

cm
NH(10)  
cacodylate buffer 
350 478 7650 
NH(10) + DNA 358 447 5560 
NH(10) 
PIPES buffer 
350 470 7290 
NH(10) + RNA 365 476 6390 
NH(10) 
25% dioxane 
350 485 7950 
NH(10) 
50% dioxane 
352 477 7440 
 
Table 4.2  Fluorescence properties of NH(10) under conditions studied and comparison 
with less polar systems (varying dioxane content).  The Stokes shift, , is calculated as 
the difference (in wavenumbers) of the excitation and emission wavelength maxima. 
 
Conclusion 
We recently reported that neomycin affinity for nucleic acids includes structures 
known to adopt A-like conformations.  We have since endeavored to explore neomycin’s 
utility in binding to B-DNA to better understand the molecular forces that dictate binding 
within the DNA major groove.  The current study explores the utility of Hoechst 33258 
binding to duplex RNA, a phenomenon that is absent historically.  From the current study 
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of NH(10) binding to duplex RNA, the following conclusions can be drawn: (1) NH(10) 
significantly stabilizes RNA over neomycin.  UV melting experiments with both 
polymeric and oligomeric DNA indicate significant shifts in Tm when compared with 
samples in the absence of ligand and in the presence of the known stabilizer neomycin.  
ITC experiments indicate a 20-fold enhancement of binding by NH(10) when compared 
with Hoechst 33258.   (2) Spectroscopic studies clearly indicate Hoechst binding (in 
NH(10)) to RNA, most likely in the minor groove, which is absent with Hoechst 33258 
alone.  A consistent increase in fluorescence is observed when NH(10) is increasingly 
titrated with RNA, as is seen when Hoechst compounds are titrated with B-DNA and is 
consistent with minor groove binding.  Experiments with Hoechst 33258 indicate 
insignificant binding, with small decreases in fluorescence as ligand is titrated with RNA.  
The microenvironment of the RNA minor groove, which is more shallow and exposed to 
bulk solvent, correlates with Stokes’ shift comparisons of NH(10) binding to both DNA 
and RNA duplexes.  (3)  CD titrations indicate a clear change in the region of Hoechst 
absorbance, consistent with Hoechst complexation.  Hoechst 33258 indicates little 
change, consistent with insignificant binding. (4)  Viscosity experiments suggest 
cooperative groove binding by both neomycin and Hoechst 33258.  Solution viscosity of 
RNA with NH(10) significantly decreases with increasing NH(10) concentrations, and is 
lower than that observed with neomycin.  The decreases in viscosity can be explained as 
cooperative binding by NH(10): Hoechst binding induces a favorable conformation for 
further NH(10) binding.  (5) Modeling studies, complementing UV melting data with 
oligomeric RNA duplexes, suggest dual groove binding by NH(10).  As seen with B-DNA, 
the NH2 in guanine repulses the imidazole N-H, and is likely responsible for the 
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diminished binding to this DNA (see Chapter 2).  Similar results were observed in UV 
melting experiments with r(CGCAAAUUUGCG)2 vs. r(CGCAAGCUUGCG)2.    
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CHAPTER 5 
 
EXPERIMENTAL SECTION 
 
Biophysical and Bioanalytical Experimental 
 
 
Materials: 
Nucleic acids:  DNA and polymers were purchased from Pharmacia Biotech (Piscataway, 
NJ).  Concentrations were determined by UV absorbance using 260 = 6000 M
-1
cm
-1
 for 
polydA•poly(dT),  262 = 6600 M
-1
cm
-1 
for poly(dAdT)2, and 264 = 8520 M
-1
cm
-1
 and for 
poly(dT).  RNA polymers were quantitated by UV absorbance using 258 = 9800 (M
-1
cm
-
1
) for poly(rA) and 260 = 9350 (M 
-1
cm
-1
) for poly(rU).  For all ITC experiments with 
polymeric RNA, solutions of individual strands were dialyzed extensively (48 hrs.) 
against buffer using SpectraPor Float-A-Lyzer dialysis units, MW cutoff 3500 Da 
(Spectrum Labs, Rancho Dominguez, CA) before quantitation. The self-complementary 
oligomers r(CGCAAAUUUGCG) and r(CGCAAGCUUGCG) were purchased from 
Dharmacon (Lafayette, CO) and deprotected using standard protocols and quantitated as 
provided by the supplier.  Duplex RNA was formed by heating at 95 
o
C for 5 minutes 
before slowly annealing to room temperature and storage at 4 
o
C between experiments.  
Solutions for all experiments were in buffer consisting of 10 mM PIPES, 1 mM EDTA, 
100 mM NaCl, pH 7.0 unless otherwise noted. DNA oligomers dA22, dT22, 
d(CGCAAATTTGCG), and d(CGCAAGCTTGCG) were purchased from Integrated 
DNA Technologies (Coralville, IA) and quantitated using extinction coefficients 
provided by the supplier. Oligomer duplex formation was accomplished by slowly 
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annealing from 95 
o
C (0.2 
o
/min.).  The buffer used for polymeric DNA consisted of 10 
mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 7.2.  For dA22 and dT22, the 
buffer was identical to polymeric DNA except pH 6.8 was used.  Experiments with the 
self-complementary 12mer were done in BPES buffer (6 mM Na2HPO4, 2 mM NaHPO4, 
1 mM EDTA, 185 mM NaCl, pH 7.0). 
 
Chemicals: Neomycin B (sulfate salt) was purchased from ICN Biomedicals and used 
without further purification.  Piperidinesulfonic acid (PIPES) and NaCl were purchased 
from Fisher Scientific.  Chemicals: Neomycin B (sulfate salt) was purchased from ICN 
Biomedicals and used without further purification.  Sodium cacodylate, NaCl, and 
sodium phosphate salt were purchased from Fisher Scientific.  Hoechst 33258 was 
purchased from Acros Organics.  Conjugate NH(10) was synthesized as reported 
previously.
134
  Quantitation of Hoechst 33258 (338 = 42,000 M
-1
cm
-1
) and NH(10) ( = 
39,241 M
-1
cm
-1
) in aqueous solutions was done using UV absorbance.    Likewise, NH(22) 
was quantitated using  = 21,085 M
-1
cm
-
1, and NHP(22,18) was quantitated using  = 
53,681 M
-1
cm
-
1 as determined from UV calibration curves.  To ensure stability and 
minimum adsorption of Hoechst compounds to container walls, all solutions were stored 
in non-transparent, polystyrene tubes.   For all conjugates, the number(s) in brackets 
(subscripted) denote the number of atoms separating the respective binding moiety and 
neomycin. 
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Methods 
UV Melting: All experiments were carried out using a Cary 100E UV/Vis 
spectrophotometer equipped with a thermoelectrically controlled 12-cell holder.  All 
samples were analyzed in quartz cells (1 cm pathlength).  Lamp stability and wavelength 
alignment were checked prior to each experiment.  Unless otherwise noted, prior to 
analysis (heating from 20-95 
o
C at a rate of 0.2 deg/min., monitoring at 260, 280, and 284 
nm), samples were prepared in polystyrene tubes (Hoechst compounds, as they adsorb to 
most other plastics, glass, and quartz) and heated at 95 
o
C for 5 minutes before slowly 
annealing to room temperature.  In all experiments, concentrations of DNA were 15 M 
for poly(dA)•2poly(dT), 20 M for poly(dAdT)2, and1 M (in duplex) for all oligomers.  
Ligand concentrations varied, and are stated in the Figure legends; [poly(rA)•poly(rU)] = 
20 M/base pair.  Melting temperature (Tm) assignments were done using first derivative 
analysis provided by the Cary software.  In a typical melting experiment, samples (either 
1 mL or 2 mL) are first vortexed, centrifuged, and degassed before loading into cuvettes 
and heating slowly (0.2 deg/min) while monitoring for UV absorbance.  The dissociation 
of strands (triplex to duplex and single strand or duplex to single strands) corresponds to 
the loss of base stacking accompanied with helix formation.  Often a four stage method 
can be used, in which annealing profiles (slow cooling at 0.2 deg/min) can be gathered.  
These annealing profiles are useful in determining triplex transitions, as they are often 
accompanied by hysteresis (shift in Tm in heating profile versus Tm in annealing profile) 
due to the slow rate of triplex formation (slower than can be detected even at low rates of 
temperature decreases in the UV instrument) versus that of dissociation (upon heating).   
 
 215 
 
Isothermal Titration Calorimetry (ITC): Measurements were performed at 20 
o
C on a 
MicroCal VP-ITC (MicroCal, Inc., Northampton, MA). In a typical experiment, 10 L 
aliquots of ligand (150 M for neomycin, 100 M for NH(10)) were injected from a 250 
L rotating syringe (300 rpm) into an isothermal sample chamber containing 1.42 mL of 
poly(rA)•poly(rU)duplex solution that was 40 M/bp.  Each experiment of this type was 
accompanied by the corresponding control experiment in which 10 L aliquots of 
identical drug solutions were injected into a solution of buffer alone. The duration of each 
injection was 10 s, and the delay between injections was 300 s.  The initial delay prior to 
the first injection was 60 s.  Each injection generated a heat burst curve (microcalories 
per second vs. seconds). The area under each curve was determined by integration using 
Origin (version 5.0) software to obtain a measure of the heat associated with that 
injection. The heat associated with each drug-buffer injection was subtracted from the 
corresponding heat associated with each drug-DNA injection to yield the heat of drug 
binding for that injection.  Binding isotherms were fit using an identical site binding 
model in the Origin software provided by MicroCal. 
 
Fluorescence titrations: All Equilibrium binding experiments were done using a Photon 
Technology International instrument (Lawrenceville, NJ) at ambient (22 
o
C) temperature.  
For RNA experiments, a solution of NH(10) (serially diluted to working concentrations) 
was excited at 342 nm (slits = 3 nm) and resulting emission curves (from 390-600 nm) 
were recorded after serial additions of a concentrated RNA solution (poly•polyU was 543 
M, r(CGCAAAUUUGCG)2 was 60 M, and r(CGCAAGCUUGCG)2 was 40 M).   
After each addition, the solution was mixed by pipetting up and down with a Pasteur 
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pipette treated with silanizing agent (Sigmacote) to avoid ligand adsorption to the glass.  
Sample equilibrium was monitored by continually exciting/scanning the sample at 
different times, and was usually reached within 2 minutes.  A silanized (SigmaCote) 
cuvette was used in all experiments.  All data were normalized to account for the (small) 
dilution of sample upon addition of substrate.  For DNA experiments, a solution of ligand 
(serially diluted to working concentrations) was excited at its respective max (slits = 2,4 
or 6 nm) and resulting emission curves (from 390-600 nm) were recorded after serial 
additions of a concentrated DNA solution (polydA•polydT was 200 M base-1). After 
each addition, the solution was mixed by pipetting up and down with a Pasteur pipette 
treated with silanizing agent (Sigmacote) to avoid ligand adsorption to the glass.  Sample 
equilibrium was monitored by continually exciting/scanning the sample at different 
times, and was usually reached within 2 minutes. All data were normalized to account for 
the (small) dilution of sample upon addition of substrate. For the self-complementary 
12mer experiments, individual samples of varying ligand:DNA ratios were prepared, all 
with a constant [ligand] of 100 nM.  A silanized (SigmaCote) or polystyrene cuvette was 
used in all experiments.  Corresponding fluorescence data were fit using Kaleidagraph 
according to the following equation: 
 
Fo + ((Fb-Fo)/(2CT))*(([DNA]/N + CT + 1/Kb)-(([DNA]/N + CT + 1/Kb)
2
-
4*[DNA]/N*CT)
1/2
) 
 
where Fo is fluorescence of ligand in the absence of DNA, Fb is fluorescence of fully 
bound ligand, CT is the total ligand concentration, Kb is the binding constant, N is the 
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binding site size, and [DNA] is DNA concentration at each titration.  Values for Fo, Fb, 
and Kb can be determined by curve fitting a plot of fluorescence versus [DNA].  Binding 
site size N can be determined by mixing curve analysis (Job plots) or by titrations of 
constant [DNA] with concentrated ligand to determine the number of base pairs per 
ligand, n, at relatively high concentrations (5 M DNA with ligand concentrations up to 5 
M).172 In fitting to the theoretical independent site model, the values of DNA (in base 
pairs) can be divided by N, represented as the number of identical base pairs containing a 
single binding site, to provide values for binding site concentration.  For Hoechst 33258, 
the value N = 10 was used in accordance with the literature.
169,171,260
  Since Hoechst 
33258 has been shown to target upwards of 6 A/T base stretches, a value of N = 10 was 
used since it has been shown that N = 2(n-1),
198
 where n equals the number of base pairs 
bound by ligand. 
 
CD Spectropolarimetry titrations: Circular dichroism (CD) experiments were done at 20 
o
C using a Jasco J-810 spectropolarimeter.  A concentrated solution of ligand (500 M 
neomycin or NH(10)) was added to a 40 M solution of poly(rA)•poly(rU)and allowed to 
stir constantly before scanning from 350-220 nm.  As with fluorescence experiments, 
equilibrium was determined by periodically scanning the sample over a period of time 
(up to 10 minutes) for the first few additions of ligand, and was reached within 3 minutes. 
All data were normalized to account for the (small) dilution of sample upon addition of 
ligand. 
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Viscometry: Viscosity measurements were conducted using a Cannon-Ubbelohde 75 
capillary viscometer submerged in a water bath at 27 + 0.05 
o
C.  Flow times of buffer 
only followed by RNA (1030 L of 100 M in base pair) were recorded in triplicate 
before titrations of concentrated ligand solutions (500 M) with mixing by bubbling of 
air (using a pipette bulb) through the solution.  Flow times after each titration were 
recorded in triplicate.  In all cases, standard deviations were less than 0.1 s.  All RNA 
solutions were in PIPES10 buffer (10 mM PIPES, 1 mM EDTA, pH 7.0) containing 100 
mM NaCl.  Flow times for buffer alone were in the range of 106 s, whereas RNA alone 
was approx. 110 s.  Flow times for ligand titrations into RNA ranged from 110 to 107 s.  
DNA polymers were in 10 mM sodium cacodylate buffer containing 150 mM KCl, 1 mM 
MgCl2, pH 7.2).  Flow times for buffer alone were in the range of 106 s, whereas DNA 
alone was approx. 112 s.  Flow times for ligand titrations into DNA ranged from 110 to 
108 s.   The viscosity for each titration was determined using the relationship
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where L is length of RNA complexed with ligand, Lo is length of DNA/RNA alone,  is 
intrinsic viscosity, t is flow time of complex, tb is flow time of buffer, and to is flow time 
of RNA alone.  Data were plotted in the form of relative viscosity, L/Lo,versus r (ratio of 
bound ligand to RNA concentrations) with a comparison to theoretical intercalation (1 + r 
versus r) to convey the differences in ligand binding to that of intercalation. 
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Computer Modeling: The DNA duplex d(CGCAAATTTGCG)2 was extracted from pdb 
entry 296d, RNA duplex r(CGCAAATTTGCG)2 was obtained from PDB entry 1al5,
251
 
and r(CGCAAGCUUGCG)2  was constructed in Macromodel using PDB entry 1al5.  
Energy minimization reached a convergence threshold of 0.02 kJ/mol in all cases.  DNA 
duplex d(CGCAAATTTGCG)2 was extracted from pdb entry 296d.
145
 Conformational 
optimization of neomycin, docked in the closest proximity for its 5’ position to Hoechst-
linker, was carried out prior to attachment to Hoechst using a Monte Carlo routine in 
MacroModel, using AMBER* force field and water as solvent.   A similar protocol was 
used for the Hoechst 33258 and pyrene moieties.  Structural minimizations converged on 
a gradient to within 0.02 kJ/mol.  Five of the six amines in neomycin were protonated, in 
agreement with NMR studies of neomycin,
150,151
 as well as the terminal amine in the 
piperazine ring of the Hoechst moiety. 
 
Competition Dialysis:  Samples of nucleic acid (180 L of 75 M in base) were dialyzed 
for 24 hours against a 400 mL solution of ligand (1 M).  The dialysis units were 
prepared using Snakeskin
®
 dialysis tubing (MWCO 3500) and mini-dialysis units (Pierce 
Chemical Co., Rockford, IL).  After removal of 150 L solution from dialysis unit and 
addition of 10% SDS (16.7 L) to a final [SDS] = 1%, samples were allowed to sit for 30 
minutes before dilution to 2 mL and fluorescence analysis.  As a precaution, prior to 
dialysis the mini-units, containing 200 mL deionized water, were dialyzed for 24 hours 
before removal and inspection for volume changes (using a micropipette) to confirm the 
absence or presence of leaks in each individual unit.   
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Chemical Synthesis Experimental 
 
 
General Procedure for Chemical Synthesis 
 
 Air and moisture sensitive reactions were carried out under argon or nitrogen 
using a balloon feeding the neutral gas into the flask via a rubber septum tightly fit in the 
flask connection.  Flasks were flame dried.  All chromophores were kept from light using 
aluminum foil or brown glassware.  All organic solvents were evaporated using a Buchi 
rotary evaporator.  A LabConco lyophilizer was used to remove water from heat sensitive 
solutions.  Analytical thin layer chromatography was done using glass coated silica, 230-
400 mesh, provided by Sorbent Technologies.  Plates were developed using UV light, 
ninhydrin, or permanganate stains with heating.  Flash chromatography used silica gel, 60 
mesh, provided by Sorbent Technologies. 
 
Materials 
 
Neomycin B (sulfate salt) was purchased from ICN Biomedicals and used without further 
purification.  DIAD (diisopropylazodicarboxylate) and 1,1’-thiocarbonyldi-2(1H)-
pyridone (TCDP) were purchased from Aldrich Chemical Co.; all other reagents and 
solvents were purchased from Acros Organics and used without further purification.  
Reaction solvents were distilled over calcium hydride (pyridine, dichloromethane, DMF) 
or sodium metal (diethyl ether, dioxane, ethanol).  Dry EtOH for imidate formation was 
distilled first with sodium metal, with further distillation over magnesium pellets.  
Synthetic reagents 5-trifluoroacetamidopentanol,
155
 diol monotosylates,
262,263
 TSTU,
264
 
monoprotected diamines,
265
 and crucial intermediate 8
149,156
 were prepared according to 
published procedures.   
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Synthesis 
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Scheme 5.1  Synthetic scheme for the preparation of an electrophilic (isothiocyanate) 
derivative of neomycin. Reagents and conditions:  (i) di-tert-butyldicarbonate, NEt3, 
DMF, H2O, 91% (ii) 2,4,6-triisopropylbenzenesulfonyl chloride, pyridine, 71% (iii) 
aminoethanethiol, Na metal, EtOH, 76% (iv)  thiocarbonyldipyridone, CH2Cl2, DMAP, 
95%.  
 
N-Boc protected neomycin 2.  To neomycin 1, sulfate salt (2 g, 2.2 mmol) in water (32 
mL) and NEt3 (4 mL) was added DMF (32 mL) before addition of di-tert-
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butyldicarbonate (4.2  g, 19.5 mmol).  The solution was stirred at 65 
o
C for five hours 
before bringing to room temperature and overnight stirring.  The organics were 
evaporated under high vacuum, and water was added (200 mL), giving a white precipitate 
of the crude product.  The solid was filtered before dissolving in CH2Cl2 and rinsing with 
brine.  After drying with sodium sulfate, the solution was concentrated and purified over 
a silica column using a gradient of MeOH in CH2Cl2.  Yield: 2.43 g.  Rf 0.36 (9:1 
CH2Cl2:MeOH); 
1
H NMR (500 MHz, CDCl3):  6.01 (br s, 1H), 5.21 (br s, 1H), 4.96-
4.92 (m, 2H), 4.77 (br s, 1H), 4.33 (br s, 1H), 4.28-3.29 (m, 17H), 3.04 (br s,1H), 2.00 (br 
s, 1H), 1.43 (s, 54H); MS (MALDI-TOF)  m/z for C53H94N6NaO25 [M+Na]
+
 1237.6, 
found 1237.4. 
 
Compound 3.  A solution of 2 (530  mg, 0.44 mmol) in dry pyridine (10 mL) containing 
2,4,6-triisopropylbenzenesulfonyl chloride (4.3 g, 14.2 mmol) was stirred at room 
temperature under argon for 28 hours.  TLC indicated a slightly less polar spot 
corresponding to product, with a faint amount of starting material left.  The solution was 
neutralized with 1 N HCl and 300 mL EtOAc was added and partitioned with 150 mL 
water.  The EtOAc layer was saved and the aqueous extract was further rinsed with 
EtOAc (2x100 mL) and the organics were combined and washed with brine before drying 
over sodium sulfate.  The organics were evaporated and a concentrated solution of crude 
product was purified using column chromatography with a gradient of  3.3% to 4% 
MeOH in CH2Cl2.  The corresponding sulfonic acid eluted with the product (indicated in 
NMR), and was removed with saturated bicarbonate washes.  Yield was 459 mg (71%).   
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An alternative procedure was also used in the preparation of 2 and is as follows: 
A solution of 2 (1 g, 0.82 mmol) in dry pyridine (30 mL) containing 2,4,6-
triisopropylbenzenesulfonyl chloride (8 g, 26.3 mmol) was stirred at room temperature 
under argon for 72 hours.  TLC indicated complete uptake of 2.  The pyridine was 
evaporated along with co-evaporations with toluene (2x10 mL).  To the residue was then 
added ether, which gave a suspension of the pyridinium salt.  After sitting at room 
temperature for 10 minutes, the solid was filtered off and rinsed liberally with ether.  
After evaporation of the ether solution and loading onto silica gel column in a minimal 
amount of a 1:1 mixture of EtOAc:hexane, the crude mixture was purified using a 
gradient of gradient of ethyl acetate (50 to 100%) in hexane to afford 600 mg (49%) of 
pure product.  Rf 0.40 (9:1 CH2Cl2:MeOH); 
1
H NMR (500 MHz, CDCl3):  6.12 (br s, 
1H), 5.83 (br s, 1H), 5.32-4.80 (m, 4H), 4.25-3.04 (m, 20H), 1.44 (s, 54H), 1.26 (m, 
18H); MS (MALDI-TOF)  m/z for C68H116N6O27S [M+Na+2H]
+
 1507.8, found 1507.4. 
 
Neomycin amine (4). Freshly cut sodium metal (837 mg, 36.4 mmol) was dissolved in 
dry ethanol (30 mL) over a period of 20 minutes. Aminoethanethiol hydrochloride (1.82 
g, 16.2 mmol) was added to the solution at room temperature and stirred for 15 min 
before addition of 2 (600 mg, 0.4 mmol) dissolved in dry EtOH in three portions.  After 
stirring at room temperature under argon for 18 hours, the ethanol was evaporated and 
approx. 10 mL phosphate buffer was added (pH 5.5).  The solution was cooled on an ice 
bath for 15 minutes.  The suspension was filtered and washed liberally with cold water.  
The solid was then taken up in CH2Cl2 and purified on a silica gel column using a 
gradient of MeOH (0 to 15%) in CH2Cl2 to afford 390 mg (76%) product.  Rf 0.38 (85:15 
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CH2Cl2:MeOH).  ); 
1
H NMR (500 MHz, CD3OD):  5.39 (br s, 1H), 5.15 (br s, 1H), 4.25 
(1H), 4.09 (br s, 1H), 3.75-3.16 (m, 18H), 2.86 (br s, 1H), 2.77 (br s, 1H), 1.96 (br s, 1H), 
1.45 (s, 54H); MS (MALDI-TOF)  m/z for C55H99N7O24S [M]
+
 1274.5, found 1273.7. 
 
Neomycin isothiocyanate (5) Compound 4 (40 mg, 31.4 mol) was dissolved in dry 
CH2Cl2 (5 mL) before addition of TCDP (11.4 mg, 49.2 mol) and DMAP (2 mg).  The 
solution was stirred under argon at room temperature.  Reaction was complete within 30 
minutes.  After concentration the solution in CH2Cl2 was purified via column 
chromatography using a gradient of MeOH (0 to 5%) in CH2Cl2 to afford 39 mg (95%) 
product.  Rf 0.55 (10:1 CH2Cl2:MeOH); MS (MALDI-TOF) m/z for C56H99N7O25S2 
[M+H2O]
+
 1334.55, found 1333.69; IR (CH2Cl2):  = 2302 cm
-1
 (N=C=S). 
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Scheme 5.2  Reagents and Conditions:  (i) 5-trifluoroacetamido-1-pentanol, PPh3, DIAD, 
dioxane, r.t., 2h,  84%; (ii) (a) HCl(g), EtOH, 0 
o
C, quant.; (b) 2-(3,4-diaminophenyl)-6-
(1-methyl-4-piperazinyl)benzimidazole (8), HOAc, reflux, 4h, 38%; (b) K2CO3 in 5:2 
MeOH:H2O, r.t., overnight, 94%; (iii) (a) isothiocyanate 5, pyridine, DMAP, 72%; (b) 
1:1 TFA:CH2Cl2, trace ethanedithiol, quant. 
 
Compound 7.  To a solution of p-cyanophenol (6) (662 mg, 5.6 mmol), 5-(N-
trifluoroacetamido)-1-pentanol (1.3 g, 6.7 mmol), and triphenylphosphine (1.75 g, 6.7 
mmol) in dry dioxane (90 mL) was added DIAD (diisopropylazadicarboxylate, 1.3 mL, 
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6.7 mmol) dropwise at 0 
o
C over a period of 30 minutes.  Dissolution of the resulting 
cooled suspension was allowed by bringing the reaction mixture to room temperature 
before subsequent additions of DIAD.  Upon final addition of DIAD, the solution was 
stirred at room temperature for an hour.  The reaction was judged complete by TLC (1:1 
ethyl acetate:hexane).  The dioxane was removed in vacuo and the resulting residue was 
purified by flash chromatography using a gradient of 0 to 8 % EtOAc in CH2Cl2 to give 
1.4 g (84%) of 2.  Rf (CH2Cl2): 0.19.  
1
H NMR (300 MHz, CDCl3):  7.59 (d, 2H, J=8.8), 
6.92 (d, 2H, J=8.8), 4.04-3.99 (m, 2H), 3.45-3.38 (m, 2H), 1.90-1.80 (m, 2H), 1.73-1.66 
(m, 2H), 1.59-1.49 (m, 2H). MS (MALDI-TOF) m/z for C14H16F3N2O2 [M]
+
 301.28, 
found 301.59. 
 
Compound 9.   A solution of 7 (180 mg, 0.6 mmol)  was suspended in dry ethanol (5 mL) 
and stirred in an ice bath.  Rapid bubbling of anhydrous HCl gas into the orange solution 
was allowed for 45 minutes.  The saturated acidic solution was then stored at 4 
o
C 
overnight before evaporation of the alcohol followed by dry ether washes (3x10 mL) and 
drying under reduced pressure to give 229 mg (quant.) of pure, brittle, white solid.   
The resulting imidate (90 mg, 235 mol) was combined with diamine 8 (30 mg, 
93 mol) in glacial acetic acid and stirred under argon gas.  The solution was heated to 
reflux and stirred for 5 hours.  TLC at this point showed the appearance of a new, less 
polar compound which displayed light green fluorescence under long UV.  (Starting 
diamine displays purple fluorescence under long UV and is slightly more polar in TLC). 
The solution was concentrated under reduced pressure and dissolved in a small amount of 
water.  The deep red solution was then basified with concentrated NH4OH, resulting in a 
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brown suspension, which after sitting for 30 minutes at room temperature resulted in a 
brown precipitate which was filtered and dried by co-evaporation with toluene (3 times) 
followed by ether wash and removal of solvents in vacuo, giving a light brown solid (52 
mg, 38%) of 9 that was of sufficient purity.  Rf (6:4:0.1 CH2Cl2:MeOH:NEt3)= 0.60 
(fluorescent).  
1
H NMR (300 MHz, CD3OD):   8.23 (s, 1H), 8.03 (d, 2H, J=8.4), 7.91 (d, 
1H, J=8.7), 7.65 (d, 1H, J=8.7), 7.50 (d, 1H, J=8.3), 7.13 (s, 1H), 7.10-7.04 (m, 3H), 4.04 
(m, 2H), 3.30-3.23 (m, 6H, partially masked by solvent signal), 2.76 (m, 4H), 2.43 (s, 
3H), 1.83 (m, 2H), 1.65-1.50 (m, 4H); MS (MALDI-TOF) m/z for C32H34F3N7O2 [M]
+
 
605.65, found 605.75. 
 
Compound 10.  The triflouroacetyl group of 9 was removed using the following 
procedure. Compound 9 (15 mg, 24.7 umol), was dissolved in a solution of K2CO3 (17 
mg, 123 umol) in a 2:1 mixture of MeOH:water (1.5 mL) and stirred at room temperature 
overnight.  TLC showed a highly fluorescent spot more polar than the starting material 
(Rf=0 in 6:4:0.1 CH2Cl2:MeOH:NEt3).  The solution was concentrated to a dry residue 
before dissolving in EtOH, filtering, and evaporation of EtOH to yield 11.5 mg (88%) of 
sufficiently pure amine, which was immediately used in the next step without further 
purification.  
The corresponding free amine of 9 (10 mg, 18.9 umol) was dissolved in 3 washes 
of dry pyridine (3 mL) from a round bottom flask and transferred to flask containing 
freshly prepared neomycin isothiocyanate, 5 (10 mg, 7.7 umol).  The solution was stirred 
under argon gas at room temperature overnight.  TLC showed apparent completion of 
reaction and a new spot corresponding to product at Rf = 0.51 (8:2 CH2Cl2:MeOH).  The 
 228 
 
pyridine was removed under reduced pressure and the residue was taken up in CH2Cl2 
and silica gel, which after evaporation of solvent was loaded on a silica gel column and 
purified by flash chromatography.  The desired conjugate 10 was isolated as a yellow 
solid (10 mg, 59%). Rf = 0.51 (8:2 CH2Cl2:MeOH); 
1
HNMR (500 MHz, CD3OD):  8.18 
(s, 1H), 7.97 (d, 2H, J=8.4), 7.86 (d, 1H, J=8.8), 7.61 (s, 1H), 7.43 (s, 1H), 7.05-6.95 (m, 
3H), 6.57 (1H), 6.43 (1H), 5.30 (1H), 5.05 (1H), 4.54 (1H), 4.17 (1H), 4.00 (m, 2H), 3.81 
(1H), 3.7-3.0 (22H), 2.80-2.69 (7H), 1.90-1.70 (3H), 1.65-1.40 (4H), 1.36 (54H); MS 
(MALDI-TOF) m/z for C56H84N14NaO13S2 [M+Na]
+
 1824.89, found 1824.75 
 
NH(10) (11)  Compound 10 (10 mg), was stirred in a solution of 1:1 trifluoroacetic 
acid/dry CH2Cl2 (2 mL) at room temperature for 4 hours.  TLC showed absence of 
starting material.  The solution was then concentrated, dissolved in water and lyophilized 
overnight to afford a flaky yellow solid (6 mg, 89%) of 11.  The product was judged 
sufficiently pure by analytical HPLC (Supelcosil LC18S column; eluent: aqueous 0.1% 
TFA with a gradient of 0 to 100% of a 95:5 acetonitrile:water mixture over a period of 20 
minutes; flow rate=1.2 mL/min; T=ambient; retention time of product = 8 minutes). 
1
H 
NMR (500 MHz, D2O): 8.21 (s, 1H), 8.07 (d, 2H, J=7.8), 7.97 (d, 1H), 7.86 (d, 1H, 
J=7.8), 7.75 (d, 1H, J=9.1), 7.39 (s, 1H), 7.27-7.18 (m, 3H), 6.03 (s, 1H), 5.45 (s, 1H), 
5.38 (s, 1H), 5.00-3.00 (m, 32H), 2.92 (m, 4H), 2.38 (br s, 1H), 1.90-1.60 (m, 6H); MS 
(MALDI-TOF) m/z for C56H85N14O13S2 [M+H]
+
 1226.48, found 1226.41max (water) = 
345 nm; = 39,241 M-1cm-1.  
 
 229 
 
O
EtO
NH2+Cl-
N
N
N
H
N
N
NH
O
O
O
O
O
O
F3COCHN
O
O
O
O
O
F3COCHN
O
NC
O
O
O
O
O
X
O
O
O
HO
O
O
HO
i iii
iv
12
13 OH
14 OTs
15  N3
16  NHCOCF3
17
18
X =
ii
 
Scheme 5.3.  Reagents and conditions: (i) p-cyanophenol, PPh3, DIAD, dioxane, 51%; 
(ii) (a) TsCl, CH2Cl2, NEt3, 72%;  (b) NaN3, DMF, NaI, 86%; (c) H2, 10% Pd/C, EtOH, 
68%; (d) trifluoroacetic anhydride, CH2Cl2, pyridine, quant.; (iii) HCl(g), EtOH, quant.; 
(iv) 8, HOAc, 20%. 
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Scheme 5.4  Reagents and conditions: (i) pyridine, DMAP, 52%; (ii) 1:1 TFA:CH2Cl2, 
94% 
 
Compound 13.  To a solution of hexaethylene glycol 12 (1.0 g, 3.5 mmol), p-
cyanophenol (210 mg, 1.8 mmol), and triphenylphosphine (928 mg, 3.5 mmol) in 
dioxane (30 mL) was added DIAD (diisopropylazadicarboxylate; 0.7 mL, 3.5 mmol) 
dropwise at 0 
o
C over a period of 30 minutes with vigorous stirring (heterogeneous 
mixture).  After reaching room temperature and overnight stirring, the dioxane was rotary 
evaporated to a residue before dissolving in ethyl acetate (50 mL) and washing with 5% 
NaHCO3 (30 mL), water (30 mL).  The organics were dried with Na2SO4 before solvent 
removal and purification of the oil via column chromatography (gradient of 0 to 10% 
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MeOH  in EtOAc). Yield: 345 mg (51%). Rf 0.26 (9:1 EtOAc:MeOH); 
1
H NMR (300 
MHz, CDCl3):  7.59 (d, 2H, J = 7.1), 6.99 (d, 2H, J = 7.1), 4.18 (t, 2H, J = 4.7), 3.87 (t, 
2H, J = 4.8), 3.74-3.59 (m, 20H); 
13
C (75 MHz, CDCl3): 162, 134, 119, 116, 104, 73, 
71(2), 70, 68, 62;  MS (MALDI-TOF) m/z for C19H29NO7 [M]
+
 383.44, found 383.02. 
 
Compound 14.  A solution of 13 (226 mg, 0.59 mmol), p-toluenesulfonyl chloride (327 
mg, 1.7 mmol), and triethylamine (171 mg, 1.7 mmol) in dry CH2Cl2 was mixed at 0 
o
C 
under N2 atmosphere and allowed to gradually come to room temperature while stirring 
overnight.  Concentration to a residue, dissolution in CH2Cl2 (30 mL) and washes with 
dilute citric acid (2x10 mL), drying with Na2SO4, and solvent evaporation before column 
chromatography (30 to 0% hexane in EtOAc, then 0 to 10% MeOH in EtOAc) afforded 
206 mg (72%) of pure product.  Starting material (21 mg) was also recovered.  
Rf 0.43 (EtOAc); 
1
H NMR (300 MHz, CDCl3):  7.80 (d, 2H, J = 8.0), 7.58 (d, 2H, J = 
8.8), 7.35, (d, 2H, J = 7.9), 6.98 (d, 2H, J = 8.8), 4.17-4.14 (m, 4H), 3.87 (t, 2H, J = 4.6), 
3.70-3.58 (m, 18H), 2.44 (s, 3H); 
13
C (75 MHz, CDCl3): 146, 134, 130, 128, 120, 116, 
71(m), 70(2), 69, 68, 22;  MS (MALDI-TOF) m/z for C26H35NO9S [M+H]
+
 538.62, found 
538.34. 
 
Compound 15. Compound 14 (206 mg, 0.38 mmol) was mixed with NaN3 (128 mg, 1.97 
mmol) and KI (16 mg, 0.09 mmol) in DMF (5 mL) containing 3 angstrom molecular 
sieves and heated at 70 
o
C for 4 hours under argon.  TLC indicated product formation 
upon p-anisaldehyde staining (product is light yellow-brown; starting tosylate is faint 
white color upon staining).  Product and starting tosylate have identical Rf with UV 
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visualization.  DMF was removed under high vacuum (50 
o
C) and the residue was 
dissolved in CH2Cl2 (50 mL) and washed with water (2x25 mL) followed by brine (25 
mL) and dried over Na2SO4.  After sufficient solvent removal the crude mixture was 
purified over a column of silica (0 to 3% MeOH in CH2Cl2) to give 133 mg (86%) 
product. Rf 0.56 (97:3 CH2Cl2:MeOH); 
1
H NMR (300 MHz, CDCl3):  7.59 (d, 2H, J = 
8.8), 6.99 (d, 2H, J = 8.8), 4.17-4.14 (t, 2H, J = 4.7), 3.88 (t, 2H, J = 4.7), 3.72-3.66 (m, 
18H), 3.39 (t, 2H, J = 5.0); 
13
C (75 MHz, CDCl3): 163, 134, 119, 115, 105, 71(m), 
70(2), 69, 68, 51; MS (MALDI-TOF) m/z for C19H28N4O6 [M]
+
 408.45, found 408.26. 
 
Compound 16.  A solution of 15 (133 mg, 0.33 mmol) in EtOH (20 mL) and reduced on a 
Parr shaker using H2 (30 psi, 10 hrs) and 10% Pd/C.  The Pd/C was filtered using Celite 
and rinsed liberally with EtOH.  The EtOH was removed and the resulting amine 
intermdiate was dried under high vacuum to give 84 mg (68%) which was used 
immediately without characterization. 
 To the amine (84 mg, 0.22 mmol) was added MeOH (5 mL) and triethylamine 
(129 mg, 1.3 mmol) and the resulting solution was allowed to stir at 0 
o
C before dropwise 
additions of trifluoroacetic anhydride (180 L, 1.3 mmol) over a period of 20 minutes.  
The solution was allowed to come to room temperature with overnight stirring.  TLC 
indicated product formation, though consumption of starting amine was incomplete.  
Nonetheless, the solution was concentrated and taken up in EtOAc (30 mL) before 
washing with dilute citric acid (2x20 mL), water (20 mL), and brine (20 mL) and drying 
over Na2SO4.  Flash chromatography (30 to 0% hexane in EtOAc) afforded 33 mg of 
product.  However, 45 mg of starting amine was recovered after neutralization of the acid 
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layer and extracting into methylene chloride. (Quantitative yield though conversion was 
poor).  Note: later steps involving trifluoroacetylation of amines utilized pyridine, which 
gave much better conversions. Rf 0.42 (EtOAc); 
1
H NMR (300 MHz, CDCl3):  8.0 (br s, 
1H, NHCOCF3), 7.59 (d, 2H, J = 8.8), 6.98 (d, 2H, J = 8.8), 4.17 (t, 2H, J = 4.6), 3.88-
3.53 (m, 22H); 
13
C (75 MHz, CDCl3): 162, 134, 132, 130, 119, 115, 104, 71(m), 70, 69, 
68, 40; MS (MALDI-TOF) m/z for C21H29F3N2O7 [M]
+
 478.46, found 478.40. 
 
Compound 18. Compound 16 was converted it the corresponding imidate ethyl ester by 
vigorously bubbling anhydrous HCl into its solution in dry EtOH for 30 minutes before 
storage at 4
o
C overnight.  After acid removal (bubbling nitrogen through the solution into 
a sat. bicarbonate solution) and EtOH evaporation, the imidate 18 was rinsed well with 
dry ether before drying in vacuo and immediate use without characterization.   
 To the imidate 17 (33 mg, 59 mol) was added diamine 8 (19 mg, mol) and 
glacial acetic acid (2 mL) before refluxing for 8 hours under Argon.  The acetic acid was 
removed and the crude mixture was loaded onto a column of silica before purification 
using a gradient of MeOH (0 to 15%) in CH2Cl2 containing trace NEt3.  Evaporation of 
the solvent and rinse with ether afforded 9 mg (20%) of an orange-yellow solid.  Rf 0.29 
(85:15:0.1 CH2Cl2:MeOH:NEt3); 
1
H NMR (300 MHz, CD3OD):  8.25 (s, 1H), 8.05 (d, 
2H, J = 8.7), 7.93 (d, 1H, J = 8.8), 7.69 (d, 1H, J = 8.8), 7.51 (d, 1H, J = 8.7), 7.11-7.02 
(m, 4H), 4.24-4.14 (m, 2H), 3.90-3.80 (m, 2H), 3.69-3.54 (m, 18H), 3.50-3.40 (m, 2H), 
3.30-3.20 (m, 4H), 2.75-2.60 (m, 4H), 2.37 (s, 3H); MS (MALDI-TOF) m/z for 
C39H48F3N7O7 [M]
+
 783.84, found 783.58. 
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Compound 20.  The trifluoroacetyl group of 18 (9 mg) was removed using K2CO3 (7 mg) 
and a 2:1 MeOH:H2O mixture (1.5 mL) after overnight stirring at room temperature.  
Solvent removal and co-evaporation with dry pyridine (2x3 mL) before further 
dissolution in dry pyridine (2.5 mL in 3 washes) and addition to neomycin isothiocyanate 
5 (20 mg, 15.2 mol) and DMAP (1 mg) without characterization. 
 The solution containing amine, neomycin isothiocyanate, DMAP, and pyridine 
was allowed to stir at room temperature under argon for 20 hours.  After pyridine 
removal, the residue was purified via column chromatography (0 to 20% MeOH in 
CH2Cl2) to yield 12 mg product (52%).  Rf 0.65 (85:15:0.1 CH2Cl2:MeOH:NEt3); 
1
H 
NMR (500 MHz, CD3OD):  8.27 (s, 1H), 8.09 (d, 2H, J = 8.7), 7.95 (d, 1H, J = 8.8), 
7.71 (d, 1H, J = 8.8), 7.53 (d, 1H, J = 8.7), 7.17-7.06 (m, 4H), 6.93 (br s, 1H), 6.57 (br s, 
1H), 6.51 (br s, 1H), 5.40 (br s, 1H), 5.13 (br s, 1H), 4.27-4.22 (m, 2H), 4.09 (br s, 1H), 
3.90-3.20 (m, 43H), 2.92-2.80 (m, 6H), 2.52 (s, 3H), 1.44-1.42 (m, 54H); MS (MALDI-
TOF) m/z for C93H146N14O30S2 [M]
+
 2004.36, found 2004.25. 
 
NH(22) (Compound 21).  To the Boc-protected conjugate 20 (3 mg, 1.5 mol) was added 
dry CH2Cl2 (1 mL) and trifluoroacetic acid (1 mL) and 5 L ethanedithiol as a scavenger 
before stirring at room temperature for 3 hours.  Evaporation of liquids and addition of 
ether gave a light brown solid which, after subsequent rinses with ether and drying under 
vacuum, was dissolved in deionized water and lyophilized to afford 3.4 mg product 
(94%). The product was judged sufficiently pure by analytical HPLC (Supelcosil LC18S 
column; eluent: aqueous 0.1% TFA with a gradient of 0 to 100% of a 95:5 
acetonitrile:water mixture over a period of 20 minutes; flow rate=1.2 mL/min; 
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T=ambient; retention time of product = 8.1 minutes). 
1
H NMR (500 MHz, D2O):  8.78 
(d, 2H, J = 6.9), 8.61 (s, 1H), 8.10-7.80 (m, 4H), 7.70 (s, 1H), 7.32 (s, 2H), 7.20 (br s, 
1H), 6.86 (s, 1H), 6.08 (s, 1H), 5.41 (s, 1H), 5.30 (s, 1H), 4.00-2.69 (m, 55H); MS 
(MALDI-TOF) m/z for C63H98N14O18S2 [M]
+ 
1403.67, found 1403.30; UV (water): max 
(nm) = 342; = 21,085 M-1cm-1. 
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Scheme 5.5  Preparation of Hoechst 33258-pyrene-amine. Reagents and conditions: (i) 
p-cyanophenol, PPh3, DIAD, dioxane, 78%; (ii) 24, DMF, NaI, 61%; (iii) 5, DMAP, 
DMF, 65%; (iv)  (a) 8, HOAc, EtOH, 41%; (b) K2CO3, MeOH, H2O, 94%. 
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Scheme 5.6  Preparation of triple recognition agent NHP(22,18). Reagents and conditions: 
(i) pyridine, DMAP, 52%; (ii) 1:1 TFA:CH2Cl2, quant. 
 
Compound 23.  A solution of p-cyanophenol (200 mg, 1.68 mmol), triethylene glycol 
monotosylate 22 (1.02 g, 3.35 mmol), and triphenylphosphine (870 mg, 3.35 mmol) in 
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dioxane (25 mL) was stirred at room temperature while DIAD (665 L, 3.35 mmol) was 
added dropwise over a period of 30 minutes.  After overnight stirring, the dioxane was 
removed before further co-evaporations with toluene (3x10 mL) and purification over 
silica gel column (0 to 100% ether in hexane) to afford 534 mg (78%) product. Rf 0.56 
(8:2 EtOAc:hexane); 
1
H NMR (500 MHz, CDCl3):  7.73 (d, 2H, J = 8.3), 7.52 (d, 2H, J 
= 9.2), 7.28 (d, 2H, J = 8.3), 6.91 (d, 2H, J = 9.2), 4.10-4.08 (m, 4H), 3.79 (t, 2H, J = 4.8), 
3.64-3.60 (m, 4H), 3.57-3.55 (m, 2H), 2.37 (s, 3H); 
13
C (125 MHz, CDCl3): 162, 145, 
134, 133, 130, 128, 115, 104, 71, 69(3), 68, 22; MS (MALDI-TOF) m/z for 
C20H23NNaO6S [M+Na]
+
 428.70, found 428.47.   
 
Compound 25. Mono-protected diamine 24 (458 mg, 1.9 mmol) was mixed with tosylate 
23 (190 mg, 0.47 mmol), K2CO3 (150 mg, 1mmol), and KI (16 mg, 0.01 mmol) in DMF 
containing 3 angstrom molecular sieves and heated at 70 
o
C under argon overnight.  DMF 
was evaporated under high vacuum (50 
o
C) and the residue was dissolved in CH2Cl2 and 
filtered before concentration and loading onto a column of silica and purification using a 
gradient of MeOH (0 to 15%) in CH2Cl2 to afford 136 mg (61%) of product as an oil. Rf 
0.44 (85:15:0.1 CH2Cl2:MeOH:NH4OH); 
1
H NMR (500 MHz, CDCl3):  7.52 (d, 2H, J = 
8.7), 6.92 (d, 2H, J = 9.2), 4.15-4.10 (m, 2H), 3.85-3.20 (m,18), 3.05-2.95 (m, 4H); 
13
C 
(125 MHz, CDCl3): 162, 157, 141, 134, 129, 126, 119, 115, 104, 70(4), 69, 68(2), 
48(2), 40; 
19
F (500 MHz, CDCl3): -75.5; MS (MALDI-TOF) m/z for C21H30F3N3O6 
[M+H]
+ 
478.47, found 478.24.   
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Compound 27.  Compound 25 (150 mg, 0.31 mmol), pyrenebutyric acid N-hydroxy 
succinimide ester 26 (80 mg, 0.21 mmol), DMAP (2 mg) and DMF (2 mL) were mixed 
and heated at 60 
o
C overnight.  Solvent was removed under high vacuum (50 
o
C) and the 
crude mixture was purified using column chromatography using a gradient of MeoH in 
CH2Cl2 to give 100 mg (65%) pure product.  Rf  0.49 (94:6 CH2Cl2:MeOH); 
1
H NMR 
(500 MHz, CDCl3):   8.25 (d, 1H, 9.2), 8.07 (d, 2H, J = 7.8), 8.03-7.98 (m, 2H), 7.95-
7.89 (m, 3H), 7.78 (d, 1H, J = 7.8), 7.40-7.36 (m, 4H), 6.75 (d, 1H, J = 8.7), 6.70 (d, 1H, 
J = 9.2), 3.92 (t, 1H, J = 4.6), 3.83 (t, 1H, J = 4.6), 3.66 (t, 1H, J = 4.6), 3.22-3.55 (m, 
11H), 2.42-2.35 (m, 2H), 2.15-2.10 (m, 2H); 
13
C (125 MHz, CDCl3) 136, 134, 131.5, 
131, 130, 129, 128(2), 127(2), 126, 125(3), 124, 119, 115(2), 104, 70(8), 69(6), 68(2), 
49(2), 46, 40(2), 33(2), 32, 27(2); 
19
F (500 MHz, CDCl3): -75.5; MS (MALDI-TOF) m/z 
for C41H44F3N3O7 [M]
+ 
747.80, found 747.70.  
 
HP(13) (28) Compound 27 was converted it the corresponding imidate ethyl ester by 
vigorously bubbling anhydrous HCl into a its solution in dry in EtOH for 30 minutes 
before storage at 4
o
C overnight.  After acid removal (bubbling nitrogen through the 
solution into a sat. bicarbonate solution) and EtOH evaporation, the imidate was rinsed 
well with dry ether before drying in vacuo and immediate use without characterization. 
 To the corresponding imidate of 27 was added diamine 8 and a 3:1 dry 
EtOH:glacial acetic acid solution (2 mL) before refluxing for 8 hours under Argon.  The 
acetic acid was removed and the crude mixture was loaded onto a column of silica before 
purification using a gradient of MeOH (0 to 15%) in CH2Cl2 containing trace NEt3.  The 
product N-trifluoroacetamide of 28 is represented by an intense yellow-green 
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fluorescence under long UV.  Rf 0.6 (85:15:0.1 CH2Cl2:MeOH:NH4OH).  Unknown 
benzimidazole by-products, fluorescent purple under long UV, were difficult to separate, 
therefore the crude product was deprotected as indicated below, with full 
characterization.  MALDI MS confirmed product: [M]
+
 1053.18, found 1053.00. 
Deprotection of the corresponding trifluoroacetamide (14 mg, 13.3 mol) was 
removed by stirring with a 2:1 mixture of MeOH:water (1.5 mL) containing K2CO3 (25 
mg, 0.18 mmol) for 24 hours before solvent removal, dissolution in MeOH and filtration, 
further co-evaporation of MeOH with toluene (2x3 mL) and purified over a short column 
of silica with a gradient of 20-50% MeOH in CH2Cl2 until less polar impurities were 
flushed off (which fluoresced purple under long UV) before elution of a 1:1 
CH2Cl2:MeOH mixture containing 2% NEt3.  Product fluoresces yellow-green under long 
UV.  After evaporation of solvent and rinse with ether, 12 mg (94%) of the pure amine 
was obtained.  
1
H NMR (500 MHz, CDCl3):  8.44 (d, 1H, J=8.7), 8.25-7.90 (m, 12H), 
7.48-7.38 (m, 1H), 7.30-6.93 (m, 5H), 4.13 (m, 2H), 3.80-3.10 (m, 22H, peaks masked by 
solvent signal), 2.93-2.89 (m, 4H), 2.05-1.95 (m, 2H); MS (MALDI-TOF) m/z for 
C57H64N8O6 [M]
+ 
957.17, found 957.77. 
 
Compound 29.  The amine 28 was taken up in dry pyridine (2x0.5 mL) and mixed with 
neomycin isothiocyanate 5 (20 mg, 15.2 mol) and DMAP (1 mg) and stirred at room 
temperature under argon for 24 hours.  TLC indicated product of similar Rf to other 
conjugates.  Pyridine was removed under high vacuum with co-evaporations with toluene 
(3x2 mL) and taken up in a CH2Cl2/MeOH mixture and loaded onto a silica gel column 
for purification using a gradient of MeOH in CH2Cl2 to afford 15 mg (52%) of pure 
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product.  Rf 0.70 (85:15:0.1 CH2Cl2:MeOH:NEt3); 
1
H NMR (500 MHz, CDOD3): 8.31 
(d, 2H, J = 3.2, 9.2), 8.23-7.80 (m, 11H), 7.85 (d, 1H, J = 7.8), 7.53 (d, 1H, J = 8.7), 7.16 
(s, 1H), 7.08 (d, 1H, J = 10.1), 7.01 (d, 1H, J = 8.7), 6.96 (d, 2H, J = 8.7), 5.40-5.38 (m, 
2H),  5.12 (s, 1H), 4.24-4.20 (m, 2H), 4.07-3.17 (m, 46H), 2.82-2.68 (m, 4H), 2.60-2.50 
(m, 4H), 2.46 (s, 3H), 2.15-2.10 (m, 2H), 1.95-1.90 (m, 1H), 1.42 (s, 54 H); MS 
(MALDI-TOF) m/z for C113H161N15O30S2 [M+2H]
+ 
2275.7, found 2275.3. 
 
NHP(22,18) 30.  To the Boc-protected conjugate 29 (5 mg, 2.2 mol) was added dry 
CH2Cl2 (1 mL) and trifluoroacetic acid (1 mL) and 5 L ethanedithiol as a scavenger 
before stirring at room temperature for 3 hours.  Evaporation of liquids and addition of 
ether gave a light brown solid which, after subsequent rinses with ether and drying under 
vacuum, was dissolved in deionized water and lyophilized to afford 6 mg product 
(quant.). The product was judged sufficiently pure by analytical HPLC (Supelcosil 
LC18S column; eluent: aqueous 0.1% TFA with a gradient of 0 to 100% of a 95:5 
acetonitrile:water mixture over a period of 20 minutes; flow rate=1.2 mL/min; 
T=ambient; retention time of product = 8.9 minutes). 
1
H NMR (500 MHz, D2O+ 
CF3CO2D):  8.66 (br s, 1H), 8.51 (br s, 1H), 7.96 (br s, 1H), 7.52-6.30 (d, 14H), 5.96-
5.80 (m, 3H), 5.30 (s, 1H), 4.10-2.97 (m, 52H), 2.64-2.17 (m, 5H), 1.98-1.92 (m, 2H), 
1.85-1.70 (m, 2H); MS (MALDI-TOF) m/z for C83H113N15NaO18S2 [M+Na]
+ 
1696.0, 
found 1696.6; UV (water): max (nm) = 345; = 53,674 M
-1
cm
-1
. 
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Scheme 5.7  Synthesis of NP(18).  Reagents and conditions: (i) (a) pyrenebutyric acid, 
TSTU, DMF, NEt3, 64%; (b) TFA/CH2Cl2, 96%; (ii)(a) neomycin isothiocyanate 5, 
pyridine, 62%; (b) 1:1 TFA:CH2Cl2, ethanedithiol, 96%. 
 
Compound 31.  Pyrene butyric acid (144 mg, 0.5 mmol), TSTU 
264
 (156 mg, 0.5 mmol), 
NEt3 (70 L), and DMF (2.5 mL) were stirred and generated compound 26 in situ and in 
the presence of monoprotected diamine 24.   The mixture was stirred at room temperature 
under N2 overnight.  Ether (50 mL) was added and the solution was rinsed with dilute 
citric acid (3x20 mL), saturated bicarbonate (3x20 mL), water (20 mL), and brine (10 
mL) before drying of the ether over sodium sulfate.  The solution was concentrated and 
purified over silica gel using the following conditions: 100% CH2Cl2, 8:2 CH2Cl2:ether, 
4:6 CH2Cl2:ether, 97:3 CH2Cl2:MeOH, 94:6 CH2Cl2:MeOH, all in 100 mL volumes over 
a small bed of silica.  Rf 0.64 (85:10:5 CH2Cl2:ether:MeOH).  Yield was 161 mg (64%). 
1
H NMR (500 MHz, CDCl3):  8.28 (d, 1H, J=9.2), 8.13 (d, 2H, J=4.1), 8.07 (m, 2H), 
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8.0-7.94 (m, 3H), 7.83 (d, 1H, J=7.8), 6.03 (br s, 1H, NH), 4.94 (br s, 1H, NH), 3.60-3.10 
(m, 14H) 2.27-2.17 (m, 4H), 1.41 (s, 9H); MS (MALDI-TOF) m/z for C33H42N2O3 [M]
+ 
514.70, found 514.66. 
 
Compound 32.  Deprotection of 31 (65 mg, 0.12 mmol) was accomplished by stirring in a 
1:1 TFA: CH2Cl2 mixture (1 mL) for 2 hours before solvent evaporation, rinse with 
bicarbonate, and drying to give 50 mg of free amine (96%).  The amine was taken up in 
dry pyridine (0.5 mL) and added to a flask containing 5 (10 mg, 7.6 mol).  The solution 
was stirred under N2 at room temperature overnight.  TLC indicated product (Rf 0.6 in 
9:1 CH2Cl2:MeOH).  Pyridine was removed under high vacuum and co-evaporated 
further with toluene (2x2 mL).  Column chromatography using a gradient of MeOH (0 to 
10%) in CH2Cl2 to afford 8 mg (62%) of product.  
1
H NMR (500 MHz, CDCl3):  8.36 
(d, 1H), 8.20-7.90 (m, 6H), 7.62-7.58 (m, 1H), 7.45-7.41 (m, 1H), 6.55-6.50 (m, 1H), 
6.43-6.40 (m, 1H), 4.20-3.16 (m, 35H) 2.89-2.80 (m, 4H), 2.40-2.35 (m, 2H), 2.20-2.10 
(m, 2H), 1.43 (s, 54H); MS (MALDI-TOF) m/z for C82H127N9NaO27S2 [M]
+ 
1758.06, 
found 1758.56. 
 
Compound 33 (NP(18)). A solution of 32 (5 mg, 2.88 mol) was stirred in a 1:1 mixture of 
dry CH2Cl2:TFA containing trace ethanedithiol at room temperature, under N2 for three 
hours.  The liquids were evaporated and the solid was taken up in deionized water before 
lyophilization to afford 5 mg product (96%). The product was judged sufficiently pure by 
analytical HPLC (Supelcosil LC18S column; eluent: aqueous 0.1% TFA with a gradient 
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of 5 to 100% acetonitrile over a period of 20 minutes; flow rate=1.5 mL/min; T=ambient; 
retention time of product = 14.6 minutes).  
1
H NMR (500 MHz, D2O):  8.38 (d, 1H, 
J=9.2), 8.28 (t, 2H, J=6.9), 8.23 (d, 2H, J=8.3), 8.13 (s, 2H), 8.09 (t, 1H, J=7.8), 7.99 (t, 
1H, J=7.8), 7.69 (t, 1H, J=4.4), 7.54 (d, 1H, J=6.4), 5.96 (d, 1H, J=4.1), 5.32 (d, 1H, 
J=4.2), 5.00 (s, 1H), 4.22-3.08 (m, 32H), 2.81 (d, 1H), 2.55-2.36 (m, 6H), 2.21-2.17 (m, 
2H), 1.82 (q, 1H); MS (MALDI-TOF) m/z for C52H91N9O15S2 [M+2H]
+ 
1136.37, found 
1136.75; UV (water): max (nm) = 343;  = 19,625 M
-1
cm
-1
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Scheme 5.8  Sythesis of Hoechst-diamine: (a) 22, PPh3, DIAD, dioxane, 78%; (b) 24, 
K2CO3, NaI, DMF, 61%; (c) (i) trifluoroacetic anhydride, pyridine, NEt3, 58%; (d) (i) 
HCl(g), MeOH, quant. (ii) 8, MeOH, HOAc, 28%. 
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Scheme 5.9  Synthesis of Neomycin-Neomycin-Hoechst conjugate: (a) 5, pyridine, 
DMAP, 45%; (b) 36, TFA/CH2Cl2, trace ethanedithiol, 85%. 
 
Compound 34.   To a solution of 25 (180 mg, 0.377 mmol) in dry pyridine (2 mL) and 
triethylamine (1 mL) was added trifluoroacetic anhydride (100 L, 0.64 mmol) dropwise 
at 0
o
C.  The solution was brought to room temperature and allowed stirring overnight.  
Solvents were removed by rotary evaporation, with co-evaporations with toluene (2x5 
mL) and drying under high vacuum (50 
o
C).  After addition of diethyl ether, the 
pyridinium salt was filtered.  Further salt was removed by rinsing the organics with cold 
water (3x5 mL) and brine (1x5 mL).  Trace NEt3 was removed by purifying the syrup 
over silica gel using a gradient of ethyl acetate (up to 10%) in ether.  Yield was 125 mg 
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(58%).  Rf 0.53 (95:5 CH2Cl2:MeOH).  
1
H NMR (500 MHz, CDCl3)  7.57 (d, 2H, 
J=8.3), 6.95 (d, 2H, J=8.7), 4.18-4.12 (m, 2H), 3.88-3.81 (m, 2H), 3.75-3.50 (m, 20H); 
19
F (500 MHz, CDCl3): -68.5, -75.7. 
 
Compound 35.  Anhydrous HCl was rapidly bubbled through a solution of 34 (56 mg, 98 
mol) in dry methanol (3 mL) at 0 oC for 20 minutes.  The solution was then sealed 
sufficiently and stored at 4 
o
C overnight.  TLC showed the absence of starting material 
and a more polar product.  After bringing to room temperature, the gas was removed by 
purging with nitrogen into an aqueous sodium bicarbonate bath, and ethanol was 
evaporated by rotary evaporation.  After liberal washes with ether, the resulting 
crystalline solid was dried under high vacuum to yield 63 mg (quant.) of product, which 
was used immediately in the coupling step without characterization. 
Freshly prepared 8 and the imidate methyl ester of 34 (21 mg, 34 mol) in dry 
MeOH (2 mL) glacial acetic acid (0.5 mL) was heated to reflux for 6 hours.  TLC 
indicated products characteristic of Hoechst compounds (bright yellow fluorescence).  A 
faint amount of the trifluoroacetyl-protected product was observed (Rf 0.33 in 1:1 
CH2Cl2:MeOH with trace NEt3).  A more polar product was later identified (after 
purification) as the de-trifluoroacetylated product.  The reaction solution was 
concentrated and loaded onto a silica gel column before purification: gradient of MeOH 
in EtOAc followed by a 10:10:1 mixture of acetone:MeOH:NEt3 to push off the free 
diamine product, which eluted as a bright yellow-green fluorescent product of sufficient 
purity.  Triethylamine in the eluted product was removed by rinses with CH2Cl2.  Yield 
(deprotected product): 6 mg (28%);  
1
H NMR (500 MHz, CD3OD)  8.28 (s, 1H), 8.09 
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(d, 2H, J=8.7), 7.95 (d, 1H, J=8.7), 7.71 (d, 1H, J=8.3), 7.52 (d, 1H, J= 8.7), 7.20-7.12 
(m, 3H), 7.07 (d, 1H, J=8.7), 4.25-4.20 (m, 2H), 3.80-3.60 (m, 12H), 3.35-3.30 (m, 4H), 
3.15-2.98 (m, 4H), 2.90-2.85 (m, 4H), 2.73-2.65 (m, 4H), 2.38 (s, 3H); MS (MALDI-
TOF) m/z for C37H50N8NaO5 [M+Na]
+
 686.84, found 686.96. 
 
Compound 36 (Boc-protected Neo-Neo-Hoechst 33258 conjugate). 
A solution of diamine 35 (3 mg, 4.3 mol) in dry pyridine (2 mL) containing DMAP (1 
mg) was added to a dry flask containing neomycin isothiocyanate 7 (10 mg, 7.6 mmol) at 
room temperature.  The solution was allowed to stir under argon overnight at 45 
o
C.  TLC 
indicated the presence of a fluorescent product, also positive for anisaldehyde 
staining/charring.  The pyridine was evaporated, followed by co-evaporation with toluene 
(2x2 mL), and chromatography over silica (gradient of MeOH in CH2Cl2) afforded 6.5 
mg (45%) of a light brown solid.  Rf = 0.50 in 86:14 CH2Cl2:MeOH. 
1
H NMR (500 MHz, 
D2O): 8.20 (s, 1H), 8.00 (d, 2H, J=8.7), 7.89 (m, 1H), 7.64 (br s, 1H), 7.42 (br s, 1H), 
7.09 (d, 2H, J=8.7), 6.98-6.86 (m, 2H), 6.42 (br s, 1H), 5.35-5.20 (m, 2H), 5.00 (br s, 
2H), 4.17-3.00 (71H), 2.90-2.70 (8H), 2.62-2.56 (m, 4H), 2.29 (s, 3H), 2.00-1.80 (m, 
4H), 1.43 (br s, 108H). MS (MALDI-TOF) m/z for C149H244N22O53 [M]
+ 
3319.91, found 
3319.88. 
 
Compound 37 (Neo-Neo-Hoechst 33258 conjugate) 
A solution of 36 (6.5 mg, 1.96 mol) in 1 mL of 1:1 CH2Cl2:TFA containing trace 
ethanedithiol (1 L) stirred at room temperature for 5 hours.  Solvents were evaporated 
before dissolution in dI H2O (2x1 mL), filtering over 0.2 m filter, freezing and 
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lyophilization to give 6.4 mg (85%).  The product was judged sufficiently pure by 
analytical HPLC (Supelcosil LC18S column; eluent: aqueous 0.1% TFA with a gradient 
of 5 to 100% acetonitrile over a period of 20 minutes; flow rate=1.5 mL/min; T=ambient; 
retention time of product = 8.5 minutes). 
1
H NMR (500 MHz, D2O): 8.40 (s, 1H), 7.76-
6.60 (m, 9H), 5.95-5.82 (m, 2H), 5.35 (br s, 2H), 5.24 (br s, 2H), 4.45-2.88 (82H), 2.68 
(s, 3H), 2.21-2.12 (m, 2H), 1.59-1.50 (m, 2H);  MS (MALDI-TOF) m/z [M+H]
+
 2119.52, 
calcd for C89H149N22O29S4 2119.37. UV (water): max (nm) = 342. 
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GLOSSARY OF ABBREVIATIONS 
 
AMBER Assisted model building and energy refinement 
BOC tert-butoxycarbonyl 
 Chemical shift in ppm downfield from tetramethylsilane 
DMAP 4-(dimethylamino)pyridine 
DMF N,N’-dimethylformamide 
DMSO Dimethylsulfoxide 
HEG Hexaethylene glycol 
ITC Isothermal Titration Calorimetry 
MALDI-TOF Matrix Assisted Laser Desorption/Ionization-Time of 
Flight 
NMR Nuclear Magnetic Resonance 
TFA Trifluoroacetic acid 
TPS 2,4,6-triisopropylbenzenesulfonyl 
TCDP 1,1’-thiocarbonyldi-2-(1H)pyridine 
TFO Triplex forming oligonucleotide 
TSDU O-succinimidyl-1,3-dimethyl-1,3-trimethyleneuronium 
tetrafluoroborate 
A3T3  d(CGCCAAATTTGCG)2 
A3U3 d(CGCAAAUUUGCG)2 
A2GCT2 d(CGCAAGCTTGCG)2 
A2GCU2 r(CGCAAGCUUGCG)2 
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NMR of compound 2 
 
 
 
MALDI MS of compound 2 
C53H94N6NaO25 
MW(+Na) = 1237.4 
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NMR of compound 3 
 
 
 
MALDI MS of compound 3 
C68H116N6O27S 
MW(+Na,2H) = 1507.8 
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MALDI MS of compound 4 
 
C55H99N7O24S  
MW = 1274.5 
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NMR of compound 5 
 
 
IR of compound 5 
C55H99N7O24S  
MW(+H2O) = 1334.6 
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MALDI MS of compound 7 
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NMR of compound 9 
C14H16F3N2O2  
MW = 301.3 
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H NMR of compound 10 
 
C32H34F3N7O2  
MW = 605.7 
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HPLC chromatogram of compound 11.  Conditions: Reverse phase (Supelcosil LC18S) 
column; eluent: aqueous 0.1% TFA with a gradient of 5 to100% acetonitrile over a period 
of 20 minutes; flow rate = 1.5 mL/min; T = ambient. 
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MALDI MS of compound 13 
 
C19H29NO7  
MW = 383.4 
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MALDI MS of compound 14  
C26H35NO9S 
MW = 538.62 
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H NMR of compound 15 
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MALDI MS of compund 15 
 
 
 
1
H NMR of compound 16 
C19H28N4O6  
MW = 408.5 
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MALDI MS of compound 16 
 
C21H29F3N2O7  
MW = 478.5 
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MALDI MS of compound 18 
 
 
C39H48F3N7O7  
MW = 783.8 
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MALDI MS of compound 20 
 
C93H146N14NaO30S2  
MW(+Na) = 2004.36 
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MALDI MS of compound 21 
 
C63H98N14O18S2  
MW = 1403.7 
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HPLC chromatogram of compound 21. Conditions: Reverse phase (Supelcosil LC18S) 
column; eluent: aqueous 0.1% TFA with a gradient of 5 to100% acetonitrile over a period 
of 20 minutes; flow rate = 1.5 mL/min; T = ambient. 
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C NMR of compound 23 
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MALDI MS of compound 23 
 
 
 
1
H NMR of compound  25 
 
C20H23NNaO6S  
MW(+Na) = 428.7 
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F NMR of compound 25 
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MALDI MS of compound 25 
 
 
1
H NMR of compound 27 
 
C21H30F3N3O6 
MW(+H) = 478.5 
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MALDI MS of compound 27 
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H NMR of compound 28 
 
C41H44F3N3O7 
MW = 747.8 
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MALDI MS of compound 28 
 
 
 
1
H NMR of compound 29 
 
C57H64N8O6 
MW = 957.2 
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MALDI MS of compound 29 
 
 
 
1
H NMR of compound 30 
C113H161N15O30S2 
MW(+2H) = 2275.7 
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MALDI MS of compound 30 
 
0
0.1
0.2
0.3
0.4
0.5
300 320 340 360 380 400
A
b
s
.


342
 = 53,674 M
-1
cm
-1
 
UV Scan of compound 30 
 
 
C83H113N15NaO18S2 
MW(+Na) = 1696.0 
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HPLC chromatogram of compound 30. Conditions: Reverse phase (Supelcosil LC18S) 
column; eluent: aqueous 0.1% TFA with a gradient of 5 to100% acetonitrile over a period 
of 20 minutes; flow rate = 1.5 mL/min; T = ambient. 
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H NMR of compound 31 
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C NMR of compound 31 
 
 
MALDI MS of compound 31 
 
C33H42N2O3 
MW = 514.7 
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1
H NMR of compound 32 
 
 
 
 
MALDI MS of compound 32 
 
C82H127N9NaO27S2 
MW(+Na) = 1758.02 
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1
H NMR of compound 33 
 
 
 
 
 
C52H91N9O15S2 
MW(+2H) = 1136.4 
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MALDI MS of compound 33 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
300 310 320 330 340 350 360 370 380
A
b
s
.

 
UV spectrum of compound 33 
 
 
HPLC chromatogram of compound 33. Conditions: Reverse phase (Supelcosil LC18S) 
column; eluent: aqueous 0.1% TFA with a gradient of 5 to100% acetonitrile over a period 
of 20 minutes; flow rate = 1.5 mL/min; T = ambient. 
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1
H NMR of compound 34 
 
 
 
 
19
F NMR of compound 34 
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1
H NMR of compound 35 
 
 
 
MALDI MS of compound 35 
 
C37H50N8NaO5 
MW(+Na) = 686.8 
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1
H NMR of compound 36 
 
 
 
MALDI MS of compound 36 
C149H244N22O53 
MW = 3319.9 
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1
H NMR of compound 37 
 
 
 
C89H149N22O29S4 
MW = 2119.4 
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MALDI MS of compound 37 
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UV spectrum of compound 37 
 
HPLC chromatogram of compound 37. Conditions: Reverse phase (Supelcosil LC18S) 
column; eluent: aqueous 0.1% TFA with a gradient of 5 to100% acetonitrile over a period 
of 20 minutes; flow rate = 1.5 mL/min; T = ambient. 
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Standard fluorescence scans (top) and curve (at 475 nm) of Hoechst 33258 at various 
concentrations.  Solutions (3 mL) of ligand in buffer were analyzed for fluorescence from 
380-600 nm; exc = 355 nm; slits = 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 
mM NaCl, pH 7.0.  Samples contained 0.05% SDS, as found in samples for competition 
dialysis experiments.  
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Standard fluorescence scans (top) and curve (at 475 nm) of NH(10) at various 
concentrations.  Solutions (3 mL) of ligand in buffer were analyzed for fluorescence from 
380-600 nm; exc = 355 nm; slits = 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 
mM NaCl, pH 7.0.  Samples contained 0.05% SDS, as found in samples for competition 
dialysis experiments.  
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Competition dialysis of Hoechst 33258 with various nucleic acids:  Fluorescence scans 
(top) and corresponding bar graph after analysis.  Samples of nucleic acid (180 L of 75 
M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 M) 
before removal of 150 L from dialysis unit and addition of 10% SDS (16.7 L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM 
NaCl, pH 7.0.   
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Competition dialysis of NH(10) with various nucleic acids:  Fluorescence scans (top) and 
corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L of 75 
M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 M) 
before removal of 150 L from dialysis unit and addition of 10% SDS (16.7 L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
 300 
 
 
0
1 10
4
2 10
4
3 10
4
4 10
4
5 10
4
6 10
4
420 440 460 480 500 520
Neo-5-Hoechst + Duplex DNA
Competition Dialysis
calf thymus DNA
polydApolydT
22dT duplex
20T2C duplex
18T4C duplex
16T6C duplex
14T8C duplex
12T10C1 duplex
12T10C2 duplex
self comp. 12mer duplex
dialysate
 
0 1 2 3 4 5
calf thymus DNA
polydApolydT
22T duplex
20T2C duplex
18T4C duplex
16T6C duplex
14T8C duplex
12T10C1 duplex
12T10C2 duplex
self comp. 12mer
NH1 + Duplex DNA
Competition Dialysis
[Neo-5-Hoechst] in M
 
 
Competition dialysis of NH(10) with DNA duplex 22mers of various A/T content:  
Fluorescence scans (top) and corresponding bar graph after analysis. exc = 355 nm; slits 
= 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of 
nucleic acid (180 L of 75 M in base) were dialyzed for 24 hours against a 400 mL 
solution of  ligand (1 M) before removal of 150 L from dialysis unit and addition of 
10% SDS (16.7 L) to a final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL 
before fluorescence analysis. 
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Competition dialysis of NH(10) with various nucleic acids:  Fluorescence scans (top) and 
corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L of 75 
M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 M) 
before removal of 150 L from dialysis unit and addition of 10% SDS (16.7 L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
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Competition dialysis of NH(10) with DNA duplex 22mers monitored at different dialysis 
times:  Fluorescence scans (top) and corresponding bar graph after analysis. exc = 355 
nm; slits = 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  
Samples of nucleic acid (180 L of 75 M in base) were dialyzed for 24 hours against a 
400 mL solution of  ligand (1 M) before removal of 150 L from dialysis unit and 
addition of 10% SDS (16.7 L) to a final [SDS] = 1%.  After 30 min., samples were 
diluted to 2 mL before fluorescence analysis. 
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Competition dialysis of Hoechst 33258 with DNA duplex 22mers of various A/T content:  
Fluorescence scans (top) and corresponding bar graph after analysis. exc = 355 nm; slits 
= 2 nm; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of 
nucleic acid (180 L of 75 M in base) were dialyzed for 24 hours against a 400 mL 
solution of  ligand (1 M) before removal of 150 L from dialysis unit and addition of 
10% SDS (16.7 L) to a final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL 
before fluorescence analysis. 
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Competition dialysis of Hoechst 33258 with various nucleic acids:  Fluorescence scans 
(top) and corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 
mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L 
of 75 M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 
M) before removal of 150 L from dialysis unit and addition of 10% SDS (16.7L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
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Competition dialysis of NH(10) with various nucleic acids:  Fluorescence scans (top) and 
corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L of 75 
M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 M) 
before removal of 150 L from dialysis unit and addition of 10% SDS (16.7L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
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Competition dialysis of NH(10) with various nucleic acids:  Fluorescence scans (top) and 
corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L of 75 
M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 M) 
before removal of 150 L from dialysis unit and addition of 10% SDS (16.7L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
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Competition dialysis of Hoechst 33258 with various nucleic acids:  Fluorescence scans 
(top) and corresponding bar graph after analysis. exc = 355 nm; slits = 2 nm; buffer = 8 
mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0.  Samples of nucleic acid (180 L 
of 75 M in base) were dialyzed for 24 hours against a 400 mL solution of  ligand (1 
M) before removal of 150 L from dialysis unit and addition of 10% SDS (16.7 L) to a 
final [SDS] = 1%.  After 30 min., samples were diluted to 2 mL before fluorescence 
analysis. 
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UVmixing curve of poly(dA)•poly(dT) and poly(dT) in the presence of NH(10):  
Equimolar solutions (30 M) of poly(dA)•poly(dT) and poly(dT) containing NH(10) (2 
M) were mixed in varying ratios to a volume of 0.5 mL before heating at 95 oC for 5 
min., slow cooling to room temp. and incubation at 4 
o
C for 16 hours before UV analysis 
at 260 nm. T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, 
pH 7.2. 
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Poly(dA)•2poly(dT) CD – detected melting: Samples of DNA (40 M) were heated from 
20 to 96 
o
C at a rate of 0.2 
o
/min while scanning from 350-210 nm every 2 degrees.  Plots 
are cross sections the the 3D scans at indicated wavelengths.  buffer:  10 mM sodium 
cacodylate, 0.5 mM EDTA,150 mM KCl, pH 7.20 
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NH(10) + poly(dA)•2poly(dT)CD-detected melting:  Samples of DNA (40 M) containing 
NH(10) (10 M) were heated from 20 to 96 
o
C at a rate of 0.2 
o
/min while scanning from 
350-210 nm every 2 degrees.  Plots are cross sections the the 3D scans at indicated 
wavelengths.  .  buffer:  10 mM sodium cacodylate, 0.5 mM EDTA,150 mM KCl, pH 
7.20 
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Fluorescence mixing curve of NH(10) with poly(rA)•poly(rU):  Equimolar solutions (0.9 
M) of NH(10) and poly(rA)•poly(rU) were mixed in varying ratios to a volume of 3 mL 
before fluorescence analysis. exc = 355 nm; slits = 2 nm; buffer = 8 mM Na2PO4, 2 mM 
NaHPO4, 185 mM NaCl, pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2.  Injections of 15 L ligand 
(300 M) were made into DNA (28 M in duplex) every 400 seconds with an injection 
duration of 4 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 300 mM 
NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer.  Injections of 15 L ligand (300 M) were 
made into buffer every 400 seconds with an injection duration of 4 seconds; T = 20 
o
C; 
buffer = 8 mM Na2PO4, 2 mM NaHPO4, 300 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 subtracting blank titration 
data.  Injections of 15 L ligand (300 M) were made into DNA (28 M in duplex) every 
400 seconds with an injection duration of 4 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 300 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer at 9.4 
o
C (literature reproduction).
161
  
Injections of 15 L ligand (300 M) were made into buffer every 400 seconds with an 
injection duration of 4 seconds; T = 9.4 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 300 
mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer at 9.4 
o
C and increased injection duration time. 
Injections of 15 L ligand (300 M) were made into buffer every 400 seconds with an 
injection duration of 30 seconds; T = 9.4 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 
300 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 9.4 
o
C and increased 
injection duration time. Injections of 15 L ligand (300 M) were made into DNA (21 
M in duplex) every 400 seconds with an injection duration of 30 seconds; T = 9.4 oC; 
buffer = 8 mM Na2PO4, 2 mM NaHPO4, 300 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 9.4 
o
C and increased 
injection duration time, subtraction of blank titration data. Injections of 15 L ligand (300 
M) were made into DNA (21 M in duplex) every 400 seconds with an injection 
duration of 30 seconds; T = 9.4 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 300 mM 
NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer. Injections of 3 L ligand (3 mM) were made 
into buffer every 400 seconds with an injection duration of 6 seconds; T = 20 
o
C; buffer = 
8 mM Na2PO4, 2 mM NaHPO4, 300 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer,185 mM NaCl.  Injections of 15 L ligand 
(300 M) were made into buffer every 400 seconds with an injection duration of 30 
seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into buffer,185 mM NaCl, fresh buffer.  Injections of 15 
L ligand (300 M) were made into buffer every 400 seconds with an injection duration 
of 30 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl,  pH 
7.0. 
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ITC titration of Hoechst 33258 into buffer, 185 mM NaCl, extensively dialyzed Hoechst 
33258.  Injections of 15 L ligand (300 M) were made into buffer every 400 seconds 
with an injection duration of 30 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM 
NaHPO4, 185 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 (100 M) into buffer.  Injections of 6 L ligand (100 M) 
were made into buffer every 300 seconds with an injection duration of 12 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl,  pH 7.0. 
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ITC titration of Hoechst 33258 into cacodylate buffer.  Injections of 15 L ligand (300 
M) were made into buffer every 400 seconds with an injection duration of 30 seconds; T 
= 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 30 mM NaCl, pH 6.8. 
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Excess site ITC titration of Hoechst 33258 into buffer.  Injections of 5 L ligand (94 M) 
were made into buffer every 300 seconds with an injection duration of 10 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG) at 15 
o
C.  
Injections of 5 L ligand (94 M) were made into DNA (10 M in duplex) every 300 
seconds with an injection duration of 10 seconds; T = 15 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 20 
o
C.  
Injections of 3 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 30 
o
C.  
Injections of 3 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 30 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 40 
o
C.  
Injections of 3 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 40 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of NH(10) into d(CGCAAATTTGCG)2 at 20 
o
C (blank 
subtracted).  Injections of 5 L ligand (25 M) were made into DNA (20 M in duplex) 
every 300 seconds with an injection duration of 10 seconds; T = 20 
o
C; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of NH(10) into d(CGCAAATTTGCG)2 at 30 
o
C (blank 
subtracted). Injections of 3 L ligand (25 M) were made into DNA (20 M in duplex) 
every 300 seconds with an injection duration of 6 seconds; T = 30 
o
C; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of NH(10) into d(CGCAAATTTGCG)2 at 40 
o
C (blank 
subtracted).  Injections of 3 L ligand (25 M) were made into DNA (20 M in duplex) 
every 300 seconds with an injection duration of 6 seconds; T = 40 
o
C; buffer = 8 mM 
Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 20 
o
C.  
Injections of 8 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 30 
o
C.  
Injections of 8 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 30 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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Excess site ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at 40 
o
C.  
Injections of 8 L ligand (25 M) were made into DNA (20 M in duplex) every 300 
seconds with an injection duration of 6 seconds; T = 40 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
 324 
 
 
0.00
0.02
0.04
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
µ
c
a
l/
s
e
c
0.0 0.5 1.0 1.5 2.0
0
2
4
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
 
ITC titration of Hoechst 33258 into buffer at lower concentrations.  Injections of 15 L 
ligand (25 M) were made into buffer every 300 seconds with an injection duration of 30 
seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at lower concentrations.  
Injections of 15 L ligand (25 M) were made into DNA (2.5 M in duplex) every 300 
seconds with an injection duration of 30 seconds; T = 20 
o
C; buffer = 8 mM Na2PO4, 2 
mM NaHPO4, 185 mM NaCl, pH 7.0. 
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ITC titration of Hoechst 33258 into d(CGCAAATTTGCG)2 at lower concentrations 
(blank subtracted):  Injections of 15 L ligand (25 M) were made into DNA (2.5 M in 
duplex) every 300 seconds with an injection duration of 30 seconds; T = 20 
o
C; buffer = 8 
mM Na2PO4, 2 mM NaHPO4, 185 mM NaCl, pH 7.0. 
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ITC titration of Hoechst 33258 into cacodylate buffer:  Injections of 4 L ligand (714 
M) were made into buffer every 300 seconds with an injection duration of 8 seconds; T 
= 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 35 mM NaCl, pH 6.8. 
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ITC titration of Hoechst 33258 into 
t
RNA (brewers yeast):  Injections of 4 L ligand (714 
M) were made into RNA (10 M in strand) every 300 seconds with an injection 
duration of 8 seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 35 
mM NaCl, pH 6.8. 
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ITC titration of Hoechst 33258 into 
t
RNA (brewers yeast), blank subtracted:  Injections 
of 4 L ligand (714 M) were made into RNA (10 M in strand) every 300 seconds with 
an injection duration of 8 seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 
mM EDTA, 35 mM NaCl, pH 6.8. 
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Reverse ITC titration of 
t
RNA (brewers yeast) into Hoechst 33258:  Injections of 8 L 
RNA (303 M) were made into ligand (12 M) every 300 seconds with an injection 
duration of 16 seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 
35 mM NaCl, pH 6.8. 
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Reverse ITC titration of 
t
RNA (brewers yeast) into NH(10):  Injections of 4 L RNA (303 
M) were made into ligand (5 M) every 300 seconds with an injection duration of 8 
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seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 35 mM NaCl, 
pH 6.8. 
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Reverse ITC titration of 
t
RNA (brewers yeast) into buffer:  Injections of 4 L RNA (303 
M) were made into buffer every 300 seconds with an injection duration of 8 seconds; T 
= 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM EDTA, 35 mM NaCl, pH 6.8. 
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Reverse ITC titration of 
t
RNA (brewers yeast) into Hoechst 33258 (blank subtracted):  
Injections of 8 L RNA (303 M) were made into ligand (12 M) every 300 seconds 
with an injection duration of 16 seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 
0.1 mM EDTA, 35 mM NaCl, pH 6.8. 
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Reverse ITC titration of 
t
RNA (brewers yeast) into NH(10) (blank subtracted):  Injections 
of 8 L RNA (303 M) were made into ligand (12 M) every 300 seconds with an 
injection duration of 16 seconds; T = 20 
o
C; buffer = 10 mM sodium cacodylate, 0.1 mM 
EDTA, 35 mM NaCl, pH 6.8. 
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Melting profile of intramolecular triplex in the presence of NH2.  Samples of DNA (1 
M in triplex) were mixed with varying drug concentrations (0 – 3 M) and heated to 95 
o
C for 5 minutes before slow cooling to room temperature.  After incubation at 4 
o
C for 
16 hours, samples were heated from 10 – 95 oC at 0.2 deg/min., with absorbance 
monitored at 260 nm.  All samples were in 10 mM Na cacodylate, 0.1 mM EDTA, 150 
mM KCl, pH 6.8.  Intramolecular triplex: d(T)10-HEG-d(A)10-HEG-d(T)10 where HEG = 
hexaethylene glycol. 
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UV Melting Profiles of 22mer triplex/duplex of varying A/T content.  Samples of DNA 
(1 M in triplex) were mixed with ligand (4 M) and heated at 95 oC for 5 minutes 
before slow cooling to room temp. and incubation at 4 
o
C, thereafter heating from 10 – 
95
o
C at 0.2 deg/min and monitoring UV absorbance at 260 nm.  All samples were in 10 
mM Na cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 6.8.  For brevity, the 
complementary purine strand nomenclature is left out of the caption. 
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Samples of DNA (15 M) were mixed with ligand in buffer (10 mM sodium cacodylate, 
0.5 mM EDTA, 150 mM KCl, pH 7.2) before heating at 95 
o
C for 5 minutes and slow 
annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument software. 
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UVmelting profiles of d(A)22•d(T)22  with NNH.  Samples of DNA (1 M in duplex) 
were mixed with ligand (1 and 3 M from left to right) in buffer (10 mM sodium 
cacodylate, 0.5 mM EDTA, 150 mM KCl, pH 6.8) before heating at 95 
o
C for 5 minutes 
and slow annealing to 20 
o
C before UV analysis at 260 nm from 20 to 95 
o
C at heating 
rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument 
software. 
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UVmelting profiles of r(CGCAAAUUUGCG)2 with NNH.  Samples of RNA (1 M in 
duplex) were mixed with ligand (1, 2, and 3 M) in PIPES buffer (10 mM PIPES, 1 mM 
EDTA, 100 mM NaCl, pH 7.0) before UV analysis at 260 nm from 20 to 95 
o
C at heating 
rate of 0.2 
o
/min.  Tm values were determined by first derivative analysis using instrument 
software. 
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Blank ITC titration of neomycin (250 M) into PIPES buffer.  Four injections of 10 L 
were made at 20 
o
C.  Heat burst curves generated from binding were processed and curve 
fit using Origin 5.0. PIPES buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
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ITC titration of neomycin (250 M) into r(CGCAAAUUUGCG)2.  Twenty five 
injections of 10 L were made into 6 M duplex at 20 oC.  Heat burst curves generated 
from binding were processed and curve fit according to a two – binding site model using 
Origin 5.0. PIPES buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
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Blank ITC titration of neomycin (175 M) into PIPES buffer.  Four injections of 10 L 
were made at 20 
o
C.  Heat burst curves generated from binding were processed and curve 
fit using Origin 5.0. PIPES buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
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ITC titration of neomycin (175 M) into r(CGCAAAUUUGCG)2.  Twenty five 
injections of 10 L were made into 4 M duplex at 20 oC.  Heat burst curves generated 
from binding were processed and curve fit was attempted (resulting in high error) using 
Origin 5.0. PIPES buffer: 10 mM PIPES, 1 mM EDTA, 100 mM NaCl, pH 7.0. 
 
